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UNDERSTANDING THE BIOLOGICAL FUNCTION OF PHOSPHATASES OF 
REGENERATING LIVER, FROM BIOCHEMISTRY TO PHYSIOLOGY 
 
Phosphatases of regenerating liver, consisting of PRL-1, PRL-2 and PRL-3, 
belong to a novel protein tyrosine phosphatases subfamily, whose overexpression 
promotes cell proliferation, migration and invasion and contributes to tumorigenesis and 
metastasis. However, although great efforts have been made to uncover the biological 
function of PRLs, limited knowledge is available on the underlying mechanism of PRLs’ 
actions, therapeutic value by targeting PRLs, as well as the physiological function of 
PRLs in vivo.  
To answer these questions, we first screened a phage display library and 
identified p115 RhoGAP as a novel PRL-1 binding partner. Mechanistically, we 
demonstrated that PRL-1 activates RhoA and ERK1/2 by decreasing the association 
between active RhoA with GAP domain of p115 RhoGAP, and displacing MEKK1 from 
the SH3 domain of p115 RhoGAP, respectively, leading to enhanced cell proliferation 
and migration.  
Secondly, structure-based virtual screening was employed to discover small 
molecule inhibitors blocking PRL-1 trimer formation which has been suggested to play 
an important role for PRL-1 mediated oncogenesis. We identified Cmpd-43 as a novel 
PRL-1 trimer disruptor. Structural study demonstrated the binding mode of PRL-1 with 
the trimer disruptor. Most importantly, cellular data revealed that Cmpd-43 inhibited 
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PRL-1 induced cell proliferation and migration in breast cancer cell line MDA-MB-231 
and lung cancer cell line H1299.  
Finally, in order to investigate the physiological function of PRLs, we generated 
mouse knockout models for Prl-1, Prl-2 and Prl-3. Although mice deficient for Prl-1 
and Prl-3 were normally developed, Prl-2-null mice displayed growth retardation, 
impaired male reproductive ability and insufficient hematopoiesis. To further investigate 
the in vivo function of Prl-1, we generated Prl-1-/-/Prl-2+/- and Prl-1+/-/Prl-2-/- mice. 
Similar to Prl-2 deficient male mice, Prl-1-/-/Prl-2+/- males also have impaired 
spermatogenesis and reproductivity. More strikingly, Prl-1+/-/Prl-2-/- mice are completely 
infertile, suggesting that, in addition to PRL-2, PRL-1 also plays an important role in 
maintaining normal testis function. 
In summary, these studies demonstrated for the first time that PRL-1 activates 
ERK1/2 and RhoA through the novel interaction with p115 RhoGAP, targeting PRL-1 
trimer interface is a novel anti-cancer therapeutic treatment and both PRL-1 and PRL-2 
contribute to spermatogenesis and male mice reproductivity. 
 
Zhong-Yin Zhang, Ph.D., Chair 
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CHAPTER 1: INTRODUCTION 
1.1 Protein Tyrosine Phosphatases 
Protein tyrosine phosphorylation is a key mechanism in signal transduction 
controlling many cellular events, including cell proliferation, migration, differentiation, 
survival, as well as apoptosis (1,2). Protein tyrosine kinases (PTKs) and protein tyrosine 
phosphatases (PTPs) regulate these reversible phosphorylation events by adding and 
removing phosphate, respectively. The equilibrium of kinase-phosphatase activity is 
important to maintain normal homeostasis in a resting state and to respond to various 
extracellular stimuli. 
In humans, 107 genes have been identified as PTP superfamily members (2). 
These PTPs are classified into four groups based on the amino acid sequences of 
catalytic domains (Figure 1). The first group is Class I cysteine-based PTPs which 
consists of 99 members. This group can be further classified into two subgroups, 
classical PTPs, which contain 38 well-known tyrosine-specific PTPs members, and 
VH1-like or “dual-specific” PTPs, which consist of 61 members. Classical PTPs can be 
divided into receptor PTPs (RPTPs) and non-receptor PTPs (NRPTPs). The 
transmembrane RPTPs are represented by 21 members, such as RPTPα, RPTPβ and 
CD45, while the intracellular NRPTPs consist of 17 phosphatases, such as PTP1B, PTP-
MEG2 and SHP2. The VH1-like PTPs can be divided into several diverse groups 
including MKPs, atypical DSPs, Slingshots, PRLs, CDC14s, PTENs and Myotubularins. 
The second group is Class II cysteine-based PTPs which constitute of one member, low-
molecular-weight PTP. Class III cysteine-based PTPs are tyrosine/threonine specific 
phosphatases containing three members of Cdc25 cell cycle regulators. These three 
groups share similar active site structure and catalytic mechanism with an active site  
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 Figure 1. Classification of PTP superfamily. 
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Protein tyrosine phosphatase superfamily, consisting of 107 members, is divided into 
four classes based on the amino acid sequence of the catalytic domain. The class I 
cysteine-based PTPs have 99 members that are divided into two subfamilies: tyrosine-
specific classical PTPs (38 members) and VH1-like or dual specificity phosphatases 
(DSPs, 61 members). Classical PTP subfamily is further divided into two groups: 
receptor PTPs (RPTPs, 21 members) and non-receptor PTPs (NRPTPs, 17 members). 
The DSP subfamily is divided into seven different groups: MAPK phosphatases (MKPs, 
11 members), atypical DSPs (19 members), phosphatases of regenerating liver (PRLs, 3 
members), slingshot phosphatases (SSHs, 3 members), cell division cycle 14 
phosphatases (CDC14s, 4 members), PTEN phosphatases (5 members) and 
myotubularin-related phosphatases (MTMRs, 16). The class II cysteine-based PTPs has 
only one member which is low-molecular-weight PTP (LMW-PTP). The class III 
cysteine-based PTP family comprises three members in Cdc25 family. The class IV 
aspartic acid-based PTP family members are encoded by the four eyes absent homologue 
(EYA) genes. BRO1, baculovirus BRO1 homology; C1, protein kinase C conserved 
region 1; C2, protein kinase C conserved region 2; CA, carbonic anhydrase-like domain; 
CAAX, farnesylation signal; Cad, cadherin-like juxtamembrane sequence; CBD, 
carbohydrate-binding module; CC, coiled-coil domain; CDC25, CDC25-homology 
domain; DENN, DENN domain; FERM, band 4.1/ezrin/radixin/moesin homology; FN, 
fibronectin-like domain; GTD, guanylyltransferase domain; HD, histidine domain; Ig, 
immunoglobulin-like domain; KIM, kinase interaction motif; MAM, 
Meprin/A2/PTPRM homology domain; PBM, PDZ binding motif; PDZ, postsynaptic 
density-95/discs large/ZO1 homology; PEP, N-terminal peptidase-like domain; PH, 
pleckstrin homology domain; PH-G, pleckstrin homology-“GRAM” domain; PTB, 
phosphotyrosine-binding domain; Sec14, Sec14p homology; SH2, Src homology 2 
domain; TM, putative transmembrane segment. 
 
cysteine as the nucleophile. In stark contrast, the last group of PTPs, Class IV Asp-based 
PTPs, utilized a different catalytic mechanism with a key aspartic acid. Four members of 
EYA proteins were discovered recently and classified into this family. Altogether, PTP 
superfamily consists of various genes that work together to regulate cellular tyrosine 
phosphorylation levels in many physiological processes. 
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The balance of cellular tyrosine phosphorylation is essential for normal cell 
processes, whereas the disruption of equilibrium of kinase-phosphatase activity can 
ultimately results in various diseases including cancer. It is well documented that many 
PTKs, such as receptor tyrosine kinases (RTKs), are considered as oncogenes. Aberrant 
activation of PTKs will cause deleterious cell proliferation, leading to cancer 
development. PTPs conventionally are thought to be tumor suppressors by counteracting 
PTKs activity and attenuating signals for cell proliferation. However, recent studies have 
shown that 22 PTPs may also have oncogenic properties by mutation, overexpression or 
amplification (3). For examples, the Src homology-2 domain-containing phosphatase 
SHP2, encoded by PTPN11, is the first identified proto-oncogene in the PTP 
superfamily. While germline mutations in PTPN11 cause Noonan syndrome and 
LEOPARD syndrome, somatic gain-of-function PTPN11 mutations were observed in 
juvenile myelomonocytic leukemia, and rarely in adult leukemias and solid tumors (4,5). 
Even though the detailed mechanisms need to be elucidated, increasing evidence has 
suggested that PTP1B, encoded by PTPN1 gene, plays an oncogenic role in breast cancer, 
ovarian cancer, gastric cancer, pancreatic cancer and prostate cancer by overexpression 
and amplification (6-10). Other PTP family members are also implicated in cancer 
progression including PRLs (3). All these results demonstrated that PTPs are potential 
therapeutic targets in cancer treatment and inhibition of these PTPs may provide medical 
benefits. 
1.2 Phosphatases of Regenerating Liver 
Phosphatases of the Regenerating Liver (PRLs) represent a unique subfamily of 
PTPs with three members (PRL-1, 2 and 3), sharing a high degree (>75%) of amino acid 
sequence identity (11-13). PRL-1 was the first identified member of PRL family that 
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showed increased expression in regenerating liver (11). Later on, two other members, 
PRL-2 and PRL-3, were found by sequence homology searches (14). Amino acid 
sequences of human and mouse PRL-1 or PRL-2 are 100% identical, while PRL-3 
sequences from mouse and human are slightly different (Figure 2). Like other PTPs, 
PRLs contain the canonical phosphatase motif C(X)5R. The unique feature of PRL 
phosphatases is that they possess a C-terminal prenylation motif CAAX (Where C is 
cysteine that could be prenylated, A is an aliphatic amino acid). Once prenylated, they 
will localize to the plasma membrane and early endosomal compartments (15). Mutation 
of the CAAX box or treatment with farnesyl transferase inhibitors will re-localize PRLs 
to the nucleus, suggesting the translocation of PRLs from plasma membrane to nucleus 
depends on the removal of prenylation signal (15-17). PRLs also share an adjacent 
polybasic region with a cluster of positive charges, which facilitates the membrane 
binding. Both the prenylation group and the polybasic residues are required for their 
proper localization and full biological activity (17). It is noteworthy that PRLs may be 
susceptible to redox regulation and their activity could be inhibited by the formation of a 
disulfide bond at their active sites (18-20).   
Several PRL structures have been reported (17,21-23). The structures of PRL-1 
and PRL-3 revealed that the active sites are shallow and wide, indicating that both 
shorter side-chains of phospho-Ser and phospho-Thr and longer side- chain of phospho-
Tyr can be dephosphorylated. This feature of PRLs allows its access to a broad range of 
substrates, and classifies PRLs into the subfamily of dual specificity phosphatases (DSP) 
(21). In addition, the structures of PRL-1 solved by us and others also revealed a trimeric  
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Figure 2. Amino acid sequence alignment of human and mouse PRLs. 
The amino acids sequence alignment was generated by ClustalX. The active site C(X)5R 
motif, polybasic region and the prenylation motif CAAX are boxed. 
 
arrangement (Figure 3A & 3B, created by Sijiu Liu). The trimerization of PRL-1 
provides a membrane-binding surface with polybasic residues and the adjacent C-
terminal prenylation motif to anchor PRL-1 on the inner plasma membrane (17,23) 
(Figure 3B). Furthermore, residues involved in the trimer interface are identical or 
similar among all PRLs, suggesting that trimerization is a general property for all PRL 
enzymes. This is supported by the evidence that PRL-3 can also form trimers both in 
vitro and in vivo (17). Since PRLs are all implicated as oncogenes, targeting the trimer 
interface by small molecule inhibitors may provide a novel approach to develop anti-
cancer therapeutics (see details in Chapter 3). 
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Figure 3. Crystal structure of PRL-1 trimer. 
A. Vertical view of PRL-1 trimer. B. Horizontal view of PRL-1 trimer attached to inner 
plasma membrane. All figures were created with PyMol (DeLano Scientific; 
http:/www.pymol.org) by Sijiu Liu. Each monomer is labeled as different color (green, 
red and yellow). Active site is black, and C-terminal tail is blue.  
 
The expression patterns of PRL-1, -2 and -3 transcripts in human and mouse have 
been well-studied (14,24,25). Both PRL-1 and PRL-2 were found to be expressed in 
almost all organs by in situ hybridization (24). Interestingly, PRL-1 expression level was 
relatively lower than PRL-2. The broad expression pattern of PRL-1 and PRL-2 indicates 
that they function in basic cell signaling that exists in most tissues. In contrast, PRL-3 is 
primarily expressed in heart and skeletal muscle (14). However, a recent study revealed a 
more ubiquitous but low level expression of PRL-3 protein in a number of other tissues 
such as spleen, pancreas, brain, lung, thymus, colon, and small intestine, but not in liver 
and kidney (26). These organs that have low levels of PRL-3 or even no PRL-3 
expression will be susceptible to the oncogenic effect due to elevated PRL-3, which may 
explain why overexpression of PRL-3 will lead to enhanced tumorigenesis and 
metastasis in so many tissues. 
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1.3 PRLs and Cancer 
As mentioned previously, cellular protein tyrosine phosphorylation level is 
balanced by the actions of PTKs and PTPs. Dysregulation of PTK and PTP activity 
results in aberrant tyrosine phosphorylation, which contributes to the development of 
many human diseases, including cancer (27,28). Because many PTKs have been 
implicated in oncogenesis, people may believe that PTPs should act as tumor suppressors 
because of their counteractive action on PTKs. However, accumulating evidence 
suggested that some of the PTPs may also function as oncogenes. To date, about 22 
human PTPs have been reported in human cancers with potential oncogenic function (3). 
Overexpression of PRLs has been found in a variety of late-stage tumors and 
their distant metastatic sites, which makes PRLs intriguing biomarkers and attractive 
targets in cancer (Table 1). In 2001, it was reported that PRL-3 expression was 
dramatically up-regulated in liver metastases of colorectal cancer (CRC) compared to its 
expression in primary tumors and normal colorectal epithelium (29). Since then, a 
number of studies have focused on the association between PRL-3 overexpression and 
CRC progression. For examples, further investigations have revealed that PRL-3 
expression is also elevated in primary CRC tumors compared to normal tissues (30-34). 
PRL-3 overexpression was found not only in liver metastasis of CRC, but also other 
organs including lung, brain, ovary, peritoneum and lymph nodes (30,31,33,34). Most 
importantly, PRL-3 expression level in primary CRC is correlated with its progression to 
liver and lung metastasis as well as venous invasion (30). Clinically, high level of PRL-3 
expression in primary CRC has significance in predicting reduced survival rate (30,33). 
Thus, PRL-3 is an ideal prognostic marker for cancer progression and outcome in 
patients with CRC.  
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Table 1. The implication of PRLs in human malignancy 
Cancer type PRL-1 PRL-2 PRL-3 
Colorectal (34) (34) (29-34) 
Breast  (35) (36-39) 
Gastric (40)  (41-48) 
Ovarian   (49,50) 
Liver (40,51) (40) (52,53) 
Oral   (54) 
Nasopharyngeal   (55) 
Uvea   (56) 
Cervical   (57) 
Esophageal (58)  (58) 
Lung (59) (60) (61) 
Brain   (62) 
Multiple Myeloma   (63,64) 
Acute Myeloid Leukemia  (65) (66-68) 
Prostate  (69)  
Pancreas (70) (70)  
 
The expression of PRL-3 has been widely investigated in other cancer types after 
the initial investigation in CRC by Saha et al. To date, up-regulation of PRL-3 has been 
found in a variety of late-stage neoplasms and/or metastases (Table 1). For examples, 
Radke et al. reported that mRNA expression of PRL-3, but not PRL-1 or PRL-2, was 
significantly higher in malignant breast cancer compared to benign breast tissue (36). At 
the same time, Wang et al. investigated 382 breast cancer patients and found that breast 
cancer patients with high PRL-3 expression in the tumor had a worse disease-specific 
survival (DSS) rate than those with low PRL-3 expression, and PRL-3 showed a 
significant correlation with DSS in node-negative patients (37). Miskad found that, 
compared to primary gastric cancer, the incidence of PRL-3 expression was significantly 
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higher in lymph node metastasis (41). Similarly, it was also reported that PRL-3 
expression is significantly higher in peritoneal metastasis than primary gastric cancers 
(42). Wu et al. demonstrated that PRL-3 expression was enhanced in human liver 
carcinoma compared with normal liver tissue (71). In ovarian cancers, there was a 
significant correlation between PRL-3 expression and disease progression (49). Ming et 
al. also reported that PRL-3 expression is correlated with cancer progression and poor 
post-operative survival in non-small cell lung cancer (72).  
PRL-1 and PRL-2 phosphatases are also implicated in many types of cancers 
(Table 1). However, the expression of PRL-1 and PRL-2 in human malignancy has not 
been extensively studied. Wang et al. determined the expression of PRL-1 and PRL-2 in 
colorectal carcinoma samples and found that both PRL-1 and PRL-2 are highly 
expressed in lymph node metastases (34). In addition, PRL-2 overexpression in prostate 
carcinoma was reported by Wang et al. (69). PRL-2 expression was also significantly 
elevated in primary breast tumors compared to corresponding normal tissue, and was 
also increased in metastatic lymph nodes compared to primary tumors (35). Recently, 
PRL-1 and PRL-2 expression in 285 normal, benign, and malignant human tissues of 
diverse origin was determined. Both PRL-1 and PRL-2 were significantly overexpressed 
in hepatocellular carcinomas, while PRL-1 was also strongly expressed in gastric 
carcinomas (40).  
In conclusion, all these studies demonstrate that elevated PRLs expression is 
associated with the progression of different types of human malignancies, and PRLs are 
potential biomarkers and therapeutic targets for cancer treatment. 
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1.4 The Function of PRLs in Cell Culture 
It is clear that elevated PRLs expression is correlated with tumor progression and 
metastasis. To further investigate the function of PRLs, many studies have focused on 
cell culture systems, either by overexpression or ablation of PRL expression, then 
observing the consequence of this alteration on cancer-related cell properties, such as 
cell proliferation, migration or invasion. 
Zeng et al. demonstrated that overexpression of PRL-1 and PRL-3 promoted cell 
migration in wound healing and Trans-well assays, and increased cell invasion by 
Matrigel assay in Chinese hamster ovary (CHO) cell line (13). In addition, PRL-1 and 
PRL-3 overexpressing cells strongly induced lung and liver metastases after injection of 
cells into mouse tail veins (13). The key conclusion from this study is that PRL 
overexpression observed in human tumors possibly plays a causal role in tumorigenesis 
and metastasis but not simply a biomarker in the tumor progression. Similar results were 
reported by using a soft agar assay (73). High level of PRL-3 expression was also 
reported in the highly metastatic melanoma cell line B16-BL6 compared to the parental 
B16 cell line (71). Additionally, overexpression of PRL-3 in parental B16 cell line 
increases the migration and invasion rate to the level comparable to that in B16-BL6 
cells.  Injection of PRL-3 overexpressing B16 cells to mouse model also results in 
increased tumor growth and metastases in the liver and lung. Furthermore, PRL-3-
induced oncogenic property could be reversed by treating B16-BL6 cells with PRL-3 
specific siRNA to knock down endogenous PRL-3 expression (74). Finally, it is also 
suggested that PRL-3 overexpression promotes angiogenesis during tumor development. 
Up-regulation of PRL-3 expression was observed in tumor vasculature (31,75). Injection 
of PRL-3 expressing cells into nude mice increased the development of highly 
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vascularized tumors (30,73,76). PRL-3 overexpression is able to induce tube formation 
in human dermal microvascular endothelial cells (HMVEC) (77). 
In addition to PRL-1 and PRL-3, overexpression of PRL-2 in D27 hamster 
pancreatic ductal epithelial cells also increased proliferation and tumor formation (12). 
Knocking down PRL-2 in metastatic breast cancer cells MDA-MB-231 decreased 
anchorage-independent growth and cell migration (35). Moreover, PRL-2 knockdown by 
siRNA markedly inhibited cell migration and invasion in lung cancer cell line A549 (78). 
However, only limited information about PRL-2 actions is current available, and further 
investigation is required. 
Therefore, mounting evidence suggests that cancer-associated phenotypes in 
many different types of cancer cells are sensitively altered in response to PRLs’ level 
change. Either overexpression or reduction of PRLs leads to dramatic phenotypic 
changes, suggesting that endogenous PRLs expression is critical for basic cellular events. 
1.5 Signaling Mediated by PRLs 
Excess of PRLs contributes to the acquisition of tumor-associated phenotypes. In 
order to obtain the detailed mechanism about PRLs, many studies have also focused on 
the cell signaling pathways that are regulated by PRLs. Overall, PRLs promote cell 
proliferation and migration through a number of signaling pathways, including the 
PI3K/Akt, Src, Rho family of small GTPases and p53 signaling.  
It is reported that PRL-2 and PRL-3 positively regulate PI3K/Akt signaling by 
down-regulating the expression of tumor suppressor PTEN (79-81). PTEN is a dual 
specificity phosphatase that can dephosphorylate D3 position of the lipid second 
messenger phosphatidylinositol 3, 4, 5-trisphosphate (PIP3), through which PTEN 
reverses the activity of PI3K (82). In DLD-1 human colorectal cancer cells stably 
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expressing PRL-3, the serine/threonine protein kinase Akt was activated, and its 
substrate GSK-3β was inactivated by phosphorylation. Overexpression of PRL-3 but not 
its phosphatase-dead mutant PRL-3 (C104S) down-regulates PTEN protein level in 
DLD-1 cells. RT-PCR examination indicates that mRNA levels of PTEN were not 
changed, implying that PTEN down-regulation by PRL-3 is a post-transcriptional event 
(79). Recently, we have generated Prl-2 deficient mice (see details in Chapter 4) and 
demonstrated that ablation of Prl-2 up-regulates PTEN and thereby inactivates Akt in the 
placenta, resulting in decreased proliferation of glycogen cells, which are potential 
energy source in placenta, and impaired placenta function. Conversely, overexpression 
of PRL-2 in HEK293 cells promotes Akt activation by down-regulating PTEN through 
the proteasome pathway (80). Similarly, Prl-2 deficiency also results in elevated PTEN 
level in the testis, which attenuates the PI3K/Akt pathway, leading to increased germ cell 
apoptosis and decreased male mouse reproductive capacity. In contrast, increasing PRL-
2 expression in GC-1 mouse spermatogonia cells reduces PTEN and promotes Akt 
activation. PRL-2-mediated PTEN reduction is through enhanced PTEN degradation as 
assessed by a cycloheximide chase experiment. (81). Most recently, we also found an 
up-regulation of PTEN and inactivation of PI3K/Akt signaling in hematopoietic stem 
and progenitor cells (HSPCs) from Prl-2-null mice (83). These studies demonstrate that 
both PRL-2 and PRL-3 activate PI3K/Akt signaling pathway by down-regulation tumor 
suppressor PTEN. Notably, PTEN loss-of-function and PI3K/Akt pathway activation are 
frequently observed in human cancers, indicating a potential mechanism underlying 
PRL-mediated tumorigenesis. 
In addition, PRL-3 also promotes epithelial-mesenchymal transition (EMT), a 
process during which epithelial cells lose cell-cell adherens and convert to migratory and 
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invasive cells. EMT is characterized by loss of adherens junctions and desmosomes 
(cell-cell interaction) with the acquisition of focal adhesions (cell-matrix interaction). 
PRL-3 overexpression in DLD-1 cells reduced the expression of epithelial markers E-
Cadherin and γ-Catenin, and enhanced the expression of mesenchymal markers Snail 
and Fibronectin (79). Interestingly, PRL-3-mediated disassembly of adherens junction 
complex may contribute to PTEN degradation, because PTEN stability is controlled by 
Vinculin through the interaction of the adherens junction protein β-Catenin with the 
scaffold protein MAGI-2 (84). In line with this notion, PRL-2 overexpression also down-
regulates both Vinculin and β-Catenin, two major components of adherens junction 
complexes (80,81). Similar to PRL-2, PRL-3 overexpression also results in reduction of 
Vinculin expression in HeLa and CHO cells (79), suggesting that PRLs may share a 
common mechanism in regulating adherens junctions components and PTEN stability. In 
addition to adherens junctions, Integrin-centered focal adhesions are also regulated by 
PRLs. It has been proposed that Integrin α1 is an interacting protein of PRL-3, and PRL-
3 promotes the dephosphorylation of Integrin β1 (85), suggested that PRL-3 is involved 
in both adherens junctions and focal adhesions.  
Src kinase is also activated upon PRL-1 and PRL-3 overexpression (86-88). In 
line with this, several Src downstream effectors including STAT3 and ERK1/2 are also 
activated following PRL-1 and PRL-3 overexpression (86-88). Src tyrosine kinase is 
implicated as an oncogene that works under multiple receptor-mediated signaling 
pathways. Aberrant Src activation hijacks these signaling networks to facilitate the PRL-
3 induced tumorigenesis and metastasis in PRL-3 overexpression HEK293 cells (87). Src 
is auto-inhibited by the internal interaction between SH2 domain and phosphorylated 
Tyr527 in its C-terminal tail. Once Tyr527 is phosphorylated by C-terminal Src Kinase 
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(CSK), Src activity is inhibited (89). It is suggested that the negative regulator Csk is 
down-regulated in PRL-3 overexpressing cells to induce Src activation (86). Moreover, 
PRL-3-mediated Src activation is attributable to translational control of Csk expression 
(90). Activation of Src will result in the tyrosine phosphorylation of the adaptor protein 
p130Cas, which is a key player in focal adhesion formation (91). Consistent with the 
elevated Src activity observed in PRL-3 overexpression cells, p130Cas phosphorylation as 
well as the interaction between p130Cas and Vinculin was increased (86). Interestingly, a 
recent report suggested that PRL-2 suppression by siRNA in A549 cells also down-
regulates p130Cas expression (78), which is consistent with a previous observation that 
p130Cas was also decreased in PRL-1-silencing A549 cells (59), implying that all PRLs 
are able to regulate p130Cas in the focal adhesion complex. Together with the function of 
PRLs in adherens junctions, all these data indicate that PRLs definitely modulate the 
turnover and function of adherens junctions and focal adhesions to facilitate cell 
migration and invasion. 
Rho family of small GTPases (Rho, Rac and Cdc42) regulates actin cytoskeleton 
dynamics through modulating actin polymerization, focal adhesion formation and cell 
motility. The first evidence that put PRLs into Rho GTPases signaling is reported by 
Fiordalisi et al. (16). They found that PRL-1 and PRL-3 overexpression in SW480 
colorectal carcinoma cells significantly increased active RhoA and RhoC level. In 
contrast, active Rac level was significantly reduced by PRL overexpression, whereas 
Cdc42 activity was unaffected. Treatment with specific inhibitor for Rho kinase ROCK, 
a key Rho effector, attenuated the PRL-dependent motility and invasion, suggesting that 
PRLs acts upstream of Rho and ROCK signaling to promote cell migration and motility. 
Recently, the same proup further demonstrated that Src-mediated PRL-3 
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phosphorylation is required for PRL-3-induced Rho activation, motility and invasion, 
indicating that Src not only is a key effector downstream of PRL-3, but also may act as a 
switch on PRL-3 to initiate the migration and invasion (92). 
A recent phage display screening by us identified p115 RhoGAP, also known as 
ARHGAP4, as a PRL-1 binding protein (93). Like other RhoGAPs, p115 RhoGAP plays 
a negative role in RhoA activation by increasing the intrinsic GTPases activity which 
converts GTP-bound active RhoA to GDP-bound inactive RhoA. In addition, p115 
RhoGAP also inhibited MAP/ERK pathways through interaction with and inhibition of 
MAP/ERK kinase kinase 1 (MEKK1) (94). It is worthy to test the possibility that PRL-1 
activates RhoA and ERK1/2 by inhibiting p115 RhoGAP function, and thereby promotes 
cell migration and proliferation (see details in Chapter 2).  
PRLs are also possibly involved in cell cycle regulation. The localization of PRL-
1 in HeLa cells is controlled in a cell cycle dependent manner (95). PRL-1 localized to 
the endoplasmic reticulum (ER) in non-mitotic cells, while it moved to centrosomes and 
spindle apparatus in mitotic cells, suggesting that PRL-1 plays a role in spindle dynamics. 
Overexpression of PRL-1 and PRL-2 in D27 cells enhanced cell cycle progression 
possibly through down regulation of p21, a cyclin-dependent kinase inhibitor (96). 
Recently, it is reported that PRL-1 and PRL-3 are new p53 transcriptional target genes, 
and also down-regulates p53 through Mdm2 and Pirh2 (97-99). p53 is a well-
characterized tumor suppressor that is the most commonly inactivated in numerous 
tumors (100-102). It is widely accepted that p53 inhibits tumor formation through 
activation of cell cycle arrest, apoptosis and senescence. Reducing PRL-3 expression 
levels in MEF cells led to cell cycle arrest through increased p53 expression, while 
overexpression of PRL-3 also resulted in G1 arrest, indicating that basal expression of 
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PRL-3 in MEF cells seems to be critical to ensure cell cycle progression via facilitating 
G1/S transition (97). In accord with the results shown in MEF cells, up-regulation of 
PRL-3 in HCT116 colorectal cancer cells decreased p53 expression. However, it 
inhibited p53-mediated apoptosis rather than cell cycle arrest (99).  
Overall, all those studies on the PRLs-mediated signaling pathways suggested 
that PRLs are multifunctional proteins that involved in four signaling pathways, 
PI3K/Akt pathway, Src pathway, Rho family pathway and p53 pathway. All those 
signaling pathways mainly control two cell functions, EMT and cell cycle regulation, 
both of which contribute to PRLs’ oncogenic function. 
1.6 Therapeutic targeting of PRLs 
Pharmacological inhibition of PRLs has gained widespread attention since the 
identification of PRLs as potential therapeutic targets in cancer treatment. Several PRLs 
inhibitors have been discovered to date (Figure 4).  
Pentamidine [1,5-di(4-amidinophenoxy)pentane], a drug clinically used for 
treatment of leishmaniasis, has been identified as a pan inhibitor for all PRLs with anti-
cancer potential in a melanoma xenograft mouse model (103). However, pentamidine 
inhibits not only PRLs but also other PTPs including PTP1B, suggesting the real in vivo 
target and mechanism are still not clear. In a high throughput screening using chemical 
library of Korea Chemical Bank, BR-1, one of the rhodanine derivatives, was discovered 
as PRL-3 inhibitor with IC50 value of 0.9 μM and reduced invasion of B16F10 cells, 
which have high levels of endogenous PRL-3 expression compared to the parental cell 
line B16F0 (104), and strongly inhibited migration and invasion of PRL-3 
overexpressing DLD-1 cells (105). Daouti et al. reported the first selective PRLs 
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 Figure 4. Chemical structure of small molecule inhibitors for PRLs. 
Pentamidine is a pan inhibitor for all PRLs with low potency. The Rhodanine derivative 
is a PRL-3 inhibitor with IC50 value of 0.9 μM. Thienopyridone is another potent and 
specific pan PRLs inhibitor with IC50 values of 173, 277 and 128 nM for PRL-1, PRL-2 
and PRL-3, respectively. Natural products ginkgetin and sciadopitysin inhibited PRL-3 
with IC50 values of 25.8 and 46.2 μM, respectively.  
 
inhibitor, thienopyridone, which suppresses tumor cell anchorage-independent growth in 
soft agar (106). Thienopyridone potently and selectively inhibited all three PRLs in vitro 
with IC50 values of 173, 277 and 128 nM for PRL-1, PRL-2 and PRL-3, respectively. 
Thienopyridone reduced tumor cell three-dimensional growth by a novel mechanism 
involving p130Cas cleavage and anoikis, a form of programmed cell death induced by 
anchorage-dependent cells detaching from the surrounding extracellular matrix (ECM). 
Ginkgetin and sciadopitysin, two biflavonoids isolated from the MeOH extract of the 
young branches of Taxus cuspidata, inhibited PRL-3 with IC50 values of 25.8 and 46.2 
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μM, respectively (107). These are the first report of natural products that inhibit PRL-3. 
Park et al. reported that 12 novel PRL-3 inhibitors with diverse structures and IC50 
values ranging from 10 to 50 μM were identified by virtual screening (108). Recently, 
curcumin, the natural product from spice turmeric, has been shown to prevent B16BL6 
cells from invading by selectively down-regulating PRL-3 but not PRL-1 and PRL-2 
mRNA expression (109). However, this inhibition of PRL-3 transcription is possibly 
through other targets in cancer cells. Antibody-based cancer therapies have better 
specificity and thus improved efficacy compared to standard small molecule inhibitors. 
Most recently, Guo et al. identified a novel PRL-3 antibody that effectively retarded 
metastatic tumors that express endogenous PRL-3 (110). However, the mechanism by 
which this antibody can target intracellular PRL-3 is still not understood. 
Collectively, many efforts have been made to establish novel therapeutic tools by 
targeting PRLs. However, none of those have been tested in clinical trials due to low 
specificity or limited information on mechanisms of action. Developing better PRLs 
inhibitors with higher specificity are still required for anti-cancer therapeutics. 
1.7 Genetic models for PRLs 
Despite numerous studies having been performed to understand PRLs action, 
they all used cultured cells aberrantly or ectopically expressing PRLs. Thus the exact 
biological function of PRLs remains unknown. Recently, several studies with Prl-null 
mice were reported. Our group published the first study on Prl-2 knockout mice (see 
details in Chapter 4) and demonstrated that deletion of Prl-2, the most ubiquitously 
expressed Prl family member, impaired placental development and growth in both 
embryos and adult mice (80). At the molecular level, PRL-2 activated the anti-apoptotic 
kinase Akt by down-regulating the tumor suppressor PTEN through degradation in the 
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proteasome, which is consistent with cell based studies where PRL-2 elicited oncogenic 
activity by negatively regulating PTEN, thereby activating the PI3K-Akt pathway (79). 
This study provided the first evidence that PRL-2 is required for extra-embryonic 
development. Following this discovery, we also found a similar functional role for PRL-
2 in spermatogenesis. Prl-2 deficient mice exhibited testis hypotrophy, reduced sperm 
production and impaired reproductive ability (81). Mechanistically, Prl-2 deficiency 
results in elevated PTEN level in the testis, which attenuates the Kit-PI3K-Akt pathway, 
resulting in ectopic germ cell apoptosis. Collaborating with Dr. Michihiro Kobayashi in 
Dr. Yan Liu’s lab, we also found that Prl-2 deficiency results in ineffective 
hematopoiesis and impaired long-term repopulating ability of hematopoietic stem cells 
(HSCs) (83). Biochemical data demonstrated that Prl-2 deletion impairs the activation of 
SCF/KIT signaling via down-regulating PTEN in hematopoietic stem and progenitor 
cells (HSPCs), leading to reduced HSPCs proliferation. All these data support the 
conclusion that PRL-2 plays a pro-proliferative and pro-survival role in different tissues 
through down-regulation of PTEN and subsequent activation of PI3K/Akt signaling. 
The first gene-targeted murine knockout for Prl-3, the most widely 
studied Prl family member, was reported by Zimmerman et al. (26,111). Mice deficient 
for Prl-3 have no obvious phenotype except that fewer homozygous-null males were 
observed at weaning. Similar to Prl-2 null mice, Prl-3 deficient mice also exhibited an 
approximate 10% decrease in body mass. Prl-3-null mice treated with carcinogen 
azoxymethane and dextran sodium sulfate developed 50% fewer colon tumors than wild-
type mice, highlighting the potential value of this phosphatase as a therapeutic target in 
colon cancer (26). Following this study, Zimmerman et al. further demonstrated that 
colon tumor tissue developed in Prl-3-null mice had less tumor microvessel density 
20 
 
compared to wild-type controls, and endothelial cells derived from Prl-3 deficient mice 
displayed significantly reduced migration in vitro, suggesting that PRL-3 is involved in 
VEGF signaling and contributes to pathological angiogenesis (111).  
At the same time, we also independently generated Prl-3-null mice (see details in 
Chapter 4). We also found a significant decrease of Prl-3-/- birth rate, suggesting indeed 
loss of PRL-3 leads to survival disadvantage. However, we did not observe any 
significant reduction in body mass in Prl-3-null males, which may be due to difference 
in genetic background of animals used in the experiments. While Zimmerman et al. used 
C57BL/6J strain with 5 generations of backcrossing, our results were derived from a 
C57BL6/129P2 mixed genetic background. Further investigations were required to 
establish the physiological role of PRL-3 in vivo. 
In addition to mouse knockout models, several groups are also working on PRLs 
transgenic mice. Hardy et al. reported the first PRL-2 transgenic mouse model by co-
expressing both activated ErbB2 and PRL-2 in the mammary epithelium (35). 
Mammary-targeted overexpression of PRL-2 did not exhibit spontaneous tumorigenesis, 
but they accelerated development of mammary tumors initiated by introduction of an 
activated ErbB2 transgene. However, the effects of PRL-2 overexpression in other tumor 
models, as well as the oncogenic potential of transgenic mice with two other PRL family 
members, PRL-1 and PRL-3, require further investigation. 
Most recently, Pagarigan et al. reported the first study of PRL overexpression in 
Drosophila, another genetically controlled organismal model (112). The Drosophila 
genome encodes a single PRL protein (dPRL-1), which is highly similar (74-76%) to all 
three human PRLs. Strikingly, they found that overexpression of dPRL-1 broadly 
resulted in growth inhibition, suggesting that Drosophila PRL performs as a tumor 
21 
 
suppressor. Further evaluations are needed to explain the opposing outcomes observed in 
different genetic organisms. 
All together, the studies in mice not only revealed the oncogenic role of PRLs by 
in vivo carcinogenesis models, but also demonstrated the important physiological 
function of PRLs in normal development. However, the physiological role of PRL-1 is 
still unclear due to the lack of Prl-1 deficient mice (see details in Chapter 4). In addition, 
due to the high homology of PRLs, it is possible that two other PRLs may compensate 
for the loss of a single isoform. Thus, to establish the complete physiological functions 
of PRLs, it is necessary to generate double or even triple knockout mice for Prls (see 
details in Chapter 5).  
1.8 Research gaps and thesis objectives 
Since the discovery of PRL phosphatases, an intense interest has been focused on 
PRLs’ role in promoting cancer. Numerous studies support their strong implication in 
biological process during tumorigenesis and metastasis. However, there still exist 
unanswered questions regarding the mechanisms, therapeutic values and physiological 
functions of PRLs. First of all, PRLs have been implicated as oncogenes that alter 
signaling pathways affecting basic cell processes. However, little is known about the 
detailed mechanisms underlying PRLs actions. Secondly, given their pathogenic role in 
tumorigenesis and metastasis, PRL phosphatases are attractive therapeutic targets to 
develop anti-cancer agents. However, very few effective PRLs inhibitors have been 
developed. Finally, while PRLs have been widely studied in cell culture systems, the real 
physiological role of PRLs in vivo is still unknown. The work described in this 
dissertation will cover three projects: 1) Phage display was used to identify PRL-1 
binding partners; 2) Virtual screening was utilized to develop small molecule inhibitors 
22 
 
targeting PRL-1 trimer interface; and 3) Mice that are deficient for PRL-1, PRL-2 or 
PRL-3 were generated to investigate the in vivo functions of PRLs. Identification of 
PRL-1 interacting proteins will benefit our understanding on the molecular mechanism 
by which PRL-1 promotes cell migration and proliferation. Development of small 
molecule inhibitors that interfer with the PRL-1 trimer interface may provide novel 
agents for anti-cancer treatment. Generation of knockout mice for individual Prl genes 
will contribute to the understanding of the physiological functions of PRLs in vivo. 
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CHAPTER 2: PRL-1 PROMOTES ERK1/2 AND RHOA ACTIVATION 
THROUGH A NOVEL INTERACTION WITH P115 RHOGAP 
2.1 Overview 
Among all PRLs, PRL-1 was the first identified member, whose expression was 
induced during liver regeneration after partial hepatectomy (11). Subsequently, PRL-1 
expression was found to be elevated in many tumor cell lines, and cells expressing high 
levels of PRL-1 exhibited enhanced proliferation and anchorage-independent growth 
(11,12,95,96). PRL-1 also promotes cell invasion and tumor metastasis. For example, 
overexpression of PRL-1 in CHO or HEK293 cells displays enhanced cell motility and 
invasiveness (13,17). CHO cells with elevated PRL-1 also preferentially form metastatic 
tumors in nude mice (13). Furthermore, an increase in PRL-1 expression enhances 
motility and invasion of SW480 colon adenocarcinoma cells (16), while knockdown of 
endogenous PRL-1 inhibits human A549 lung cancer cell invasion (59). These results 
suggest an oncogenic role for PRL-1 in cancer development and metastatic progression. 
However, less knowledge is available with respect to the underlying mechanisms. 
2.2 Hypothesis and Specific Aims 
Recently, biochemical studies revealed that PRL-1 promotes cell proliferation 
and invasion by up-regulating both ERK1/2 and RhoA (16,17,88,113). ERK1/2 are 
serine/threonine kinases that are required for many fundamental cellular processes 
including cell proliferation, survival and motility (114), while the Rho family of 
GTPases are mainly recognized as key regulators of actin cytoskeletal dynamics and cell 
migration (115,116). However, the underlying mechanism by which PRL-1 activates 
ERK1/2 and RhoA remains to be established. Through a phage display library screening, 
I identified a novel PRL-1 binding peptide, corresponding to a sequence motif located in 
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the SH3 domain of p115 Rho GTPase-activating protein. Like other RhoGAPs, p115 
RhoGAP lowers the active RhoA level by accelerating the cycling between the 
biologically active GTP-bound form and inactive GDP-bound form. In addition, p115 
RhoGAP also inhibits the MAP/ERK pathways through interaction with and inhibition 
of MAP/ERK kinase kinase 1 (MEKK1) (94). Given the inhibitory role of p115 
RhoGAP in ERK1/2 and RhoA activation, I hypothesized that PRL-1 promotes 
ERK1/2 and RhoA activation through the novel interaction with p115 RhoGAP. To 
test this hypothesis, I developed two specific aims: 1) to validate the interaction between 
PRL-1 and p115 RhoGAP via biochemical, cellular and structural studies; and 2) to 
determine the mechanism of PRL-1 mediated ERK1/2 and RhoA activation through the 
interaction with p115 RhoGAP. The work described here will contribute to the 
understanding of the molecular mechanism by which PRL-1 promotes cell proliferation 
and migration and the overall biological functions of PRLs in tumorigenesis and 
metastasis.  
2.3 Materials and Methods 
2.3.1 Materials 
Anti-HA, anti-His, anti-GST, anti-RhoA, anti-Actin and anti-MEKK1 antibodies 
were purchased from Santa Cruz Biotechnology. Anti-Flag and anti-p115 RhoGAP 
antibodies were from Sigma. Polyclonal anti-ERK1/2, anti-pERK1/2 (Thr-202/Tyr-204) 
and anti-Myc antibodies were obtained from Cell Signaling (Beverly, MA). Dulbecco’s 
modified Eagle’s medium (DMEM), fetal bovine serum, penicillin, and streptomycin 
were from Invitrogen.  
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2.3.2 Phage display 
The PH.D.-12 phage display peptide library kit (New England Biolabs) was used 
to screen PRL-1 binding peptides according to manufacturer’s instructions. On day 1, 3 
μg of recombinant PRL-1 was coated in a well of 96-well plate at 4°C overnight. On day 
2, 200 μL MPBS (2% (v/v) non-fat milk in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM 
NaH2PO4, 1.4 mM KH2PO4, pH 7.4)) was added to the well with shaking for 1 hr at 
room temperature to block non-specific binding. During this time, the input phage was 
mixed in 100 μL MPBS and incubated for 1 hr at room temperature in an empty well to 
allow any “sticky” phage to adhere to the plastic. Then the protein/MPBS solution was 
discarded and the well was washed five times with 200 μL PBST [0.1% (v/v) Tween in 
PBS]. The phage/MPBS solution was transferred from the pre-clearing well to the PRL-
1-coated well incubating for 2 hrs at RT on the shaker. After washing away unbound 
phage with 200 μL PBST for five times, the bound phage was eluted by adding 100 μL 
0.1 M HCI for 10 min at room temperature on the shaker. Eluted phage was transferred 
to a tube and immediately neutralized by adding 50 μL 1 M Tris-HCI buffer (pH 7.4). A 
small part of this output phage was used for titration and the rest was amplified to get an 
input titer of 1013 phage for the following panning. A total of four rounds of panning 
were performed to obtain PRL-1 specific phages. Individual phage clones were 
amplified and single strand DNA was isolated according to the manufacturer’s 
instruction. The sequence of the 12 amino acid PRL-1 binding peptide was obtained by 
DNA sequencing. 
2.3.3 Cell culture and transfection 
HEK293 cells and mouse embryonic fibroblast cells were grown in DMEM 
supplemented with 10% fetal bovine serum, penicillin (50 units/mL), and streptomycin 
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(50 μg/mL) under a humidified atmosphere containing 5% CO2. HEK293 cells were 
seeded at 40% confluency in antibiotic-free medium and grown overnight. Transfection 
was performed using Fugene 6 (Roche, Indianapolis, IN) according to the 
manufacturer’s recommendations.  
2.3.4 Immunoblotting and immunoprecipitation 
Cells were grown to 70% confluency, washed with ice-cold phosphate-buffered 
saline, and lysed on ice for 30 min in lysis buffer (50 mM Tris-HCl [pH 7.4], 150 mM 
NaCl, 1% Triton X-100, 10% glycerol) supplemented with a complete protease inhibitor 
tablet (Roche). Cell lysates were cleared by centrifugation at 15000 rpm for 10 min. The 
lysate protein concentration was estimated using a BCA protein assay kit (Pierce). For 
immunoprecipitation, 3 μg of antibody was added to 1 mg of cell lysate and incubated at 
4 °C for 4 hrs with protein A/G-agarose beads. After being extensively washed, the 
protein complex was boiled with sample buffer, separated by SDS-PAGE, transferred 
electrophoretically to a nitrocellulose membrane, and immunoblotted with appropriate 
antibodies followed by incubation with horseradish peroxidase-conjugated secondary 
antibodies. The blots were developed by the enhanced chemiluminescence technique 
(ECL kit, GE Biosciences). Representative results from at least two independent 
experiments are shown. 
2.3.5 GST pull-down assay 
Pull-down assays were performed with GST, GST fusion Peptide 1, or GST-
SrGAP-SH3 bound to reduced glutathione agarose after washing 3 times in Tris-buffered 
saline. Purified His-PRL-1 proteins or cell lysates containing HA-PRL-1 were added to 
immobilized GST fusions in binding buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% 
glycerol 0.5% Triton X-100, 5 mM EDTA and proteinase inhibitors cocktail) and 
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incubated for 2 hrs at 4°C in a tube rotator. After centrifugation, the beads were kept on 
ice and washed 3 times for 5 min each in washing buffer (50 mM Tris-HCl, pH 7.5, 150 
mM NaCl, 10% glycerol, 0.1% Triton X-100, 5mM EDTA and proteinase inhibitors 
cocktail). The washed beads were boiled in loading buffer for 5 min and separated in 
SDS-PAGE gel. Proteins were transferred to PVDF and immunostained with anti-His, 
anti-HA and anti-GST antibodies. 
2.3.6 Effector pull-down assay 
Effector pull-down assay was performed to monitor RhoA activity. Cells were 
lysed in a buffer containing 20 mM Tris-HCl, pH 7.6, 100 mM NaCl, 1% Triton X-100, 
10 mM MgCl2, 2 mM NaF, and protease inhibitors cocktail for 30 min at 4 °C. Cell 
lysate was incubated with the GST-RBD domain of Rhotekin immobilized on reduced 
glutathione agarose for 2hr at 4°C in a tube rotator. The level of active RhoA was 
detected by Western blotting with anti-RhoA antibody. 
2.3.7 GAP activity assay 
Immunoprecipitated p115 RhoGAP activity was measured by analyzing the ratio 
of GTP and GDP bound to RhoA as described (117). Recombinant human RhoA protein 
was purified as described (118) and was loaded with [α-32P] GTP by incubation 10 min 
at 30 °C, in 50 mM Tris  HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1 mg/mL BSA, 6 
μM GTP, 5 μCi [a-32P]GTP, 1 mM dithiothreitol.  MgCl2 was added to 10 mM and free 
nucleotide removed by washing beads 3X with the loading buffer minus GTP.  Proteins 
were then eluted by incubating beads with 100 μL of 100 mM Tris HCl, pH 8.0, 10 mM 
MgCl2 and 20 mM glutathione on ice for 20 min. GTP loaded RhoA was then incubated 
with Flag-p115 RhoGAP produced by transient transfection in 293 cells and 
immunoprecipitation with anti-Flag antibody in a 50 μL final reaction volume containing 
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25 mM Tris HCl (pH7.5), 1.5 mg/mL BSA, 7.5 mM MgCl2, 2 mM dithiothreitol at room 
temperature for 1 hr. The reaction was stopped by addition of 4 μL 0.5 M EDTA and 1 
μL 10% SDS and RhoA protein denatured by incubation at 68°C, 5 min and guanine 
nucleotides separated by thin layer chromatography on polyethyleneimine cellulose 
plates TLC plate (J. T. Baker, Inc., Phillipsburg, NJ) using 0.75 M KH2PO4/HCl, pH 3.4 
as solvent. Chromatograms were dried and Ras-bound GDP and GTP were visualized by 
autoradiography.  
2.3.8 Immunofluorescence and confocal microscopy 
Mouse Embryo Fibroblast (MEF) cells were cultured directly on glass coverslips 
in 6-well plates. Twenty-four hours later, cells were transfected with the indicated 
constructs. After an additional 24 h, cells were fixed with 4% paraformaldehyde in 
phosphate-buffered saline (PBS) for 10 min at room temperature, permeabilized with 0.2% 
Triton X-100 in PBS for 10 min, and blocked with BSA. Monoclonal antibody to Flag 
(M2) was applied for 1 h, followed by 1h incubation with Texas Red-conjugated anti-
mouse immunoglobulin G (Jackson ImmunoResearch Laboratories). DNA staining (0.5 
µg of Hoechst no. 33258/mL; Sigma) was used to identify cell nuclei. After washing with 
PBS, the coverslips were mounted with anti-fade mounting solution. Confocal 
microscope images were obtained with a Zeiss AxioObserverZ1 microscope with a Plan 
Apochromat ×63 oil immersion objective and processed with Zeiss Axiovision 4.7.  
2.3.9 Cell migration assay 
Cell migration was assessed as described previously (88) with some 
modifications. The assay was performed with Transwells (6.5 mM diameter; 8 μM pore 
size polycarbonate membrane) obtained from Corning (Costar, Acton, MA). Cells (3.75 
× 105) in 1.5 mL of serum-free medium were placed in the upper chamber, whereas the 
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lower chamber was loaded with 2.6 mL of medium containing 10% FBS. After 
incubation at 37 °C with 5% CO2 for 24 h, the total numbers of cells that migrated into 
the lower chamber was counted with a hemacytometer.  
2.3.10 siRNA knockdown 
Duplex siRNAs were provided by Proligo at a concentration of 50 μM. The 
siRNA sequences were as follows: human p115 RhoGAP-1, 5′- 
CUGAGGUGCCGCUGCUGGAdTdT (sense), 5′- 
UCCAGCAGCGGCACCUCAGdTdT (antisense), target position 2880; p115 RhoGAP-
2, 5′- GCGUGAAUGCCGAGGCCAAdTdT (sense), 5′- 
UUGGCCUCGGCAUUCACGCdTdT (antisense), target position 575. siRNAs were 
transfected by RNAiFect (Qiagen), and the knockdown of targeted genes was verified 
after 72 hrs by Western blotting analysis. 
2.3.11 Luciferase assay 
Luciferase assays were modified as previously described (88). Cells were 
transfected with SRE.L triple repeat promoter-luciferase construct (119). Cells were 
harvested and lysed 48 hrs after transfection. Luciferase activities were determined using 
the luciferase assay system (Promega, Madison, WI) according to the manufacturer’s 
specifications. Individual assays were normalized by internal Renilla luciferase activity. 
Experiments were performed in triplicate and repeated three times with similar results. 
The statistics were done using a Student’s t-test, with a P of <0.05 considered significant. 
2.3.12 Protein purification, crystallization and data collection 
PRL-1 without tag (residues 4-160) was sub-cloned into pET21a, and the vector 
was transformed into Escherichia coli BL21-(DE3). Transformed cells were grown at 
37°C in Luria broth (LB) containing 100 mg/mL ampicillin for 4 hrs until the OD600 
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reached 0.6, and then induced for overnight at room temperature with 0.4 mM IPTG. 
Cells were harvested by centrifugation (6000 rpm for 15 min at 4 °C), and the cell pellets 
from 1.5 L of LB medium were suspended in 30 mL of ice-cold buffer A consisting of 
50 mM NaCl, 20 mM MES (pH 5.8), and 1 mM EDTA. In this stage, trypsin inhibitor 
and PMSF were also added to buffer A to final concentration of 0.05 mg/mL and 0.1 
mM, respectively. The suspensions were passed twice through a French Press at 1000 
psi, and the cell lysates were centrifuged at 4 °C for 30 min at 15000 rpm. The 
supernatants were mixed with 0.5 g beads of CM Sephadex C50 (Sigma-Aldrich) at 4 °C 
for 1 h, and then the mixture was transferred to an empty column. The column was 
washed by 200 mL of buffer A, and then eluted with 20 mL of buffer B (500 mM NaCl, 
20 mM MES (pH 5.8), 5 mM DTT). The elution was dialyzed for 6 hrs at 4 °C against 1 
L buffer A, and then loaded onto a Mono S column equilibrated at 4 °C with buffer A. 
The column was washed with 10 mL of buffer A and then eluted with a 40 mL of linear 
gradient of 0 to 1 M NaCl in buffer A. The column fractions were analyzed by 
measuring the absorbance at 280 nm and by carrying out SDS-PAGE analysis. The 
fractions were combined and concentrated at 4 °C to ≤ 1 mL using an Amicon 
concentrator and then loaded onto a gel filtration column Superdex 75. The column was 
eluted with buffer A, and fractions which contain protein were combined and 
concentrated to 7 mg/mL and stored at −80 °C. The sample PRL-1 was shown to be 
homogeneous by SDS-PAGE analysis. 
PRL-1 (7 mg/mL) was mixed with Peptide 1 with a molar ratio of 1:2, and PRL-
1•Peptide 1 were co-crystallized by vapor diffusion in hanging drops at 4 °C. Drops 
containing 1:1 volumes of the protein in stock buffer (20 mM Tris-HCl, pH 7.5) and 
reservoir solution A (20% PEG 3350, 0.1 M NaCl, 0.1 M Bis-Tris pH 6.4) were 
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equilibrated against reservoir solution A. The crystal was transferred into reservoir 
solution B (28% PEG 3350, 0.1 M NaCl, 0.1 M Bis-Tris pH 6.4, 0.2 mM Peptide 1), 
soaked for 5 hours, and flash-cooled in liquid nitrogen. X-ray data were collected at 100 
K at SBC-CAT beamline 19-BM at the Advanced Photon Source (Argonne, IL) equipped 
with a mosaic CCD detector. All data were processed with HKL3000 (120). 
2.3.13 Structural determination and refinement 
The structure of PRL-1•Peptide 1 was solved by molecular replacement using 
program AMoRe (121). The structure of PRL-1 (PDB entry code 2ZCK) (23), without 
the solvent molecules, was used as the search model. The structure was refined to 2.8 Å 
resolution with the program CNS1.1 (122). The progress of the refinement was evaluated 
by the improvement in the quality of the electron density maps, and the reduced values 
of the conventional R factor and the free R factor (123) (3.3% of the reflections omitted 
from the refinement). Electron density maps were inspected and the model was modified 
on an interactive graphics workstation with the program O (124). Finally, water 
molecules were added gradually as the refinement progressed. They were assigned in the 
Fo - Fc difference Fourier maps with a 3σ cutoff for inclusion in the model. 
2.4 Results 
2.4.1 Identification and characterization of a PRL-1 binding peptide 
In order to discover new PRL-1 binding proteins and get new insight into the 
mechanism that accounts for PRL-1 mediated ERK1/2 and RhoA, I screened a 12-mer 
phage display peptide library against (His)6-tagged recombinant PRL-1 and identified 
Peptide 1 (GWWSLIPPKYIT) as a putative PRL-1 binding peptide. Consistent with this 
peptide interacting with PRL-1, purified GST-Peptide 1 fusion protein, but not GST, was 
capable of precipitating (His)6-tagged recombinant PRL-1 from solution (Figure 5A, 
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Figure 5. Identification and characterization of a PRL-1-binding Peptide 1. 
A. In vitro GST pulldown assay verified the interaction between His6-tagged PRL-1 and 
GST-Peptide 1. B. Synthetic Peptide 1 blocks binding between PRL-1 and GST-Peptide 
1. C. GST-Peptide 1 pulls down HA-tagged PRL-1 from HEK293 cell lysate. D. GST-
Peptide 1 co-immunoprecipitates (IP) HA-PRL-1 from HEK293 cells. Data shown are 
representative of triplicate experiments with similar results. Panel A, C and D were 
generated by Yong Luo. 
 
created by Yong Luo). The concentration dependent displacement of PRL-1 from GST-
Peptide 1 fusion protein by synthetic Peptide 1 but not by a scrambled peptide indicates 
the specificity of this interaction (Figure 5B). In addition, GST-Peptide 1 pulled down 
HA-PRL-1 from HEK293 cell lysate (Figure 5C, created by Yong Luo), and GST-
Peptide 1 readily co-immunoprecipitated with HA-PRL-1 when both were expressed in 
HEK293 cells (Figure 5D, created by Yong Luo). Collectively, these results indicate that 
Peptide 1 directly binds PRL-1 both in solution and in mammalian cells.  
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2.4.2 Identification of p115 RhoGAP as a PRL-1 binding protein 
Then we launched a BLAST search using Peptide 1 as a query to identify PRL-1 
binding proteins. The top hit was the human protein p115 RhoGAP (125), a member of 
the Slit-Robo (Sr) GAP family of proteins that have attributed roles in axon guidance 
and cell migration (93,126). All members of the SrGAP family (SrGAP1, 2, 3 and p115 
RhoGAP) contain an N-terminal Fes/CIP4 (Cdc42-interacting protein 4) homology 
(FCH) domain, a central RhoGAP domain and a C-terminal SH3 domain (125,127). 
Because Peptide 1 shares strong sequence identity with contiguous residues in the SH3 
domains of all srGAP proteins (Figure 6A), we compared their relative association with 
PRL-1 by co-immunoprecipitation.  For this purpose, Flag-tagged p115 RhoGAP, 
SrGAP1, 2, and 3 were transfected into HEK293 cells stably expressing HA-PRL-1. 
Protein complexes were immuno-isolated from cell lysates using anti-HA antibody and 
immunoblotted with antibodies against Flag or HA. The result revealed that PRL-1 co-
immunoprecipitates with all SrGAP family members (Figure 6B, generated by Yong 
Luo). Consistently, GST pulldown assays demonstrated that PRL-1 directly binds the 
SH3 domains of each SrGAP (Figure 6C, generated by Yong Luo), but not to a truncated 
p115 RhoGAP lacking its SH3 domain nor to ArhGAP9, an SH3 domain containing 
RhoGAP that is not in the SrGAP family (Figure 6D). Further, GST-Peptide 1 disrupts 
the intracellular association between PRL-1 and p115 RhoGAP (Figure 6E).  These 
findings suggest that PRL-1 binds p115 RhoGAP through a short motif in its SH3 
domain.  
We next examined the subcellular co-distribution of PRL-1 and p115 RhoGAP. 
Flag-tagged p115 RhoGAP and GFP-tagged PRL-1 were co-expressed in mouse 
embryonic fibroblast cells and their cellular localization was visualized by confocal  
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 Figure 6. Identification of p115 RhoGAP as a PRL-1-binding protein. 
A. Sequence alignment between Peptide 1 and p115 RhoGAP, SrGAP1, SrGAP2, and 
SrGAP3. B. HA-tagged PRL-1 immunoprecipitates (IP) p115 RhoGAP, SrGAP1, 
SrGAP2, and SrGAP3 from HEK293 cells. C. Recombinant His6-tagged PRL-1 binds 
the SH3 domains of p115 RhoGAP, SrGAP1, SrGAP2, and SrGAP3 in a GST pulldown 
assay. D. The interaction between PRL-1 and p115 RhoGAP depends on the SH3 domain 
of p115 RhoGAP. E. GST-Peptide 1 disrupts the interaction between HA-PRL-1 and 
FLAG-p115 RhoGAP inside HEK293 cells. F. Subcellular co-localization of PRL-1 and 
p115 RhoGAP in mouse embryonic fibroblast cells. Cells were processed for imaging 
within 24 hours after transfection with GFP-PRL-1, Flag-p115 RhoGAP, Flag-p115 
RhoGAPΔSH3, or GST-Peptide 1. p115 RhoGAP or p115 RhoGAPΔSH3 was detected 
by indirect immunostaining for the flag epitope (Red), Nuclei were stained with Hoechst 
no. 33258 dye (Blue) while GFP-PRL-1 (Green) was directly visualized. The images 
from merging the three confocal fluorescence channels are depicted where co-localization 
between red and green is seen as yellow. G. Endogenous PRL-1 immunoprecipitates 
endogenous p115 RhoGAP in H1299 cells. The Western blot shown is representative of 
triplicate experiments with similar results. Panel B and C were generated by Yong Luo. 
 
observations (15), PRL-1 was associated with plasma membrane as well as intracellular 
punctate structures dispersed throughout the cytoplasm. Similar to earlier finding that 
p115 RhoGAP localizes to the leading edges of cells via the FCH domain (93), we 
observed that p115 RhoGAP resides primarily at the cell periphery and this pattern of 
localization is independent of the SH3 domain. In agreement with our findings that p115 
RhoGAP biochemically associates with PRL-1, these two proteins highly co-localized at 
the plasma membrane and at the leading edges of cells. However, a mutant of p115 
RhoGAP lacking the SH3 domain showed no co-localization with PRL-1. In addition, 
co-transfection of GST-Peptide 1 abrogated the co-localization of p115 RhoGAP and 
PRL-1. Taken together, these results support the conclusion that p115 RhoGAP is a 
specific PRL-1 binding protein and that a motif within the SH3 domain of p115 
RhoGAP is required for binding PRL-1. We further suggest that Peptide 1 and a region 
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within the SH3 domain of p115 RhoGAP bind a common site in PRL-1. Finally, we 
determined whether PRL-1 can bind p115 RhoGAP under endogenous conditions. PRL-
1 is overexpressed in many lung cancer cell lines, including H1299 cells (95). 
Knockdown of PRL-1 in H1299 cells significantly decreases cell proliferation and 
migration (88). To demonstrate direct association of PRL-1 and p115 RhoGAP in H1299 
cells, we used anti-PRL-1 antibodies to immunoprecipitate endogenous PRL-1. As 
shown in Figure 6G, we detected p115 RhoGAP in the PRL-1 immunoprecipitates, 
indicating endogenous association between PRL-1 and p115 RhoGAP. 
2.4.3 Structural basis of PRL-1 interaction with Peptide 1/SH3 domain of p115 
RhoGAP 
To elucidate the molecular basis by which PRL-1 recognizes Peptide 1 and most 
likely the SH3 domain of p115 RhoGAP, we solved the crystal structure of PRL-1 in 
complex with Peptide 1 at 2.8 Å resolution. Data collection and structural refinement 
statistics are summarized in Table 2 (Generated by Sijiu Liu). The final atomic model 
encompasses residues 9-160 of PRL-1 in a complex with residues 4-12 of Peptide 1, as 
revealed by the unbiased Fo-Fc omit density map (Figure 7A, generated by Sijiu Liu). 
Peptide 1 binds PRL-1 in an extended β-strand conformation that lies 18 Å away from 
the PRL-1 active site (defined by the P-loop (H103CVAGLGR110)) and 20 Å from the C-
terminus of PRL-1 (Figure 7B, generated by Sijiu Liu). Complex formation between 
PRL-1 and Peptide 1 buries a contiguous surface area of 1,140 Å2 in PRL-1.  
The structure of the PRL-1•Peptide 1 complex defines a novel protein-protein 
interaction site in PRL-1 through an unexpected mode of interaction with the SH3 
domain of p115 RhoGAP. The first three residues in Peptide 1 are invisible in the 
structure, and Ser4 is exposed to solvent. Thus interactions between PRL-1 and these 
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Table 2. Data collection and refinement statistics for PRL-1•Peptide 1 complex 
Space group I 213 
Cell dimensions a=146.5, b=146.5, c=146.5 Å 
Data collection 
    Resolution range (Å) 
    No. of unique reflections 
    Completeness (%) 
    Redundancy 
    Rmergeb 
  
50.0 – 2.5 
18,287 
99.9 (99.8)a 
24.9 
0.150 (0.872)a 
Refinement 
    Resolution range (Å) 
    No. of reflections used (F≥1.5δ (F)) 
    No. of protein atoms 
    No. of peptides 
    No. of waters 
    Rworkc/Rfreed 
 
50.0 – 2.8 
12,045 
2,280 
2 
38 
18.0/20.1 
r.m.s.d.e from ideal geometry 
    Bond length (Å) 
    Bond angle  
 
0.008 
1.33° 
Average B-factors (Å2) 
    Overall 
    Protein 
    Peptide 1 
    Waters 
 
65.80 
65.45 
72.16 
61.56 
aThe values in parentheses correspond to the highest resolution shell (2.54  – 2.50 Å) 
bRmerge = ΣhΣi|I(h)i - <I(h)>|/ΣhΣiI(h)i. 
cRwork = Σh|F(h)calcd - F(h)obsd|/ΣF(h)obsd, where F(h)calcd and F(h)obsd were the refined calculated and 
observed structure factors, respectively. 
dRfree was calculated for a randomly selected 3.3% of the reflections that were omitted from refinement. 
er.m.s.d., root mean square deviation. 
 
residues, if present, are likely to be weak. Detailed interactions between PRL-1 and the 
rest of Peptide 1 are shown in Figure 7C (Generated by Sijiu Liu). Leu5 in Peptide 1 is 
engaged in hydrophobic interactions with residues Asp54 and Thr56 in PRL-1. Ile6 is 
within Van der Waals contacts with residue Asp54 and forms two weak polar interactions 
with the side-chains of Asp54 and Thr55. Hydrophobic interactions are observed between 
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Pro7 of Peptide 1 and the side-chain of Thr55 and the phenyl ring of Try53 in PRL-1. 
Pro8 is also within Van der Waals contacts with Thr55. Both Lys9 and Tyr10 contact 
PRL-1 residue His64. In addition, hydrophobic interactions exist between Tyr10 and the 
side-chains of Asp67 and Trp68, and Ile11 may interact with residues Leu66 and Trp68. 
Finally, Thr12 may form weak interactions with PRL-1 residues Trp68 and Gln79.  
 
Figure 7. Structural basis of PRL-1 interaction with Peptide 1. 
A. Overall structure of PRL-1 in complex with Peptide 1. The peptide is shown in stick 
model with the unbiased omit Fo-Fc density map contoured at 3.0σ. The P-loop and C 
terminus are shown in green and red, respectively. B. Surface representation of PRL-1 in 
complex with Peptide 1, colored by electrostatic potential calculated by DelPhi. C. Stereo 
diagram of the interactions between residues in PRL-1 (yellow) and Peptide 1 (green). D. 
Identification of the region in PRL-1 responsible for binding p115 RhoGAP by GST 
pulldown assay. E. Substitution of PRL-1 Tyr-53, His-64, and Trp-68 impairs its ability 
to bind GST-Peptide 1. F. Substitution of PRL-1 Tyr-53 and Trp-68 abrogates its ability 
to bind p115 RhoGAP in HEK293 cells. Western blots are representative of triplicate 
experiments with similar results. Panel A, B and C were generated with PyMol (DeLano 
Scientific; http:/www.pymol.org) by Sijiu Liu. 
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The residues within PRL-1 that are predicted to contact Peptide 1 from our 
structural data were probed for their requirement for interaction with both Peptide 1 and 
p115 RhoGAP. Serial truncations from either the N- or C-terminus of PRL-1 (full length 
1-173) indicated that residues 1-120 and 30-173 can still bind GST-Peptide 1, whereas 
fragments containing 1-90, 60-173, and 90-173 displayed no detectable binding (Figure 
7D). The results suggest that Peptide 1 likely binds within residues 30-120 in PRL-1. 
Additionally, the binding affinity of PRL-1 for Peptide 1 was significantly diminished 
when His64 was replaced by an Ala, and completely abolished when Tyr53 or Trp68 
were changed to an Ala (Figure 7E). Importantly, the latter two mutants also lacked the 
ability to immunoprecipitate p115 RhoGAP in HEK293 cells (Figure 7F). These results 
are in complete agreement with the structural observations that residues from Tyr53 to 
Gln79 in PRL-1 are involved in binding Peptide 1. Importantly, residues within Peptide 
1 binding site are most likely also required for binding the analogous region within the 
SH3 domain of p115 RhoGAP. 
Taken together, these results reveal a novel mode of interaction between an SH3 
domain and its binding partner where PRL-1 serves as the receptor for recognizing a 
sequence motif (corresponding to Peptide 1 residues Leu5-Thr12) within the SH3 domain 
of p115 RhoGAP. As shown in the crystal structure of SrGAP1 SH3 domain (128), 
Pro793 and Tyr796 (Pro7 and Tyr10 in Peptide 1) form ligand binding pocket 2 and 
Leu791 (Leu5 in Peptide 1) lines ligand binding pocket 3. Since there is no PxxP 
sequence in PRL-1 and residues involved in binding Peptide 1 are non-contiguous 
(Figure 7C), the recognition of Peptide 1/p115 RhoGAP SH3 domain by PRL-1 
represents a novel protein-protein interaction, which differs from the canonical SH3 
domain/PxxP binding mode. 
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2.4.4 p115 RhoGAP negatively regulates PRL-1 mediated cell migration and 
ERK1/2 and RhoA activation 
It is well documented that PRL-1 promotes cell migration through activation of 
ERK1/2 and RhoA pathways (16,17,88,113). It is also reported that p115 RhoGAP 
inhibits cell motility through its GAP domain and the C-terminal SH3 domain (93). To 
understand the functional significance of the novel PRL-1/p115 RhoGAP interaction, we 
evaluated the effect of modulating expression of p115 RhoGAP on PRL-1 mediated cell 
migration as well as on ERK1/2 and RhoA activity. We found that overexpression of 
p115 RhoGAP in cells stably transfected with PRL-1 diminished PRL-1 induced cell 
migration (Figure 8A), whereas p115 RhoGAP knock-down by siRNA enhanced PRL-1 
induced cell migration (Figure 8B). Moreover, overexpression of p115 RhoGAP also 
reduced PRL-1 mediated ERK1/2 and RhoA activation (Figure 8C). The negative effect 
of p115 RhoGAP on RhoA signaling was further confirmed by a 40% decrease in the 
transcriptional activity of the RhoA specific reporter SRE.L (Figure 8D, generated by 
Yong Luo). We conclude that p115 RhoGAP plays a negative role in PRL-1 mediated 
cell migration by down-regulating both ERK1/2 and RhoA activity.  
2.4.5 Mechanism of PRL-1 mediated ERK1/2 and RhoA activation 
p115 RhoGAP has been previously found to associate with and inhibit 
MAP/ERK kinase kinase 1 (MEKK1) through its SH3 domain (94). MEKK1 is the 
essential upstream kinase that phosphorylates and activates ERK1/2 and is required for 
cell motility. Because the region in the SH3 domain of p115 RhoGAP that corresponds 
to residues Leu5-Thr12 in Peptide 1 makes up the center of the PxxP ligand binding site, 
PRL-1 binding to this site was predicted to block canonical interactions by this domain. 
We further speculated that one consequence of such displacement of MEKK1 from p115 
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Figure 8. p115 RhoGAP negatively regulates cell migration and ERK and RhoA activation. 
A. Overexpression of p115 RhoGAP inhibits cell migration in both control HEK293 cells 
and PRL-1-expressing HEK293 cells. B. Knockdown of p115 RhoGAP enhances cell 
migration in both control HEK293 cells and PRL-1-expressing HEK293 cells. C. 
Overexpression of p115 RhoGAP reduces ERK1/2 and RhoA activation in both control 
HEK293 cells and PRL-1-expressing HEK293 cells. D. p115 RhoGAP decreases RhoA-
specific reporter activity. Results shown are representative of triplicate experiments with 
similar results. Results are presented as means ± S.D. *, P<0.01. Rel. FL/RL, relative 
fluorescence/Renilla luciferase. Panel D was generated by Yong Luo. 
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RhoGAP by PRL-1 would be the activation of ERK1/2. To test this hypothesis, control 
and cells expressing PRL-1 were transfected with Flag-tagged p115 RhoGAP and the 
amount of p115 RhoGAP associated with MEKK1 as well as the phosphorylation status 
of ERK1/2 were measured. Compared to control cells, the fraction of p115 RhoGAP 
associated with MEKK1 was reduced and the ratio of phosphorylated ERK1/2 was 
increased in PRL-1 cells (Figure 9A). This effect is likely specific, as expression of GST-
peptide 1 restored the level of p115 RhoGAP associated with MEKK1 and concordantly 
reduced ERK1/2 phosphorylation (Figure 9A). Thus, PRL-1 interaction with p115 
RhoGAP likely mitigates the inhibitory effect of p115 RhoGAP on MEKK1, resulting in 
ERK1/2 activation.  
Given that p115 RhoGAP inhibits RhoA by accelerating its catalysis of GTP 
hydrolysis to GDP (94,125), we investigated whether PRL-1 binding to p115 RhoGAP 
could modulate its ability to regulate RhoA activity. To this end, immunoprecipitated 
Flag-tagged p115 RhoGAP or p115 RhoGAP/ΔSH3 from either control or PRL-1 cells 
was incubated with purified GST-RhoA loaded with a-32P-labeled GTP. The data 
revealed that p115 RhoGAP from PRL-1 cells showed significantly lower GAP activity 
than that from the control cells (Figure 9B, generated by Yong Luo). This inhibitory 
effect of PRL-1 on p115 RhoGAP activity likely occurs via interaction with the SH3 
domain as p115 RhoGAP/ΔSH3 exhibited equal GAP activity in PRL-1 expressing or 
control cells (Figure 9B). To further define the mechanism by which PRL-1 inhibits the 
GAP activity of p115 RhoGAP, we measured the effect of PRL-1 on the binding of p115 
RhoGAP to RhoA/G14V, a constitutively active form of RhoA that stably associates 
with the GAPs due to resisting GTP hydrolysis. Control and PRL-1 expressing cells 
were transfected with Myc-RhoA/G14V and Flag-tagged p115 RhoGAP or p115 
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RhoGAP/ΔSH3. The amount of RhoA/G14V associated with p115 RhoGAP or p115 
RhoGAP/ΔSH3 was visualized by Western blot. The observation that both the full length 
and the SH3 domain deleted p115 RhoGAP bound RhoA/G14V indicates that 
recognition of RhoA by p115RhoGAP does not require its SH3 domain. In stark contrast, 
the ability of PRL-1 to block the interaction between RhoA/G14V and p115 RhoGAP 
strongly depended on the presence of the SH3 domain (Figure 9C). Apparently, 
association of PRL-1 with the SH3 domain of p115 RhoGAP prevents p115 RhoGAP 
from binding RhoA, which results in increased levels of GTP bound RhoA. Finally, 
PRL-1 mutants (PRL-1/Y53A and PRL-1/W68A), which are defective in binding p115 
RhoGAP, were unable to activate ERK1/2 or RhoA (Figure 9D). This indicates that 
physical interaction between PRL-1 and p115RhoGAP is a prerequisite for PRL-1 
mediated ERK1/2 and RhoA activation.  
2.5 Discussion 
PRLs are implicated in tumorigenesis and metastasis, but the underlying 
mechanism is still elusive. Even if increasing amount of effort has been put into the 
establishment of PRLs-mediated signaling pathways, little study is focused on the 
discovery of natural substrates or binding partners of PRLs. To date, only a limited 
number of proteins have been suggested as substrates or interaction proteins: Ezrin (129), 
Keratin 8 (130), Integrin β1 (131), and Stathmin (132). Unfortunately, those molecules 
have so far not been placed into direct context with the pathways affected by PRLs. Thus, 
the identification of substrate(s) and binding partners of PRLs is the first step to have a 
better understanding on the mechanisms of PRLs action.  
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To this end, we utilized phage display method and tried to identify potential 
PRL-1 binding partners. Phage display is a technique designed to study protein-peptide 
interactions, in which bacteriophage particles are bioengineered to express a peptide  
 
Figure 9. Molecular mechanisms of PRL-1-mediated ERK1/2 and RhoA activation. 
A. PRL-1 activates ERK1/2 by displacing MEKK1 from p115 RhoGAP. B. PRL-1 
inhibits the GAP activity of p115 RhoGAP through its interaction with the SH3 domain 
of p115 RhoGAP. C. PRL-1 directly blocks the interaction between p115 RhoGAP and 
RhoA (G14V) in an SH3 domain-dependent manner. D. PRL-1-mediated ERK1/2 and 
RhoA activation requires physical interaction between PRL-1 and p115 RhoGAP. Results 
shown are representative of triplicate experiments with similar results. Panel B was 
generated by Yong Luo. 
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library of interest fused to coat protein. In this dissertation, I used PH.D.-12 phage 
display peptide library kit from New England Biolabs. This phage display kit contains 
combinatorial library of random 12-mer peptides fused to a minor coat protein (PIII) of 
M13 phage. The titer of the library is 1.5×1013 pfu. The library contains a complexity of 
2.7×109 sequences. After four rounds of screening, several 12-mer peptides have been 
identified as PRL-1 binding peptides. By performing a BLAST search, Peptide 1 
(GWWSLIPPKYIT) matched a sequence motif in the SH3 domain of p115 RhoGAP.  
p115 RhoGAP is a member of the Slit-Robo (Sr) GAP family (SrGAP1, 2, 3 and 
p115 RhoGAP) that are implicated in axon guidance and cell migration through 
inactivation of Rho GTPases (93,126). The Rho family small GTPases act as molecular 
switches involved in fundamental cellular process. Three widely expressed members, 
RhoA, Rac1 and Cdc42 are the best characterized family members. This family of 
proteins has intrinsic GTPase activity and cycle between an active GTP-bound form and 
an inactive GDP-bound form. Guanine nucleotide exchange factors (GEFs) and GTPase 
activating proteins (GAPs) are two major classes of regulators that modulate the 
activation of GTPases. GEFs activate Rho GTPases by accelerating the release of 
guanosine diphosphate (GDP) to allow binding of new guanosine triphosphate (GTP). 
GAPs enhanced the intrinsic GTPase activity of Rho, leading to their inactivation 
(133,134). Given the role of PRL-1 in activating RhoA, we tested the hypothesis that 
PRL-1 binds to and inhibits p115 RhoGAP to turn on RhoA activation. This notion is 
supported by the data that PRL-1disrupted the interaction between p115 RhoGAP and 
RhoA/G14V, a constitutively activated RhoA. 
p115 RhoGAP has been implicated in MAP kinase pathway by the discovery of 
its interacting protein MEKK1 (94). MEKK1 is a MAP kinase kinase kinase linked to 
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ERK1/2 and JNK MAP kinase cascades (135,136). Mekk1-null cells are defective in cell 
migration, suggesting that MEKK1 is required for cell motility. The interaction between 
p115 RhoGAP and MEKK1 may prevent the association between MEKK1 with other 
components in MAP kinase pathways, leading to ERK1/2 inactivation (94). Given the 
positive role of PRL-1 in activating MAP kinase pathway and that PRL-1 shares the 
same binding site on p115 RhoGAP with MEKK1, we might expect that PRL-1 
association with p115 RhoGAP might block the interaction between p115 RhoGAP and 
MEKK1 and release MEKK1 from the inhibitory effect of p115 RhoGAP. Our data 
support this possibility, because PRL-1 overexpression reduced the interaction between 
p115 RhoGAP and MEKK1 by co-IP experiment. 
In summary, starting from an unbiased screen for PRL-1 effectors, we have 
identified p115 RhoGAP as a bona fide PRL-1 binding protein. Biochemical and cellular 
studies suggest that the SH3 domain of p115RhoGAP is required for its interaction with 
PRL-1. Structural analyses reveal that this interaction occurs via a novel protein-protein 
interaction whereby PRL-1 recognizes a conserved sequence motif in the canonical PxxP 
ligand binding site of the SH3 domain in p115 RhoGAP. The interaction between PRL-1 
and p115 RhoGAP coordinately activates the ERK1/2 pathway by displacing MEKK1 
from p115 RhoGAP and it activates RhoA by preventing its interaction with p115 
RhoGAP. Our study not only offers a mechanistic explanation for ERK1/2 and RhoA 
activation by PRL-1, but also identifies a novel p115 RhoGAP binding site in PRL-1 for 
the development of anticancer therapeutics by blocking the interaction between PRL-1 
and p115 RhoGAP. 
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CHAPTER 3: TARGETING PRL-1 TRIMER INTERFACE FOR NOVEL 
ANTICANCER AGENT  
3.1 Overview 
The PRL phosphatases belong to a novel PTP subfamily that has three members 
(PRL-1, 2 and 3), sharing a high degree (>75%) of amino acid sequence identity (11-13). 
PRL-1 expression was found to be elevated in many tumor cell lines, and cells 
expressing high levels of PRL-1 exhibited enhanced proliferation and anchorage-
independent growth (11,12,95,96). PRL-2 level is also elevated in different cancers, such 
as prostate cancer (69). Overexpression of PRL-3 in HEK293 cells also leads to higher 
growth rates (25). In addition, expression of PRL-3 was found to be highly increased in 
colon cancer liver metastasis but not in non-metastatic tumors or in normal colorectal 
epithelium (29). PRL-1 and PRL-3 display activity to enhance cell motility and 
invasiveness and induce metastatic tumor formation in mice (13,86). All these 
observations suggest that PRLs play a critical role in cancer development and metastatic 
progression, and that PRLs are potential targets for anti-cancer therapeutic development. 
However, no clinically useful and specific inhibitors of PRLs have been reported, despite 
extensive efforts having been taken to identify them (103,104). 
3.2 Hypothesis and Specific Aims 
Since all PRLs are implicated in tumor progression and metastasis, there is 
considerable interest in identifying small molecule inhibitors targeting PRLs for novel 
anti-cancer agents. Although it is difficult to make isozyme-specific PRL inhibitors due 
to the high sequence similarity among the three PRLs and the unusual wide and shallow 
catalytic pockets of PRLs revealed by structure studies (21-23,137), there still are several 
small molecules reported to inhibit PRL activity (103-108). However, further 
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investigations are required to validate the specificity and efficacy of these compounds in 
inhibiting tumorigenesis and metastasis. On the other hand, since the structures of PRL-1 
solved by us and others revealed an identical trimeric arrangement (22,23,137), 
interference with PRL trimerization would be an alternative to inhibition of the 
phosphatase activity. Trimerization provides a membrane-binding surface with polybasic 
residues and the adjacent prenylation group to anchor PRL-1 on the acidic inner 
membrane. Given the high homology among the three PRLs, trimerization revealed in 
PRL-1 may be a general property for all PRL enzymes (17). In addition, PRL-1 trimer 
formation appeared to be essential for the PRL-1-mediated cell growth and migration 
(17). Most importantly, PRLs are highly expressed in many human cancer types, but no 
evidence for point mutations in PRLs have been found, suggesting that overexpression-
induced PRL trimerization may be important for malignancies. Thus, I hypothesized that 
targeting the trimer interface of PRLs is a novel approach to develop small 
molecule inhibitors for cancer treatment. To test this hypothesis, I developed two 
specific aims: 1) to identify small molecule inhibitors targeting PRL-1 trimer interface 
and blocking PRL-1 trimer formation; and 2) to test the anti-cancer activity of PRL-1 de-
trimer inhibitors in cell based assays. These goals are designed to establish a novel 
strategy to develop PRLs inhibitors by targeting PRLs trimer interface and to 
demonstrate the potential value of PRLs trimer disruptor for anti-cancer therapy.  
3.3 Materials and Methods 
3.3.1 Virtual screening 
Asinex and ChemBridge subsets in ZINC (138) database were used as small 
molecule library for virtual screening, the coordinates were downloaded from ZINC 
website (http://zinc.docking.org) in mol2 file format. The monomer B of PRL-1 trimer 
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structure (23) (PDBID: 1ZCK) was used as receptor, and the coordinates were retrieved 
from the Protein Data Bank. DOCK6.2 program (139,140) was firstly used for rigid 
docking to result in a potential subset of PRL-1 trimer interface binding molecules, and 
then AutoDock4.01 software (141,142) was used for flexible docking to perform more 
accurate binding energy evaluation and get the most potent hit molecules. 
In the first stage docking, the structure of monomer B was processed using the 
“Dock Prep” module in UCSF CHIMERA (143), then the docking region was defined 
through a standard pipeline of running dms, sphgen, sphere_selector and showbox 
program, and the energy scoring values were calculated by grid program. About 560000 
small molecules (downloaded in 28 mol2 files, ~20000 molecules in each file) were 
submitted to dock6.mpi program to perform docking calculations simultaneously. During 
each docking, the small molecule was positioned by automated matching algorithm with 
1000 orientations, the lowest interaction energy and related conformation was recorded. 
All ligands in each mol2 file were ranked according to their lowest interaction energy, 
and top 2000 were kept for the second stage docking, that is to say, 2000 × 28 = 56000 
molecules were picked out for next screening. 
In the secondary stage docking, the structure of monomer B was processed in 
AutoDockTools1.4 software, non-polar hydrogens were merged, Gasteiger charge and 
solvation parameter were added. The docking area was designated around the surface on 
the monomer B which constitute the BA or BC interface, and the energy grids of 51 × 51 
× 63 points with 0.375 Å spacing on each axis were calculated for 17 atom types (H, HD, 
HS, C, A, N, NA, NS, OA, OS, F, P, SA, S, Cl, Br and I), as well as the electrostatic and 
desolvation potential using autogrid4 program; On the other hand, each ligand structure 
was used to generate pdbqt and dpf files using prepare_ligand4.py and prepare_dpf4.py 
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scripts. Based on these prepared files, molecular docking was carried out in autodock4 
program as follows: 10 separate docking runs were performed for each ligand. In each 
docking run, the optimal binding conformation was achieved by Lamarckian Genetic 
Algorithm with Local Search (LGALS) method. After all ligands were docked, the 
lowest binding free energy of each ligand was extracted and ranked, and hit molecules 
were picked out through binding free energy comparisons, structure similarity analyses 
and binding mode inspections. 
3.3.2 Cell culture and transfection 
HEK293 cells, H1299 cells and MDA-MB-231 cells were grown in DMEM 
supplemented with 10% fetal bovine serum, penicillin (50 units/mL), and streptomycin 
(50 μg/mL) in a 37°C incubator containing 5% CO2. HEK293 cells were seeded at 40% 
confluence in antibiotic-free medium and grown overnight. Transfection was performed 
using Lipofectamine 2000 from invitrogen according to the manufacturer’s 
recommendations.  
3.3.3 Immunoblotting and immunoprecipitation 
HEK293 cells were grown to 70% confluency, washed with ice-cold phosphate-
buffered saline, and lysed on ice for 30 min in lysis buffer supplemented with a complete 
protease inhibitor tablet (Roche). Cell lysates were cleared by centrifugation at 15000 
rpm for 10 min. For immunoprecipitation, 3 μg of each antibody was added to 1 mg of 
cell lysate and incubated at 4 °C for 4 hrs with protein A/G-agarose beads. After being 
extensively washed, the protein complex was boiled with sample buffer, separated by 
SDS-PAGE, transferred electrophoretically to a nitrocellulose membrane, and 
immunoblotted with appropriate antibodies followed by incubation with horseradish 
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peroxidase-conjugated secondary antibodies. The blots were developed by the enhanced 
chemiluminescence technique (ECL kit, GE Biosciences).  
3.3.4 In vitro and in vivo cross-linking assay 
To assess the oligomeric state of PRL-1 in vitro, the (His)6-tagged recombinant 
PRL-1 proteins were cross-linked with glutaraldehyde (Sigma, 25% glutaraldehyde 
solution, grade I). The reactions were performed in 20 μL solutions containing 5 μg of 
protein in phosphate-buffered saline (PBS, pH 7.5). Recombinant PRL-1 was treated 
with 10 μM compound for 30 min, and then cross-linked by incubating with 0.005% 
glutaraldehyde at room temperature for 10 min. The reaction was terminated by addition 
of pH 7.5 Tris-HCl (final concentration 50 mM) and 5 min incubation on ice. The 
samples were separated on SDS-PAGE and analyzed by Coomassie Blue staining. For in 
vivo cross-linking, HEK293 cells with 90% confluence were treated with 20 μM 
compound as indicated for 24 hours, and then fixed with 1% formaldehyde (Thermo, 16% 
formaldehyde solution) for 10 min at room temperature. Cells were washed twice in ice-
cold PBS and lysed on ice for 30 min following by immunoprecipitation with HA 
antibody. The reaction mixtures were analyzed by SDS-PAGE and detected by 
immunoblotting with anti-HA antibody (Santa Cruz).  
3.3.5 Wound healing assay 
Cells were grown to 90% confluence in a 12-well plate at 37 °C in an atmosphere 
of 5% CO2. A wound was created by scratching cells with a sterile 200 μL pipette tip. 
Cells were washed with PBS to remove the floating cells, and then treated with fresh 
medium containing 20 μM compound or DMSO. The wounds were photographed at 0 
hour and 24 hours under ×10 magnitude microscope. Wound healing magnitude was 
52 
 
quantified by measuring the relative wound closure compared with control cells at 24 
hours. 
3.3.6 MTT assay 
Cells were seeded in a 96-multiwell plate (1000 cells/well) containing DMEM, 
10% fetal bovine serum at 37 °C in an atmosphere of 5% CO2 overnight. Cells were then 
treated with various concentrations of compounds or DMSO for 24 and 48 hours. Cell 
proliferation was then determined by MTT assay as described previously (17) using a 
multiwall spectrophotometer (Victor 2, PerkinElmer Life Sciences). Data are presented 
as relative proliferation rate compared with control cells. 
3.3.7 Cell migration assay  
Cell migration was assessed as described previously (137) with some 
modifications. The assay was performed with Transwells (6.5 mM diameter; 8 μM pore 
size polycarbonate membrane) obtained from Corning (Costar, Acton, MA). Cells (3.75 
× 105) in 1.5 mL of serum-free medium were placed in the upper chamber, whereas the 
lower chamber was loaded with 2.5 mL of medium containing 10% FBS. Cells were 
then treated with 10 μM of different compounds as indicated. After 24 hour incubation 
(37 °C, 5% CO2), the total number of cells that had migrated into the lower chamber was 
counted with a hemacytometer. Data are presented as relative migration rate compared 
with control cells. 
3.3.8 Expression and purification of PRL-1  
PRL-1 without tag (residues 4-160) was sub-cloned into pET21a. For protein 
expression, PRL-1 was transformed into Escherichia coli BL21-(DE3). Transformed 
cells were grown at 37°C in Luria broth (LB) containing 100 mg/mL ampicillin for 4 hrs 
until the OD600 reached 0.6, and then induced for overnight at room temperature with 
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0.4 mM IPTG. Cells were harvested by centrifugation (6000 rpm for 15 min at 4 °C), 
and the cell pellets from 1.5 L of LB medium were suspended in 30 mL of ice-cold 
buffer A consisting of 50 mM NaCl, 20 mM MES (pH 5.8), and 1 mM EDTA. In this 
stage, trypsin inhibitor and PMSF were also added to buffer A to final concentration of 
0.05 mg/mL and 0.1 mM, respectively. The suspensions were passed twice through a 
French Press at 1000 psi, and the cell lysates were centrifuged at 4 °C for 30 min at 
15000 rpm. The supernatants were mixed with 0.5 g beads of CM Sephadex C50 
(Sigma-Aldrich) at 4 °C for 1 h, and then the mixture was transferred to an empty 
column. The column was washed by 200 mL of buffer A, and then eluted with 20 mL of 
buffer B (500 mM NaCl, 20 mM MES (pH 5.8), 5 mM DTT). The elution was dialyzed 
for 6 hrs at 4 °C against 1 L buffer A, and then loaded onto a Mono S column 
equilibrated at 4 °C with buffer A. The column was washed with 10 mL of buffer A and 
then eluted with a 40 mL of linear gradient of 0 to 1 M NaCl in buffer A. The column 
fractions were analyzed by measuring the absorbance at 280 nm and by carrying out 
SDS-PAGE analysis. The fractions were combined and concentrated at 4 °C to ≤ 1 mL 
using an Amicon concentrator and then loaded onto a gel filtration column Superdex 75. 
The column was eluted with buffer A, and fractions which contain protein were 
combined and concentrated to 6 mg/mL and stored at −80 °C. The sample PRL-1 was 
shown to be homogeneous by SDS-PAGE analysis. 
3.3.9 Crystallization and data collection  
For co-crystallization of PRL-1 with Analog-3, 100 μL 6 mg/mL PRL-1 was 
mixed with 6 μL stock of Analog-3 (10 mM in DMSO), then crystals were grown by 
vapor diffusion in hanging drops at 4°C, room temperature, 30°C and 37 °C respectively. 
Drops containing 1:1 volumes of protein in stock buffer and reservoir solutions were 
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equilibrated against the reservoir solution A (1.9 M amino sulfate, 100 mM sodium 
acetate, pH 4.6 ~ 4.9). The crystals were observed after 2 weeks (for 37° C), or 7 weeks 
(for 30 °C), or half year (for room temperature); No crystals were observed under 4 °C 
condition in 8 months. The crystals gotten in different temperature showed the same 
shape (long and thin rod cluster). The crystals (grown at 37 °C) was transferred into a 
reservoir solution B (90% saturated lithium sulfate,  0.5 mM Analog-3, 5% DMSO), 
soaked for 1 second, then flash-cooled in liquid nitrogen.  X-ray data were collected at 
100 K at SBC-CAT beamline 19-BM at the Advanced Photon Source (Argonne, IL) 
equipped with a mosaic CCD detector. The crystals belong to space group C2221 with 
the following unit cell parameters: a = 46.07 Å, b = 76.47 Å and c = 86.87 Å. There is 
one protein molecule in the asymmetric unit. All data were processed with HKL3000 
(144). 
3.3.10 Structural refinement of PRL-1•Analog-3  
The structure of PRL-1•Analog-3 was solved by molecular replacement using the 
program Molrep (145). The structure of PRL-1 (PDB entry code 1ZCK) (23), without 
the solvent molecules and other small molecules, was used as a search model. The map 
revealed the density for the bound Analog-3 (Figure 15). The structure was refined to 
1.90 Å resolution with the program CNS1.1 (146), first using simulated annealing at 
2,500 K, and then alternating positional and individual temperature factor refinement 
cycles. The progress of the refinement was evaluated by the improvement in the quality 
of the electron density maps, and the reduced values of the conventional R factor (R = 
Σh||Fo| - |Fc||/Σh|Fo|), and the free R factor (4.2% of the reflections omitted from the 
refinement) (123). Electron density maps were inspected and the model was modified on 
an interactive graphics workstation with the program WinCoot (147). Finally, water 
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molecules were added gradually as the refinement progressed. They were assigned in the 
Fo - Fc difference Fourier maps with a 3σ cutoff level for inclusion in the model. 
Molecular graphics were prepared by using Pymol (www.pymol.sourceforge.net). 
3.4 Results 
3.4.1 Identification of small molecule compounds targeting PRL-1 trimer interface 
Based on the observation that PRL-1 trimerization is critical for its role in 
promoting tumorigenesis and metastasis (17), we tested our hypothesis that targeting 
PRL-1 trimer interface may be a novel approach for developing anti-cancer drug. 
Utilizing in silico virtual screening, we searched the Asinex and ChemBridge subsets in 
ZINC small molecule database and tried to find compounds that could disrupt PRL-1 
trimer formation. As shown in Figure 10A (Generated by Zhihong Yu), the monomer B 
in the PRL-1 trimer structure (PDBID: 1ZCK) was selected as receptor for docking 
calculations, the surface on the monomer B which constitutes the BA interface (mainly 
including residues 122 to 142), or BC interface (mainly including residues 11 to 18, 35 
to 43, and 91 to 99) was defined as two docking regions, then the successive docking 
calculations using DOCK6.2 and AutoDock4.01 program were carried out respectively 
targeting BA and BC interface. By combining the top-ranked binding molecules of BA 
and BC interface and performing structure similarity analyses, we identified 56 hit 
molecules with diverse structure that may promisingly bind at either BA or BC interface 
(Figure 11). To select the most efficient compound(s), we used multiple protein and cell-
based assays, which are summarized in Figure 10B and shown in more details in Figure 
12.  
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Figure 10. Identification of small molecule compounds targeting PRL-1 trimer interface. 
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A. The schematic diagram of the computer-based screening process. BA_interface is the 
interface between monomer B and monomer A of PRL-1. BC_interface is the interface 
between monomer B and monomer C of PRL-1. DOCK6.2 and AD4.01 are software 
used for virtual screening. Asinex and ChemBridge are chemical databases we used in 
the experiment. The figure is created using PyMol (DeLano Scientific; 
http:/www.pymol.org). B. Screening steps and tests we performed to select PRL-1 trimer 
disruptors. Panel A was generated by Zhihong Yu. 
 
Specifically, to confirm the efficiency of those compounds to disrupt PRL-1 
trimer formation, we employed the in vitro cross-linking assay. We screened all 56 hits 
by incubating recombinant PRL-1 protein with 10 μM each compound for 30 min 
following incubation with 0.005% cross-linker glutaraldehyde for another 10 min. A 
representative gel and its quantification by trimer/monomer relative ratio are shown in 
Figure 12A. Compound 3 (Cmpd-3), Compound 26 (Cmpd-26) and Compound 43 
(Cmpd-43) could decrease PRL-1 trimer formation by 23%, 18% and 38% respectively. 
To further validate the efficiency of these three compounds to disrupt PRL-1 
trimerization in cells, we performed in vivo cross-linking assay (Figure 12B). Consistent 
with in vitro assays, 20 μM Cmpd-3, -26 and -43 could disrupt PRL-1 trimer formation 
by 40%, 60% and 80% respectively in HEK293 cells. The structures of these three 
compounds were shown in Figure 12C. Collectively, these results indicate that Cmpd-3, 
-26 and especially -43 are effective PRL-1 trimer disruptors. 
3.4.2 PRL-1 trimer disruptors inhibit PRL-1-induced cell proliferation and 
migration  
It has been shown that PRL-1 overexpression induces cell proliferation and 
migration. We have provided evidence that PRL-1 trimer formation is essential for its 
function in promoting cell proliferation and migration (17). To test whether PRL-1 
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Figure 11. 56 hits targeting PRL-1 trimer interface were identified by virtual screening. 
Asinex and ChemBridge subsets in ZINC (138) database were used as small molecule 
library for virtual screening as described in Materials and Methods. About 560,000 small 
molecules were analysed by docking calculations simultaneously. 56 hit molecules with 
diverse structure were identified as potential PRL-1 trimer disruptors. The chemical 
structures of these 56 hits were shown. 
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Figure 12. Effect of Cmpd-3, -26 and -43 on PRL-1 induced cell migration and proliferation. 
A. A representative SDS-PAGE profile of how we further confirm whether the PRL-1 
trimer interface hits decrease PRL-1 trimer formation by in vitro cross-linking assay. B. 
Selected compounds from the in vitro cross-linking assay screening were tested for their 
ability of inhibiting PRL-1 trimer formation in cells by in vivo cross-linking assay. C. 
Structures of Cmpd-3, -26 and -43. D. Cmpd-3, -26 and -43 were tested for their ability 
of inhibiting PRL-1 induced migration by wound healing assay as described in Methods. 
E. Quantification of the MTT assay by measuring the relative proliferation rate as 
described in Methods. # P<0.05 compared with control group; * P<0.05 compared with 
PRL-1 without compound treatment group. Data represent mean (SD) value from at least 
3 independent experiments. 
 
trimer disruptors inhibit PRL-1’s biological function of promoting cell proliferation and 
migration, we assayed the compound activity in PRL-1 induced cell proliferation and 
migration. In wound healing assay, consistent with previous reports, PRL-1 
overexpression promoted cell migration by 1.5 fold compared to vector control (Figure 
12D). 20 μM Cmpd-3, -26 and -43 significantly delayed wound closure induced by PRL-
1 overexpression. In MTT assays, PRL-1 overexpression increased cell proliferation by 
1.5 fold at 24 hours and 2.2 fold at 48 hours compared to vector control. Treatment with 
Cmpd-3, -26 and -43 could significantly decrease PRL-1 induced cell proliferation in a 
dose-dependent manner (Figure 12E). These results demonstrate that PRL-1 trimer 
disruptors, Cmpd-3, -26 and -43, could also inhibit PRL-1’s function in promoting cell 
proliferation and migration. Among these three compounds we tested, Cmpd-3 and -26 
have increased cell toxicity with high concentration, and Cmpd-43 has the best inhibition 
effect and no cell toxicity at high concentration (Figure 12E). Therefore, we chose 
Cmpd-43 as PRL-1 trimer disruptor to validate our hypothesis in the following 
experiments. 
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Proper analogs could help us to understand which part of the compound is critical 
for its activity. To further characterize the property of Cmpd-43, we searched the 
ChemBridge compound database, purchased four analogs of Cmpd-43 and compared the 
activity of the analogs with Cmpd-43. Compound structures are shown in Figure 13A. In 
particular, Analog-2 has the most different structure which does not contain the 4-
Iminomethyl-benzoic acid group, suggesting that it may behave differently from Cmpd-
43. Analog-1 does not have two methyl groups on the isoindoline group. Analog-3 has 
the furan ring replacing the benzoic acid group. Analog-4 has the pyrocatechol group 
replacing the benzoic acid group. These three analogs are highly similar to Cmpd-43 
with only side chain differences, indicating that they may have the similar activity as 
Cmpd-43. To validate our hypothesis, we assayed the activity of these four analogs along 
with Cmpd-43 by MTT assay for cell proliferation and Transwell assay for cell 
migration. Not surprisingly, Analog-1, -3 and -4, but not Analog-2, could inhibit PRL-1 
induced cell proliferation in a dose-dependent manner (Figure 13B). Analog-1, -3 and -4, 
but not Analog-2 at 10 μM also significantly reduced PRL-1-induced migration (Figure 
13C). Specifically, Analog-1 and -4 could inhibit PRL-1 induced cell proliferation and 
migration but less efficient than Cmpd-43. Analog-3 has even better effect in inhibiting 
PRL-1 induced cell proliferation and migration than Cmpd-43. As we expected, Analog-
2 has no effect in inhibiting either cell proliferation or migration, suggesting that the 4-
Iminomethyl-benzoic acid group is critical for Cmpd-43’s inhibitory activity. From these 
analog experiments, we found not only several compounds that either have similar 
(Analog-1 and 4) effect with or even better (Analog-3) effect than Cmpd-43 in inhibiting 
PRL-1 induced cell proliferation and migration, but also a control compound (Analog-2) 
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 Figure 13. Effect of Cmpd-43 and its analogs on PRL-1 induced cell migration and proliferation. 
A. Structures of Cmpd-43 and its analogs. B. The relative proliferation rate of PRL-1 
overexpressing cells pretreated with Cmpd-43 and its analogs at two different 
concentrations. C. The relative migration rate of PRL-1 overexpressing cells pretreated 
with Cmpd-43 and its analogs. # P<0.05 compared with control group; * P<0.05 
compared with PRL-1 without compound treatment group. Data represent mean (SD) 
value from at least 3 independent experiments 
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Figure 14. The comparison between Cmpd-43 and Analog-2. 
A. The effect of Cmpd-43 and Analog-2 in inhibiting PRL-1 trimer formation by in vivo 
cross-linking assay. B. Trimer formation of PRL-1 WT or PRL-1 G97R tested by in 
vitro cross-linking assay at two conditions. Condition 1: Cross-linked 10 min at RT; 
condition 2: Cross-linked 30 min at 4°C. C. The relative proliferation rate of either PRL-
1 WT or PRL-1 G97R in the presence of Cmpd-43 or Analog-2 at different does D. The 
relative migration rate of either PRL-1 WT or PRL-1 G97R in the presence of Cmpd-43 
or Analog-2. # P<0.05 compared with PRL-1 G97R control group; * P<0.05 compared 
with PRL-1 with Analog-2 treatment group. Data represent mean (SD) value from at 
least 3 independent experiments. 
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that has no effect to inhibit PRL-1’s cell function. With these useful chemical tools, we 
could further validate our hypothesis. 
To confirm that it is indeed through disrupting PRL-1 trimerization that Cmpd-43 
inhibits PRL-1-induced cell phenotype, we compared the efficiency of Cmpd-43 and 
Analog-2 in inhibiting PRL-1 trimer formation by in vivo cross-linking assay. As shown 
in Figure 14A, 20 μM of Cmpd-43 significantly decreased PRL-1 trimer formation in 
cells, while Analog-2 has no effect in disrupting PRL-1 trimerization. To further validate 
the specificity of Cmpd-43, we utilized PRL-1 G97R, which has defective trimer 
formation as shown previously (17). Here we also confirmed the impaired trimerization 
of PRL-1 G97R in two different conditions by in vitro cross-linking assay (Figure 14B). 
Then we performed MTT assay and Transwell assay to compare the activity of Cmpd-43 
or Analog-2 in inhibiting wild-type PRL-1 or PRL-1 G97R induced cell proliferation and 
cell migration. As shown in Figure 14C, PRL-1 G97R has significantly decreased cell 
proliferation rate compared to wild-type PRL-1. Treatment with Analog-2 was unable to 
inhibit cell proliferation of wild-type PRL-1, while treatment with Cmpd-43 could 
significantly decrease PRL-1 induced cell proliferation in a dose-dependent manner. 
However, both Analog-2 and Cmpd-43 had no effect in decreasing cell proliferation of 
PRL-1 G97R. Consistently, PRL-1 G97R has significant reduced cell migration ability 
compared to wild-type PRL-1. 10 μM of Cmpd-43, but not Analog-2, was capable of 
decreasing wild-type PRL-1 induced cell migration. However, neither Analog-2 nor 
Cmpd-43 are able to inhibit cell migration of PRL-1 G97R (Figure 14D). All these data 
suggested that Cmpd-43 specifically impaired PRL-1 induced cell function via directly 
disrupting PRL-1 trimerization. 
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Figure 15. The crystal structure of PRL-1 complex with Analog-3. 
A. Overall structure of PRL-1•Analog-3. P-loop is shown in red. Analog-3 binds to the 
back of active site and is shown by stick model. B. Unbiased Fo-Fc omit map of analog-
3 contoured at 3.0σ. C. Stereo diagram of the binding interactions between PRL-1 and 
Analog-3. Color scheme for carbon atoms: residues of PRL-1, yellow; Analog-3, light 
red. Hydrophobic contacts are shown in cyan dash lines, polar contacts are shown in red. 
D. Overall structure of PRL-1•Analog-3. PRL-1 is shown in surface representation; 
Analog-3 is shown in stick model. The interfaces between molecule B and C is shown in 
red; green for molecule B and A. E. Enlarged view of PRL-1 binding with Analog-3. 
The residues involved in interactions with Analog-3 are marked in PRL-1 surface 
representative. F. Overlay of PRL-1•Analog-3 with PRL-1 trimer. The PRL-1 trimer is 
shown in surface representative; Analog-3 of PRL-1•Analog-3 complex is shown in 
transparent surface representative. All figures were created with PyMol (DeLano 
Scientific; http:/www.pymol.org) by Sijiu Liu. 
 
3.4.3 Crystal structures of PRL-1•Analog-3 
To determine the molecular basis of PRL-1 de-trimerization by Cmpd-43, we co-
crystallized PRL-1 (residues 4-160) with Analog-3 of Cmpd-43. The 3D structure of 
PRL-1•Analog-3 was solved by molecular replacement using the coordinates of PRL-1 
apo form (PDB entry code: 1ZCK) (23) as a search model and refined to 1.90 Å 
resolution. The details of the crystals and structure solution are summarized in Table 3. 
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The overall structure of PRL-1•Analog-3 (Figure 15A, generated by Sijiu Liu) is quite 
similar with the initial model we used for molecular replacement. Like other members of 
the PTP superfamily, the PRL-1 adopts a compact α+β structure comprising a central 
five-stranded β sheet surrounded by four α helixes on one side and two α helixes on the 
other side. The PTP signature motif (H103CVAGLGR110) forms a loop (P loop) at the 
base of the active site pocket.  
Table 3. Data collection and refinement statistics for PRL-1•Analog-3 complex. 
Space group C2221 
Cell dimensions a=47.07, b=76.47, c=86.87 Å 
Data collection 
    Resolution range (Å) 
    No. of unique reflections 
    Completeness (%) 
    Redundancy 
    Rmergea 
  
50.0 – 1.84 
13,768 
98.0  
5.7 
0.113 
Refinement 
    Resolution range (Å) 
No. of reflections used (F≥2.0δ (F)) 
Completeness (%) 
    No. of protein atoms 
No. of inhibitors 
No. of ions 
    No. of waters 
    Rworkb/Rfreec 
 
50.0 – 1.9 
11,091 
87.2 
1,230 
1 
2 
102 
19.48/23.94 
r.m.s.d.d from ideal geometry 
    Bond length (Å) 
    Bond angle  
 
0.007 
1.23° 
aRmerge = ΣhΣi|I(h)i − 〈I(h)〉 |/ΣhΣiI(h)i. 
bRwork = Σh|F(h)calcd − F(h)obsd|/ΣhF(h)obsd, where F(h)calcd and F(h)obsd were the refined calculated and 
observed structure factors, respectively. 
cRfree was calculated for a randomly selected 3.6% of the reflections that was omitted from refinement. 
dr.m.s.d., root mean square deviation. 
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The final atomic model encompasses residues 4-160 of PRL-1 in a complex with 
Analog-3, as revealed by the unbiased Fo-Fc omit density map (Figure 15B, generated by 
Sijiu Liu). Analog-3 binds to the back of active site that lies 25Å away from the PRL-1 
active site [defined by the P-loop (H103CVAGLGR110)]. This binding site is defined by 
α5 helix, α4-α5 loop, β1-β2 hairpin, and the side-chain Arg159. The furan ring of 
Analog-3 reaches to the C-terminus of PRL-1 and interacts with the side-chain of 
Arg159; the other side of Analog-3 contacts with residues Asp128 and Phe132 in α5 
(Figure 15C, generated by Sijiu Liu). In previous studies, PRL-1 was always found in 
trimeric form in the crystalline state. This is true in either the apo form or in complex 
with a PRL-1 binding peptide (22,23,137). After we solved PRL-1•Analog-3 crystal 
structure, to determine whether PRL-1 is trimer or not in our new crystal structure, we 
checked the packing of PRL-1•Analog-3 in the crystal. Compared to PRL-1 trimer 
structure, there is no observable trimer pattern in the PRL-1•Analog-3 crystal structure, 
so our complex structure is not a trimer. There is a 2-fold axis that relates one monomer 
to another, but the interface between the two molecules is a small interface and 
consistent with only a crystallographic packing interface, not an interface that would be 
stable in dilute solution. So PRL-1 also is not a dimer in our crystal structure, instead, it 
is a monomer. The software PISA (148-150) was used to determine assemblies of PRL-1 
in our crystal structure. The results from PISA further conformed that PRL-1 is a 
monomer in our structure (data not shown).  
Detailed interactions between PRL-1 and Analog-3 are shown in Figure 15C 
(Generated by Sijiu Liu). A rich network of interactions ensures the precise positioning 
of the compound. For example, double ring in compound is engaged in hydrophobic 
interactions with Tyr14 in the β1-β2 hairpin, Met124 in the α4-α5 loop, and Phe132 in 
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α5. Two methyl groups on double ring contribute hydrophobic interactions with side-
chain of Met124, Asp128 and Phe132. The phenyl ring in the middle of compound is 
within van der Waals contacts with Tyr14 and Lys15 in the β1-β2 hairpin. Hydrazide 
group in compound provides Van der Waals contacts with Lys15. The furan ring in the 
compound donates van der Waals contacts with Asn16 in the β1-β2 hairpin and Arg159 
in the C-tail. Except that hydrophobic contacts between compound and protein, the 
binding mode also is stabilized by two polar interactions. One polar interaction is found 
between atom oxygen of furan ring and side-chain of Asn16, another is between oxygen 
of hydrazide and side-chain of Lys15 (Figure 15C).  
3.4.4 Analog-3 binds to the PRL-1 trimer interface 
In our previous papers (17,23,137), we reported that PRL-1 can form trimers in 
solution and in cells. In the trimer, each monomer interacts with two other monomers 
and forms two interfaces. For example, upon trimer formation, one interface was formed 
between molecule B (Figure 10A) and molecule C (Figure 10A) (BC interface, marked 
red in Figure 15D & 15E, generated by Sijiu Liu). This interface was defined by the α1 
helix, the β1-β2 hairpin, and the α3-β5 loop in the molecule B, including residues 
Glu11, Thr13, Tyr14, Lys15, Asn16, Met17, Arg18, Pro96, and Gly97; The other 
interface was formed between molecule B (Figure 10A) and molecule A (Figure 10A) 
(BA interface, marked green in Figure 15D & 15E). This interface was defined by α4-α5 
loop and α5 helix (residues 124-134) in molecule B, including residues Met124, Tyr126, 
Asp128, Val130, Gln131, Phe132. In the PRL-1•Analog-3 structure, Analog-3 binds to 
the back of active site that lies 25Å away from the PRL-1 active center. This binding site 
is defined by α5 helix, α4-α5 loop, β1-β2 hairpin, and the side-chain Arg159. In this 
binding mode, residue Arg159 in the C-tail; residues Tyr14, Lys15 and Asn16 in β1-β2 
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hairpin; residue Met124 in α4-α5 loop; residues Asp128 and Phe132 in α5 helix are 
involved in the interactions with PRL-1. The binding site overlaps with both BC 
interface and BA interface of trimer. Thus Analog-3 directly binds to the interface of 
trimer (Figure 15D & 15E) and blocks PRL-1 trimer formation. Additional, we 
superimposed three complex structures of PRL-1•Analog-3 into trimer strucrure of apo 
form of PRL-1, we found each Analog-3 in complex structure inserts into the trimer 
interface and causes strong steric hindrance against nearby Analog-3 in two other 
complex structures (Figure 15F, generated by Sijiu Liu). It further indicates that structure 
PRL-1•Analog-3 cannot form trimer, and it is a monomer. 
3.4.5 Mutagenesis validated the critical residues for Cmpd-43 binding  
In the crystal structure of PRL-1•Analog-3, residues Tyr14 and Phe132 provide 
hydrophobic interactions with Analog-3 of Cmpd-43. We hypothesized that once Tyr14 
and Phe132 were mutated to Ala, PRL-1 will lose the ability to bind the compound. Thus, 
we next tested the trimer disrupting activity of Cmpd-43 in PRL-1 Y14A and PRL-1 
F132A by in vitro cross-linking assay. We have shown that PRL-1 Y14A and F132A do 
not affect PRL-1 trimer formation (Figure 16A). Compared to wild-type PRL-1, which 
showed dramatically decreased trimerization in the presence of Cmpd-43, both PRL-1 
Y14A and PRL-1 F132A had significant less response to Cmpd-43-induced trimer 
disruption (Figure 16A). Consistently, 10 μM of Cmpd-43 was less efficient to decrease 
cell migration mediated by PRL-1 Y14A and PRL-1 F132A than wild-type PRL-1 
(Figure 16B). Taken together, Tyr14 and Phe132 of PRL-1 are critical for Cmpd-43 
binding, further demonstrating the significance of these residues in PRL-1•Analog-3 
interaction. 
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Figure 16. Effect of Cmpd-43 on PRL-1 Y14A and F132A. 
A. The effect of Cmpd-43 in inhibiting PRL-1 Y14A and F132A trimer formation by in 
vitro cross-linking assay. B. The relative migration rate of PRL-1 Y14A and F132A in 
the presence of Cmpd-43. * P<0.05 compared with WT PRL-1 with Cmpd-43 treatment 
group. Data represent mean (SD) value from at least 3 independent experiments. 
 
3.4.6 Cmpd-43 reduces the proliferation and migration in human breast cancer cell 
and lung cancer cell  
Since the trimer interface is conserved among all PRLs, we proposed that PRLs 
could also form both homo- and hetero-trimers, and that Cmpd-43 could block both 
homo- and hetero-trimer formation.  To test this hypothesis, we co-transfected each PRL 
with different tags into HEK293 cells and did immunoprecipitation assays. As we 
expected, although no interaction was detected in the absence of cross-linker (Figure 
17A & 17B), HA-tagged PRL-3 could immunoprecipitate, and also form hetero-dimer or 
hetero-trimers with either Flag-tagged PRL-2 or GFP-tagged PRL-1 after cross-linking 
(Figure 17B, 17C & 17D). In addition, Flag-tagged PRL-2 could also interact with both 
HA-tagged PRL-3 and GFP-tagged PRL-1 and form hetero-dimers or hetero trimmers in 
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Figure 17. PRLs form hetero-trimers. 
A. HA-PRL-3 cannot immunoprecipitate Myc-PRL-1 and Flag-PRL-2 in the absence of 
cross-linker. Cell lysates from HEK293 cells co-transfected with Myc-PRL-1, Flag-
PRL-2 and HA-PRL-3 were subjected for immunoprecipitaion with HA antibody, then 
blotted with HA, Flag and Myc antibodies. B. HA-PRL-3 immunoprecipitated Flag-
PRL-2 in the presence of cross-linker. Cell lysates from HEK293 cells co-transfected 
with Flag-PRL-2 and HA-PRL-3 were subjected for immunoprecipitation with HA 
antibody, then blotted with HA and Flag antibodies. C. HA-PRL-3 immunoprecipitated 
GFP-PRL-1, and Flag-PRL-2 immunoprecipitated HA-PRL-3 and GFP-PRL-1 in the 
presence of cross-linker. Cell lysates from HEK293 cells co-transfected with GFP-PRL-
1, Flag-PRL-2 and HA-PRL-3 were subjected for immunoprecipitaion with HA and Flag 
antibody, then blotted with HA and pan-PRL antibodies. D. HA-PRL-3 
immunoprecipitated Flag-PRL-2 but not Flag-p115 RhoGAP/ΔSH3 or GST in the 
presence of cross-linker. Cell lysates from HEK293 cells co-transfected with GFP-PRL-
1, HA-PRL-3, Flag-p115 RhoGAP/ΔSH3 and GST were subjected for 
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immunoprecipitaion with HA antibody, and blotted with pan-PRL, Flag and GST 
antibodies. 
 
the presence of cross-linker (Figure 17C). To rule out the possibility of non-specificity 
effect of cross-linking, we also co-transfected GFP-PRL-1 and HA-PRL-3 with two 
other proteins, Flag-tagged p115 RhoGAP/ΔSH3 and GST, that are presumably not 
associated with PRLs. We found that HA-PRL-3 only immunoprecipitated GFP-PRL-1 
but not Flag-p115 RhoGAP/ΔSH3 or GST from the lysate (Figure 17D). These data 
suggested that all PRLs are biochemically equivalent in terms of trimerization, and that 
Cmpd-43 will disrupt trimer interface among all PRLs with no selectivity. 
Given the similar function of all PRLs in promoting cancer progression, Cmpd-
43 is a novel anti-cancer agent by targeting the interface of both homo-trimer and hetero-
trimer of PRLs. To test the anti-cancer efficacy of Cmpd-43, we assayed the effect of 
Cmpd-43 in inhibiting cell proliferation and migration in human cancer cell lines. Breast 
adenocarcinoma cancer cell line MDA-MB-231 and lung cancer cell line H1299 were 
used in the experiment. It has been shown that knockdown of PRL-1 in H1299 cells 
significantly decrease cell proliferation and migration (88). PRL-2 knockdown in 
metastatic MDA-MB-231 breast cancer cells decreased anchorage-independent growth 
and cell migration (35). As shown in Figure 18A, Analog-2 has no effect in inhibiting 
cell proliferation of MDA-MB-231 and H1299 cells, while treatment with Cmpd-43 
could significantly reduce cell proliferation in MDA-MB-231 cells and H1299 cells in a 
dose-dependent manner. H1299 cell is much more sensitive to Cmpd-43 treatment than 
MDA-MB-231 cells, suggesting Cmpd-43 has some specificity in different cell types. 
On the other hand, 10 μM of Cmpd-43 but not Analog-2 could significantly decrease cell 
migration in both MDA-MB-231 cells and H1299 cells (Figure 18B). All these data 
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suggest that Cmpd-43 could inhibit cancer cell proliferation and migration, and may 
represent a lead compound of anti-cancer agent. 
 
Figure 18. Effect of Cmpd-43 on breast cancer cell MDA-MB-231 and lung cancer cell H1299. 
A. The relative proliferation rate of MDA-MB-231 cells (left panel) and H1299 cells 
(right panel) in the presence of Cmpd-43 or Analog-2 at different does. B. The relative 
migration rate of MDA-MB-231 cells (left panel) and H1299 cells (right panel) in the 
presence of Cmpd-43 or Analog-2. * P<0.05 compared cancer cells with Analog-2 
treatment group. Data represent mean (SD) value from at least 3 independent 
experiments. 
 
3.5 Discussion 
PRL-1 is believed to be an oncogene and contributes to various human 
malignancies (34,36,151). Phosphatase activity of PRL-1 is required for its oncogenic 
property (17). However, PRL-1 crystal structure indicates that the catalytic cleft of PRL-
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1 is extremely shallow and wide (22,23,137), suggesting that targeting PRL-1 active site 
for small molecule inhibitors is very difficult. Several groups have reported compounds 
that display inhibitory activity against the PRL phosphatases, including pentamidine 
(103) and rhodanine (104). However, the toxicity of these compounds is an issue due to 
low specificity. We also have tried very hard to find specific PRLs inhibitors by high 
throughput screening, but unfortunately, none of the small molecules are good PRLs 
inhibitors. Given that PRL-1 trimerization is critical for PRL-1’s cellular function of 
promoting proliferation and migration, it presents an opportunity for us to find good 
PRL-1 inhibitors by targeting the trimer interface.  
This is the first study to inhibit PRL-1’s biological function via disrupting PRL-1 
trimer formation using small molecule compound. Starting from a virtual screening for 
searching small molecule compounds targeting PRL-1 trimer interface, we identified 
three compounds as potential PRL-1 timer disruptors. Biochemical and cellular studies 
validated that Cmpd-3, -26 and -43 impair PRL-1 trimer formation both in vivo and in 
vitro, and accordingly inhibit PRL-1 induced cell proliferation and migration. Based on 
the chemical structure of Cmpd-43, we searched ChemBridge chemical database and 
purchased 4 structurally related analogs. As expected, Analog-2, which has the most 
different structure from Cmpd-43, was unable to disrupt PRL-1 trimer formation and 
could not reduce PRL-1 induced cell proliferation and migration. Analog-1, -3 and -4, 
which have similar structures with Cmpd-43, could still inhibit PRL-1’s cell function. 
Moreover, the trimerization deficient mutant PRL-1 G97R, which has dramatically low 
cell proliferation and migration ability compared to wild-type PRL-1, has no response to 
both Cmpd-43 and Analog-2 for cell proliferation and migration. Structural analyses 
revealed that, PRL-1 alone exists as a trimer in crystalline state, but the complex of PRL-
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1 with Analog-3 (Cmpd-43 analog) was a monomeric arrangement. Cmpd-43-binding 
deficient mutants PRL-1 Y14A and F132A lose the response to Cmpd-43 in decreasing 
trimer formation and inhibiting cell migration. Finally, Cmpd-43 could also inhibit cell 
proliferation and migration in breast cancer cell line MDA-MB-231 and lung cancer cell 
line H1299. Together, all the results demonstrated that targeting PRL-1 trimer interface 
could be a novel method for anti-cancer agent, and that Cmpd-43 represents a lead 
compound that inhibits PRL-1 biological function in human cancer cells. 
As shown by us and work by others, PRLs could form homo-trimers 
(17,22,23,137). In addition, it is suggested that PRLs could also form hetero-trimers due 
to the conserved trimer interface among all PRLs. We confirmed the formation of 
hetero-trimer by immunoprecipitation assays (Figure 17), which also indicated that it is 
difficult to have selective trimer disruptors for each PRL isoform. Given that all PRLs 
have the same function of promoting tumorigenesis and metastasis (11,13,25,29,86,96), 
targeting all PRLs could be a reasonable therapeutic treatment for cancer. However, 
additional experiments are required to validate the significance of hetero-trimers. In 
summary, our study provides proof of concept for a design of the non-phosphatase 
activity based inhibitors that will target PRLs trimer interface and inhibit PRLs induced 
cell proliferation and migration in a clinically beneficial manner. In addition, targeting 
PRLs trimer interface seems to be a novel and promising approach to modulate the cell 
function of PRLs. Overall, our work provides conceptual support and rationale for 
design of PRLs trimer-disruptor based anti-cancer drugs. 
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CHAPTER 4: GENERATION AND CHARACTERIZATION OF PRL 
KNOCKOUT MICE 
4.1 Overview 
PRLs play a positive role in cell signaling events and are suggested as oncogenes 
and therapeutic targets in several cancers (152,153). Overexpression of PRLs was 
frequently found in numerous tumor cell lines, and cells expressing high levels of PRLs 
exhibited enhanced proliferation, anchorage-independent growth, cell migration and 
invasion (11,12,69,86,95,96). Clinically, up-regulation of PRLs has been observed in 
many types of advanced stage tumors as well as metastatic lesions (153). It has been 
suggested that PRLs promote cell proliferation and migration through activation of 
several signaling pathways, including the Rho family of small GTPases, Src, ERK1/2, 
and PI3K (16,59,79,86,137). PRLs are strongly implicated as a driving force in 
malignancy, but limited knowledge is known about the exact physiological functions of 
these phosphatases. Our current understanding of PRLs came primarily from 
observations in clinical patient samples or cell culture models, either overexpressing or 
silencing PRLs. To define the biological function of endogenous PRLs in non-cancer 
cells, generation of genetic models with PRLs deletion is required.  
4.2 Hypothesis and Specific Aims 
Gene knockout in mouse model is a widely used genetic technique, in which a 
gene has been inactivated by replacing it or disrupting it with a piece of artificial DNA. 
The inactivation of a gene often results in mouse phenotypic alteration including 
appearance, behavior and other observable physical and biochemical characteristics. 
Information obtained from gene knockout in mice provides valuable clues about what 
this gene normally does in mice. Given that mice share many genes with humans, 
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characteristics observed from gene knockout mice may also give researchers a better 
understanding on how a related gene is involved in development and disease in humans. 
As we discussed previously, the amino acid sequences for all PRLs are conserved in 
human and mouse (Figure 2), suggesting that each PRL plays similar roles in human and 
mouse. This makes the mouse a good model organism to study the biological functions 
of PRLs in vivo. Thus, I hypothesized that knockout mouse models lacking each of the 
individual Prl genes may provide substantial insight into the physiological function 
of PRLs in vivo. To test this hypothesis, I proposed two specific aims: 1) to create Prl-1, 
Prl-2 and Prl-3 knockout mice, respectively; and 2) to characterize the phenotypes in 
Prl-1-/-, Prl-2-/- and Prl-3-/- mice. The specific goal of this project is to generate and 
analyze in vivo mouse models with Prl deletion. 
4.3 Materials and Methods 
4.3.1 Generation of Prl-1 and Prl-2 knockout mice by “gene-trapping” strategy 
Heterozygous gene trap embryonic stem (ES) cell lines for Prl-1 (Cell No.: 
CC0606; Mouse strain: 129P2/OlaHsd) and Prl-2 (Cell No.: AQ0673; Mouse strain: 
129P2/OlaHsd), containing an insertional mutation in mouse Prl-1 and Prl-2 locus 
respectively, were purchased from Mutant Mouse Regional Resource Centers 
(MMRRC). The ES cells were injected into blastocysts from C57BL/6J mice, and the 
resulting chimeric males with successful germ line transmission of the mutant allele 
were intercrossed with C57BL/6J females to generate F1 offspring. Knockout mice were 
generated by crossing heterozygous male with females. Genotyping of F1 offspring was 
performed by PCR. Primer sequences are listed in Table 4. 
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4.3.2 Construction of Prl-3 gene-targeting vector 
To generate a Prl-3-null allele, a targeting vector consisting of a 2.2-kb 5′ arm of 
homologous genomic sequence, LacZ (β-galactosidase) cassette, a neomycin resistance 
(PGK-Neor) cassette, a 5.2-kb 3′ arm of homologous genomic sequence followed by a 
DTA (Diphtheria Toxin A-chain gene) cassette was constructed. Briefly, the 5′ arm of 
the targeting vector was amplified from PRL-3 bacterial artificial chromosome (BAC) 
clone 116F7 and was inserted into the BamHI and XhoI sites of pKO vector. The 5.2-kb 
3′ arm was amplified from PRL-3 BAC clone and was constructed into the SalII and 
NotI sites of pKO vector.  
4.3.3 Generation of Prl-3 knockout mice by homologous recombination 
The targeting vector was linearized by PmeI and electroporated into ES cells in 
the Transgenic and Knock-Out Mouse Core at Indiana University Simon Cancer Center. 
The transfected ES cells were treated with neomycin for positive selection, and the 
DTA gene, which inhibits protein synthesis, was used as the negative selection marker. 
Genomic DNA was prepared from selected ES cells, and the various clones were 
screened by Southern blot analysis using DNA probes as described in Figure 19. Positive 
clones were identified and injected into blastocyst of C57BL/6J donors. Injected 
blastocysts were transplanted into pseudo-pregnant females. Chimeric animals with 
successful germ line transmission of the mutant allele were intercrossed with C57BL/6J 
females to generate F1 offspring. Knockout mice were generated by crossing 
heterozygous male with females. Genotyping of F1 offspring was performed by PCR. 
Primer sequences are listed in Table 4. Experiments on mice were carried out in 
accordance with the regulations of The Institutional Animal Care and Use Committees at 
Indiana University. 
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Table 4. Primers used in genotyping, RT-PCR and Southern blot. 
Genotyping  Forward primer Reverse primer Product 
Prl-1 wild-type allele gcagacaagtgaactgtagaaattc agtgtagcacacttctaccgttcca 633 bp 
Prl-1 mutant allele gcagacaagtgaactgtagaaattc acgacgggatcctctagag 852 bp 
Prl-2 wild-type allele acagtatggatgagtagaatc gttgctccttggttattctcac 623 bp 
Prl-2 mutant allele acagtatggatgagtagaatc gttttcccagtcacgacgttg 746 bp 
Prl-3 wild-type allele atagaggacactgctctgcggccg tccacagactgcaatggtcac 834 bp 
Prl-3 mutant allele atagaggacactgctctgcggccg gattaagttgggtaacgcca 520 bp 
RT-PCR Forward primer Reverse primer Product 
Prl-1 gaagaggccgtctccactaa atcccaggattgcgattaca 195 bp 
Prl-2 ggctgtaacagggtggaaga gccaccaacatctgggtact 302 bp 
Prl-3 ggtgctctggactctcaagg tgaccccctactctgtcctg 307 bp 
Rpl7 gctgcggattgtggagccatac cctccatgcagatgatgccaaac 170 bp 
Southern Blot Forward primer Reverse primer Product 
5’arm probe tagtaggctctgctgtgcaag cagcttcatatgcgcacac 600 bp 
3’arm probe atccaaggaacagcaaagct attgcctggacacttagacttg 540 bp 
 
4.3.4 Southern blot 
Genomic DNA extracted from ES cells was digested by XbaI, BamHI, NarI or 
ScaI respectively. After digestion, the DNA fragments were separated by electrophoresis 
in 0.7% agarose gels and transferred to Hybond-N+ membranes. 32P-labeled probes were 
made using the multiprime-labeling system (Amersham). The labeling DNA templates 
(5’ probe size: 600 bp, 3’ probe size: 540 bp) were generated by PCR using primers list 
in Table 4. Hybridizations were carried out at 60°C overnight in hybridization buffer. 
4.3.5 RNA extraction and quantitative RT-PCR 
Total RNA was extracted from tissues using Trizol reagent (Invitrogen) and 
treated with DNase I (Promega). Reverse transcription was performed using the 
SuperScript III one-step RT-PCR system (Invitrogen) at 55°C with gene-specific 
primers. Quantitative PCR was performed using SYBR Green I master mix on a 
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LightCycler 480 (Roche Applied Science), with RPL7 as the housekeeping gene control. 
All primers were listed in Table 4. 
4.3.6 Western Blot analysis 
Tissues were lysed in lysis buffer supplied with phosphatase and protease 
inhibitor mixture (Roche Applied Science). Equal amounts of protein were resolved by 
SDS-PAGE, transferred to nitrocellulose membrane and subjected to immunoblotting. 
Anti-PRL-1, anti-PRL-1/2, and anti-PRL-3 antibodies were kindly provided by Dr. Qi 
Zeng. All other antibodies were from Cell Signaling Technology. 
4.3.7 X-gal staining 
Samples were fixed in 4% PFA on ice for 1 hr, incubated in PBS/0.01%NP-40 
for 4 hrs, and stained in β-gal substrate (1 mg/mL X-gal, 5 mM K3Fe(CN)6, 5 mM 
K4Fe(CN)6, 1 mM EGTA, 0.01% NP-40 in 1xPBS) for 48h at 37°C. ). Once staining was 
complete, tissues were re-ﬁxed in 4% PFA overnight and cleared via use of increasing 
concentrations of glycerol (10–50%) for whole-mount imaging. 
4.3.8 Histology 
Tissues were fixed in 4% paraformaldehyde overnight at 4°C, embedded in 
paraffin, serially sectioned (10 μm), and stained with H&E according to standard 
methods. For immunohistochemistry, deparaffinized sections were boiled in 10 mM 
sodium citrate (pH 6.0) for 10 min to unmask antigen. Sections were then incubated with 
diluted antibodies (1:50-1:100) at 4 °C overnight. Signals were detected by 
VECTASTAIN Elite ABC kit and developed using diaminobenzidine substrate from 
Vector Laboratories (Burlingame, CA). Images were captured on a Leica DM2500 
stereomicroscope. All images are representative of at least three samples. 
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4.3.9 Statistical analysis 
Statistical significant differences were calculated using student’s t-test or χ2 test 
and represented by asterisks: *P<0.05, **P<0.01, ***P<0.001. 
4.4 Results 
4.4.1 Generation of Prl-1and Prl-2 knockout mice by “gene-trapping” 
Gene-trapping is a fast and easy way to introduce insertional mutations across the 
mammalian genome and to obtain gene-deficient alleles. In order to quickly obtain 
knockout mice for all Prls, we collaborated with Dr. Shou Weinian’s lab in the 
Department of Pediatrics, and searched the catalog in Mutant Mouse Regional Resource 
Center (MMRRC) for the availability of Prl-1, Prl-2 and Prl-3-trapped ES clones. Even 
though Prl-3-trapped ES clones were not available, there were multiple clones for both 
Prl-1 and Prl-2-trapped ES cells. The Prl-1, Prl-2 and Prl-3 genes are located on 
chromosome 1, 4 and 15 of the mouse genome, respectively. All three genes consist of 6 
exons with start codon in exon 2 and stop codon in exon 6. Thus, exon 1 and the 
majority of the exons 2 and 6 are noncoding sequences once they are transcribed. To 
completely delete Prl-1 or Prl-2 gene, we chose ES clones with insertion site upstream 
of the ATG start codon in exon 2.  
We generated Prl-1 deficient mice using targeted ES cell clone (CC0606 
obtained from MMRRC) with the gene trap vector pGT01 inserted into exon 2 (upstream 
of ATG start codon) of the mouse Prl-1 locus (Figure 19A). Similarly, Prl-2 knockout 
mice were generated using a gene trap ES cell clone (AQ0673 obtained from MMRRC), 
in which a gene trap cassette pGT01 was inserted into the first intron of the mouse Prl-2 
gene (Figure 19A). The gene trap vector contains a splice-acceptor sequence upstream of 
the reporter gene β-geo (fusion of beta-galactosidase and neomycin phosphotransferase 
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II) and a premature polyadenylation signal downstream of β-geo. The insertion of the 
gene trap cassette would eliminate endogenous gene expression, and express β-geo 
fusion protein derived by the endogenous gene promoter. The single insertion site was 
confirmed by sequencing analyses. 
ES cells with Prl-1 or Prl-2 trapped allele were injected into C57BL/6 
blastocysts respectively to generate chimeric embryos. Then pseudo-pregnant female 
mice were injected with chimeric embryos in each uterine horn and produced chimeric 
mice with mixed black and agouti coat color. Germline transmission was confirmed by 
examining the genotypes in the offsprings of chimeric males mated with C57BL/6J 
females. Cross-mating of F1 heterozygous mice gave offsprings with all three genotypes 
(Figure 19D). 
4.4.2 Generation of Prl-3 knockout mice by homologous recombination 
Homologous recombination in embryonic stem cells was used to create Prl-3 
knockout mice. In cooperation with Dr. Weinian Shou’s lab, we designed a targeting 
vector with a 5’ arm consisting of 2.2kb sequence upstream of the ATG start in exon 2 
and a 3’ arm that is a 5.2kb sequence downstream of exon 6 in order to completely 
eliminate Prl-3 gene expression. Once homologous recombination occurs, the whole 
coding sequence for Prl-3 will be replaced with beta-galactosidase and neomycin 
cassette, and endogenous Prl-3 promoter will instead drive the expression of beta-
galactosidase. A bacterial artificial chromosome (BAC) containing mouse Prl-3 gene 
was used as a template to amplify each arm for construction of the targeting vector. The 
sequence confirmed arms were then inserted into multiple cloning sites of pKO-DTA 
plasmid. The targeting vector was linearized by PmeI and then electroporated into mouse 
ES cells in the Transgenic and Knock-Out Mouse Core at Indiana University Simon 
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Cancer Center. Following transfection, PGK-driven neomycin expression was necessary 
for positive selection in the presence of G418 to eliminate non-transfected cells, while 
expression of Diphtheria Toxin A-chain (DTA) was used as negative selection to get rid 
of cells with random integration.  
250 ES cell clones were selected and then genotyped by Southern blot analysis. 
Two external probes, 5’ probe and 3’ probe (comprising approximately 300 bp 
corresponding to exon 6 of the Prl-3 locus), were radiolabeled and used to detect the 
targeted mutation. Genomic DNA of ES cell clones were digested by XbaI or BamHI for 
determination of 5’ recombination, and NarI or ScaI for detection of 3’ recombination. 
The 5’ probe will detect a specific 4.8kb or 20kb band with XbaI or BamHI digestion 
respectively, while the 3’ probe will recognize a 9.8kb or 20kb fragment with NarI or 
ScaI digestion respectively (Figure 19B). Five out of 250 ES cell clones were confirmed 
to have undergone homologous recombination. The Southern blot assays for a 
representative clone were shown in Figure 19C. 
ES cells with heterozygous Prl-3 allele were injected into C57BL/6 blastocysts. 
Chimeric embryos were implanted into pseudo-pregnant female mice. Chimeric mice 
with mixed black and agouti coat color were mated to C57BL/6J females, and offspring 
were confirmed for successful germline transmission as evidenced by genotyping with 
heterozygous alleles. Breeding F1 heterozygous mice gave offspring with all three 
genotypes (Figure 19D). 
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Figure 19. Generation of Prl-1, Prl-2 and Prl-3 deficient mice. 
A. “Gene-trapping” strategy for generating Prl-1 and Prl-2 deficient mice. Genomic 
structure for wild-type Prl-1 and Prl-2, as well as gene-trapped Prl-1 and Prl-2 were 
shown. Rectangles indicate exon segments, with coding sequence shaded. A splice-
85 
 
acceptor sequence upstream of the reporter gene β-geo (fusion of beta-galactosidase and 
neomycin phosphotransferase II) and a downstream premature polyadenylation signal 
was inserted in the exon 2 of Prl-1 gene and intron 1 of Prl-2 gene. Genotyping primers 
and product size were labeled. B. Gene targeting strategy for generating Prl-3 knockout 
mice. Genomic structure for wild-type and mutant Prl-3, as well as structure of targeting 
vector were shown. Rectangles indicate exon segments, with coding sequence shaded. 
Targeting arms (5’ arm and 3’ arm) were labeled. Probes (5’ probe and 3’ probe) used 
for Southern blot analysis were indicated. The fragment and expected size after digestion 
with each of the enzymes (XbaI, BamHI, NarI and ScaI) were indicated. Genotyping 
primers and product size were labeled. C. Southern blot for Prl-3 homologous 
recombination. Genomic DNA from wild-type ES cells and Prl-3-targeted ES cells were 
either digested with XbaI or BamHI and probed with 5’ probe, or digested with NarI or 
ScaI and probed with 3’ probe. 5’ probe gives a specific 4.8kb band and 20kb band in 
targeted ES cell DNA after XbaI and BamHI digestion, respectively; while 3’ probe 
gives a specific 9.8kb band and 20kb band in targeted ES cell DNA after NarI and ScaI 
digestion, respectively. The size for each band was indicated. D. PCR strategy for 
genotyping using mouse tail DNA.  
 
4.4.3 Validation and examination of Prl-1, Prl-2 and Prl-3 deficient mice 
To determine the knockout of Prl-1, Prl-2 and Prl-3 gene product, we first 
examined gene deletion at mRNA level by quantitative RT-PCR. Total mRNAs were 
extracted from thymus of either wild-type, Prl-1-null or Prl-2-null mice to determine the 
deletion of Prl-1 or Prl-2. Since previous report indicated that PRL-3 expression is 
restricted in heart and muscle (14), we chose to examine PRL-3 mRNA level from 
muscle. As shown in Figure 20A, I was unable to detect Prl-1 mRNA in thymus of Prl-
1-null mice.  Prl-2 mRNA was also not detectable in the same organ from Prl-2-null 
mice. Prl-3 mRNA can only be amplified from muscle of wild-type but not from that of 
Prl-3-null mice. The results here demonstrated that both “gene-trapped” deletion of Prl-
1 and Prl-2, and “gene-targeted” deletion of Prl-3 were successfully achieved.  
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Figure 20. Gene deletion resulted in knockout of PRLs at both mRNA and protein level. 
A. Quantitative RT-PCR analysis was used to detect the deletion of PRL-1 and PRL-2 
mRNA from thymus, and to detect the deletion of PRL-3 mRNA from muscle. After 
RT-PCR, samples were subjected to agarose gel analysis. B. The specificity of PRL 
antibodies were measured by Western blot on cell lysates from MEF cells with 
overexpression of individual PRLs. PRL-1 antibody only recognizes overexpressed 
PRL-1; PRL-3 antibody only recognizes overexpressed PRL-3; while PRL-1/2 antibody 
recognizes overexpressed PRL-1, PRL-2 and PRL-3 (upper bands), as well as 
endogenous PRL-1 and PRL-2 (lower bands). C. Specificity and affinity of PRL-1/2 
antibody were determined by detecting recombinant PRL proteins. D. Endogenous PRL-
1, PRL-2 and PRL3 protein products were determined by Western blot on lung and 
spleen lysates from wild-type, Prl-1-null, Prl-2-null or Prl-3-null mice.  
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Then gene knockout at protein level needs to be further validated by Western 
blot. However, the specificities of commercially available antibodies are not adequate to 
differentiate individual PRLs due to the highly similar amino acid sequence among all 
PRLs. I would like to thank Dr. Qi Zeng and her colleagues for generating and kindly 
sending us PRL-1, PRL-1/2 and PRL-3 antibodies (32). We measured the specificity of 
these three antibodies by detecting protein lysates from MEF cells individually 
overexpressing PRL-1, PRL-2 or PRL-3 (Figure 20B). PRL-1 and PRL-3 antibodies 
specifically recognized PRL-1 and PRL-3, respectively, while PRL-1/2 antibody cross-
reacted with all three PRLs with much higher affinity to PRL-1 and PRL-2. To further 
evaluate the affinity and specificity of PRL-1/2 antibody, different amount of 
recombinant PRL-1, PRL-2 and PRL-3 proteins were loaded on the gel and then 
immunoblotted with PRL-1/2 antibody. The results showed that this antibody recognized 
both PRL-1 and PRL-2 at same level but displayed about 100-fold higher selectivity 
again PRL-3 (Figure 20C). Since PRL-2 is 6 amino acids shorter than PRL-1, PRL-1/2 
antibody is able to distinguish endogenous PRL-1 and PRL-2 with such small difference 
in molecular weight. Therefore, protein lysates from lung and spleen were assayed for 
the presence of endogenous PRL-1, PRL-2 and PRL-3 protein product by combining 
PRL-1/2 antibody and PRL-3 antibody. While detectable in samples from wild-type and 
Prl-3 knockout, endogenous PRL-1 and PRL-2 proteins did not exist in Prl-1-null and 
Prl-2-null mice, respectively. PRL-3 was detectable in wild-type, Prl-1-null and Prl-2-
null lung and spleen, but not in Prl-3-null samples (Figure 20D). Interestingly, deletion 
of either Prl-1 or Prl-2 result in an up-regulation of PRL-3 at the protein level, 
suggesting that mice evolved a compensatory mechanism among different PRL isoforms 
to ensure a proper cellular PRL level for its biological function (Figure 20D).  
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Previous studies have documented that both PRL-1 and PRL-2 were found 
expressed in almost all organs, and PRL-1 expression level is relatively lower than PRL-
2 (14,24,25), whereas PRL-3 is primarily expressed in organs and tissues that contain 
muscle cells, such as heart and skeletal muscle (14). However, the information gained 
from these studies may not be accurate due to lack of any negative control. Thus, the 
knockout mice we generated were perfect negative controls for exploring PRLs gene 
expression pattern. In addition, the mutant alleles have a LacZ cassette under the 
endogenous Prl promoter, providing a novel opportunity to visualize each PRL 
transcription in different organs and cell types by detecting LacZ expression. To re-
examine the mRNA expression pattern of all PRLs, we assayed many tissue types from 
wild-type, Prl-1-/-, Prl-2-/- and Prl-3-/- mice by LacZ staining. Unfortunately, LacZ signal 
can only be detected in organs from Prl-2-/- and Prl-3-/- mice but not Prl-1-/- mice, 
indicating that the LacZ gene inserted in the Prl-1 locus is inactivated (Figure 21A). 
Compared to the background staining in wild-type control, Prl-2-/- mice displayed dark 
blue staining in all the organs we surveyed, further demonstrating the broad expression 
of PRL-2 in different organs and cell types.  
In stark contrast to the previous study (14), Prl-3-/- mice showed positive staining 
in many organs including heart (both fetal and adult heart), skeletal muscle, lung and 
brain (Figure 21A & 21B), indicating a more broader expression pattern of PRL-3, 
which is consistent with the most recent report by Zimmerman et al. (111). Moreover, in 
contrast to the more uniform staining of PRL-2 in different cell types, the expression 
pattern of PRL-3 is restricted to specific tissues or cell types, as evidenced by the uneven 
distribution between cerebral cortex and cerebellum and robust expression in blood 
vessels between ribs and in the heart (Figure 21B).  
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Figure 21. Gene expression pattern for all PRLs. 
A. LacZ staining for different organs from wild-type, Prl-1, Prl-2 or Prl-3 knockout 
mice. B. Uneven distribution of LacZ staining in brain and blood vessels of Prl-3-null 
mice. C. PRL-1, PRL-2 and PRL-3 protein expression pattern in different organs from 
wild-type mice. D. Relative PRL-1/PRL-2 level in different organs of wild-type mice.  
 
Another problem of previous studies is that they only measured the gene 
expression pattern at mRNA level by Northern blot or in situ hybridization. Owing to the 
low specificity and efficacy of antibodies, endogenous protein expression pattern of 
PRLs has not been well established. Thanks to our knockout mice for all PRLs, we have 
demonstrated the specificity of PRL antibodies in detecting endogenous PRL-1, PRL-2 
and PRL-3 expression, which gives us strong confidence to measure the protein 
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expression pattern for all PRLs. Therefore, protein lysates from different organs were 
subjected to Western blot analysis using PRL antibodies. As shown in Figure 21C, PRL-
1 and PRL-2 proteins are broadly expressed in all the organs we assayed. Given the same 
specificity of the antibody towards PRL-1 and PRL-2, the intensity of PRL-1 band 
(upper band) and PRL-2 band (lower band) reflects the relative level of endogenous 
PRL-1 and PRL-2. By comparing different organs, we found that overall PRL-1 protein 
level is relatively lower than PRL-2 in all organs we measured, from about 40% in testis 
to about 5% in muscle (Figure 21D). In contrast to the restricted expression pattern of 
PRL-3 as initial study suggested, we found endogenous PRL-3 protein is expressed in a 
more ubiquitous manner. As shown in Figure 21C, PRL-3 is detectable not only in heart 
and muscle as reported before, but also in several other organs such as brain, lung, colon, 
small intestine, spleen and thymus, which is in line with mRNA expression pattern 
determined by lacZ staining. 
Table 5. Distribution of offspring by heterozygous-heterozygous mating at weaning. 
Prl-1 +/+ +/- -/- n χ2 p 
Observed 187 353 143 683 6.44 <0.05 
Expected 171 342 171    
Prl-2 +/+ +/- -/- n χ2 p 
Observed 139 307 73 519 34.18 <0.001 
Expected 130 260 130    
Prl-3 +/+ +/- -/- n χ2 p 
Observed 111 210 76 397 7.50 <0.05 
Expected 99 199 99    
 
4.4.4 Overall phenotypic characterization of Prl-1, Prl-2 and Prl-3 deficient mice 
To characterize potential phenotypes, we first examined the birth rate of these Prl 
deficient mice by analyzing more than 400 pups produced by heterozygous mating for 
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each gene. Even though all possible genotypes were observed in the resulting offspring, 
the distribution did not exactly match the expected Mendelian ratios of 1:2:1 (Table 5). 
Among 683, 519 and 397 pups produced by Prl-1, Prl-2 and Prl-3 heterozygous mating, 
only 143, 73 and 76 animals are identified as knockouts. The numbers of knockout 
offspring are significantly less than the expected number of 170, 130 and 99, suggesting 
that deletion of individual Prl genes indeed causes survival disadvantage. However, 
further study is required to examine at which stage this partial lethality occurs.  
Then, we measured the body weight of more than 20 males and females with 
different genotypes at weaning (4 weeks old). Even though Prl-1-/- and Prl-3-/- males did 
not exhibit a significant decrease in body mass compared to wild-type males, the body 
weight of Prl-2-/- male mice dropped 19 ± 12% (Figure 22A). This phenotype did not 
have gender differences as evidenced by a 22 ± 19% body weigh decrease in Prl-2-/- but 
not Prl-1-/- and Prl-3-/- females (Figure 22B). A detailed examination revealed that each 
organ from Prl-2-/- mice weighed below normal. Since the body weight of Prl-2-/- mice is 
also smaller, we normalized organ weights by expressing them relative to body weight in 
different genotypes, and found a similar organ/whole body weight ratio in lung, liver, 
thymus, kidney and heart within different genotypes (Figure 22C & 22D). However, 
testis from Prl-2-/- males and spleen from both Prl-2-/- males and females remained 
significantly smaller even when normalized to whole body weight (Figure 22C & 22D), 
indicating that the development of these organs are affected by deletion of Prl-2. 
Interestingly, the relative brain/body weight ratios of Prl-2-/- males and females were 
larger compared to those of the wild-type controls (Figure 22C & 22D). Histological 
analysis was performed on tissue sections from different genotypes by hematoxylin and 
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Figure 22. Overall phenotypic characterization of Prl-1, Prl-2 and Prl-3 deficient mice. 
A-B. Body weights of 4-weeks-old male mice (A) or female mice (B) with different 
genotypes were determined. Body weights of Prl-2-null males and females were 
significantly less than those of wild-type, Prl-1-null and Prl-3-null males and females. 
C-D. Relative organ/body weight ratios of 3-months-old male mice (C) or female mice 
(D) were determined. Testis from Prl-2-nul males and spleen from both Prl-2-null males 
and females were significantly smaller than those from wild-type, even normalized by 
body weight. E. Histology of liver, small intestine, spleen and thymus from different 
genotypes were analyzed by H&E staining. No significant histological abnormalities 
were observed in Prl-1, Prl-2 or Prl-3 deficient mice. 
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eosin staining, and no significant abnormalities were observed (Figure 22E). It is 
noteworthy that despite the significantly smaller spleen/body weight ratio for Prl-2-/- 
mice, the overall histological structure of the Prl-2 mutant spleen has no appreciable 
differences in comparison to that of the wild-type animal (Figure 22E). 
4.4.5 Prl-2 deletion causes placental insufficiency 
Collaborating with Dr. Yuanshu Dong in our lab, we found the growth 
retardation displayed by Prl-2-/- mice starts from newborn mice and maintains 
throughout their adulthood. Lower weight of Prl-2-/- mice at birth suggests growth 
restriction during embryonic development. To examine whether this smaller body weight 
can also be observed in embryonic stage, timed mating with Prl-2 heterozygous males 
and females was performed and the embryos were harvested at E16.5. As we expected, 
the weight of Prl-2-/- embryos was about 80% of that of the wild-type littermates (Figure 
23A & 23B, generated by Yuanshu Dong). In addition, compared to wild-type 
littermates, the placental weight of the Prl-2-/- embryos was also reduced to about 80% 
(Figure 23A & 23C, generated by Yuanshu Dong), indicating impaired growth and 
development of both the placenta and embryo in Prl-2-/- mice.  
Defects in placental development can negatively impact the placenta’s ability to 
transport nutrients, thus leading to restricted fetal growth or even embryonic death (154). 
HE staining revealed that Prl-2-/- placenta had severely reduced decidua and 
spongiotrophoblast layers (Figure 23D, generated by Yuanshu Dong). Large islands of 
glycogen cells in spongiotrophoblast layer of wild-type placenta, readily recognizable by 
their vacuolated appearance, were almost absent in Prl-2 mutant placenta. In addition, 
massive invasion of glycogen cells in the decidua layer in wild-type placenta was not 
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observed in mutant placenta, likely responsible for the lost volume of the decidua layer 
in Prl-2 mutant mice (Figure 23D).  
 
Figure 23. Prl-2 deletion causes placental insufficiency. 
A. Embryos and their connected placentas of a Prl-2-/- mouse and its wild-type littermate 
at E16.5. B. Weight of wild-type and Prl-2-/- embryos at E16.5 (n=9 for both genotypes). 
*P<0.005. C. Weight of wild-type and Prl-2-/- placentas at E16.5 (n=9 for both 
genotypes). *P<0.01. D. Histological examination of E16.5 placenta sections from Prl-2-
/- mice and their wild-type littermates. (Upper panel) H&E stain at 25x. (Middle panel) 
H&E stain at 100x. Aarrowhead showed islands of glycogen cells. (Lower panel) IHC 
using antibody against Ki67 to monitor proliferating cells. The blue line showed the 
boundary between labyrinth and spongiotrophoblast layers. De, deciduas; Sp, 
spongiotrophoblast; La, labyrinth. E. Western blot analyses of signaling molecules using 
tissue lysates derived from Prl-2-/- or wild-type placenta. All panels were generated by 
Yuanshu Dong. 
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Examination of placenta at different stages further demonstrated that significant 
loss of spongiotrophoblast and glycogen cells in the spongiotrophoblast layer of Prl-2-/- 
mice occurred at or before E12.5, a time point when the three-layer placenta is just 
established and glycogen cells start to differentiate (155,156). To determine whether the 
cell loss in the spongiotrophoblast layer is due to increased apoptosis or decreased 
proliferation, TUNEL assay and Ki67 staining were performed on wild-type and Prl-2-/- 
placenta at E12.5. While there was no difference in the number of apoptotic cells, marked 
reduction in the number of proliferating cells was observed in the mutant 
spongiotrophoblast layer (Figure 23D). Thus decreased cell proliferation may be 
responsible for the reduced cell number and compromised development of the 
spongiotrophoblast layer in mutant Prl-2 placenta. 
To define the mechanism by which Prl-2 deficiency decreases cell proliferation, 
we analyzed the activation status of several PRL-mediated pathways previously 
implicated in cell cultures. As shown in Figure 23E (Generated by Yuanshu Dong), 
Western blot of lysates prepared from wild-type and Prl-2-/- placenta showed that Akt 
phosphorylation is considerably lower in the Prl-2-/- samples. Furthermore, decreased 
phosphorylation of GSK-3β, a well-established Akt substrate, was also evident in mutant 
Prl-2 placenta by Western blot (Figure 23E). A decrease in GSK-3β phosphorylation is 
expected to activate GSK-3β, which in turn will phosphorylate and inhibit glycogen 
synthase, leading to reduced glycogen production in Prl-2 mutant placenta. As a key 
component of PI3K pathway, Akt is repressed by PTEN. To determine whether the 
decreased Akt phosphorylation in Prl-2-/- placenta is due to increased PTEN level, we 
examined lysates from wild-type and Prl-2-/- placenta for PTEN. Consistent with Akt 
inactivation, deletion of Prl-2 gave rise to an increase in PTEN in placenta (Figure. 23E). 
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Taken together, the results suggest that Prl-2 deficiency impaired placenta development 
by up-regulation of PTEN and thereby inactivation of Akt. 
4.4.6 Prl-2 plays an important role in spermatogenesis 
We have mentioned earlier that, even though normalized by body weight, testis 
weight of Prl-2-/- males was still significantly smaller than that of wild-type controls 
(Figure 22C & 24A, generated by Yuanshu Dong), suggesting Prl-2 plays a role in 
spermatogenesis. To determine whether the reduced testis size affects Prl-2-/- male 
reproduction, in collaboration with Dr. Yuanshu Dong, we set up mating cages of wild-
type and Prl-2-/- males at 3 and 6 months old with wild-type virgin females for 6 
consecutive days. While at both ages Prl-2-/- males produced similar number of vaginal 
plugs as the matching wild-type animals, the average litter size derived from Prl-2-/- 
males was smaller than that from females mated to wild-type males (Figure 24B, 
generated by Yuanshu Dong). Thus, while the sexual drive appeared to be normal, the 
reproductive ability of the Prl-2-/- male was compromised. Sperm counts were next 
measured to investigate the cause of reduced fertility in Prl-2-/- male. Indeed, Prl-2-/- 
epididymis contained significantly fewer spermatozoa than wild-type, especially at 6-
month old (Figure 24C, sperm count (3.1 ± 1.3) x 106 for Prl-2-/- and (13.3 ± 0.6) x106 
for wild-type, generated by Yuanshu Dong). These results suggest that the impaired 
reproductive ability of Prl-2-/- male is due to lower sperm production. 
The structure of Prl-2-/- testes was analyzed histologically to explore the cause 
for the reduced organ size and sperm count. In 6-month old mutant testes, abnormal 
clusters of cells could be frequently found in the lumen of seminiferous tubules (Figure 
24D, generated by Yuanshu Dong). In addition, seminiferous tubules either totally or 
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partially devoid of germ cells were also observed in 6-month old Prl-2-/- testes, 
indicating a severe cell loss in these tubules (Figure 24D). 
 
Figure 24. Prl-2 plays an important role in spermatogenesis. 
A. Picture of testis from wild-type and Prl-2-/- littermates at 3 months old. B. Mating 
experiment to assess the reproductive performance of wild-type and Prl-2-/- males by 
litter size. Each male was mated with 4 wild-type virgin females every day for 6 
consecutive days. Plugged females were taken out and kept for pregnancy measurement. 
For 3 months old, WT: n=5, KO: n=8. For 6 months old, n=4 for each genotype. Data 
represent mean ± SEM. C. Sperm counts of wild-type and Prl-2-/- mice. Epididymis 
from one side of mice was removed, minced in BWW buffer, and incubated at 32 °C for 
15 min. Sperm suspension was then added to hemocytometer to count total sperm 
number. n=5 for each genotype at each time point. Data represent mean ± SEM. D. 
Histological examination of testis sections from Prl-2-/- mice and their wild-type 
littermates at 6 months old. (Upper panel) H&E staining. Red arrows show aberrant cell 
clusters. Blue stars mark empty seminiferous tubules. (Lower panel) IHC with antibody 
against cleaved-PARP was used to monitor apoptotic cells. Red arrows mark the 
apoptotic cell cluster. n=3 for each genotype. E. Western blot analyses of signaling 
molecules using germ cells isolated from Prl-2-/- or wild-type testis. All panels were 
generated by Yuanshu Dong. 
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To determine whether the seminiferous hypocellularity was due to decreased 
proliferation or increased apoptosis, we performed immunohistological staining for 
PCNA (Proliferating Cell Nuclear Antigen, a proliferation marker) and cleaved PARP 
(Poly ADP-Ribose Polymerase, an apoptosis marker) on testis sections of Prl-2-/- and 
wild-type mice at 6 months of age. While the percentage of proliferating cells in the 
testis was similar between the two genotypes, the number of cleaved PARP positive cells 
was dramatically increased in the mutant germ cells, indicating that Prl-2 deficiency 
primarily impair cell survival (Figure 24D). Thus aberrant germ cell apoptosis provides a 
potential mechanism to explain the hypotrophy of testis and decreased amount of sperms 
produced by testis in Prl-2-/- mice.  
Since SCF-Kit pathway plays an important role in regulating the proliferation and 
survival of differentiating spermatogonia and spermatocytes, increased apoptosis 
observed in Prl-2 deficient testis led us to examine signaling molecules involved in SCF-
Kit pathway. Therefore, we isolated germ cells from Prl-2-/- and wild-type testis, and 
evaluated the activation status of Kit downstream molecules. As shown in Figure 24E 
(Generated by Yuanshu Dong), Akt phosphorylation in Prl-2-/- germ cells was only 
about 50% of that in wild-type, indicating that Prl-2 deficiency impaired PI3K/Akt 
activation. To investigate the mechanism by which Prl-2 attenuates PI3K/Akt activation, 
we first analyzed Kit expression in both wild-type and Prl-2-/- germ cells. No change in 
Kit expression was observed as a result of Prl-2 deletion (Figure 24E). In placenta as 
mentioned previously, Prl-2 deficiency led to up-regulation of PTEN, an antagonist of 
PI3K/Akt signaling pathway, and therefore decreased Akt activation. To examine 
whether this is also the case in testis, we measured PTEN protein level in germ cells 
isolated from wild-type and Prl-2-/- testes. Consistent with our observation in placenta, 
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PTEN protein level was 1.6 ± 0.3 fold higher in isolated germ cells of Prl-2-/- (Figure 
24E). Therefore, impaired Akt activation in Prl-2-/- germ cells was due to increased 
PTEN expression, which suppressed Akt phosphorylation. Given the critical role of 
PI3K/Akt signaling in cell survival, it was not surprising that increased apoptosis, as 
evidenced by a 1.5 ± 0.2 fold increase in cleaved PARP protein level, was detected in 
Prl-2 deficient germ cells (Figure 24E), which is consistent with immunohistochemistry 
data for cleaved PARP (Figure 24D) in Prl-2-/- testes. Together, the data indicate that 
impaired spermatogenesis in Prl-2-/- testis is primarily, if not solely, due to blockage of 
Kit-PI3K-Akt signaling, as a result of elevated PTEN expression. 
4.4.7 Prl-2 is important for hematopoietic stem cell self-renewal 
The smaller spleen observed in Prl-2-null mice led us to investigate the role of 
Prl-2 in hematopoiesis. In collaboration with Dr. Michihiro Kobayashi from Dr. Yan 
Liu’s lab, we performed serial competitive bone marrow transplantation assays to 
examine whether Prl-2 deficiency affects hematopoietic stem cell (HSCs) function. 
Equal numbers of donor and competitor bone marrow mononuclear cells (BMMCs) were 
transplanted into lethally irradiated recipient mice. Sixteen weeks after primary 
transplantation, the repopulating ability of Prl-2-null cells was significantly lower than 
wild-type cells (Figure 25A, generated by Michihiro Kobayashi).  
To further establish that the self-renewal defect is HSC intrinsic, we purified 
wild-type and Prl-2-null LTHSCs (CD48-CD150+KSLs) and transplanted 200 of each 
into lethally irradiated recipient mice along with 300,000 wild-type competitor BMMCs. 
In this context, Prl-2-null HSCs exhibited a substantially lower contribution to 
peripheral blood production compared to control HSCs (Figure 25B, generated by 
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Michihiro Kobayashi), demonstrating that Prl-2 plays an important role in HSC 
maintenance and loss of Prl-2 impairs HSC self-renewal. 
 
Figure 25. Prl-2 is important for hematopoietic stem cell self-renewal. 
A. Lethally irradiated recipient mice (CD45.1+ and CD45.2+) were transplanted with 
5×105 bone marrow mononuclear cells (BMMCs) from wild-type and Prl-2-null mice 
(CD45.2+) plus 5×105 competitor cells (CD45.1+) in competitive repopulation assays. 
Graph shows the mean percentage (±SD) of donor-derived (CD45.2+) cells in the 
peripheral blood post-transplantation, measured at monthly intervals. n=7 for each 
genotype. B. Lethally irradiated recipient mice (CD45.1+ and CD45.2+) were 
transplanted with 200 LT-HSCs (CD48-CD150+KSLs) from wild-type and Prl-2-null 
mice (CD45.2+) plus 3×105 competitor cells (CD45.1+) in competitive repopulation 
assays. Graph shows the mean percentage (±SD) of donor-derived (CD45.2+) cells in the 
peripheral blood post-transplantation, measured at monthly intervals. n=7 for each 
genotype. C. Cell-cycle analysis of hematopoietic stem and progenitor cells was 
performed by staining with DAPI and Ki67 and analyzed by FACS. Data shown are the 
mean values ± SD. n=6 for each genotype. D. Western blot analysis of signaling 
molecules in wild-type and Prl-2-null Kit+ cells following SCF stimulation. Panel A, B 
and C werer generated by Michihiro Kobayashi.  
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To assess the effect of Prl-2 deficiency on proliferation, we stained Prl-2-null 
hematopoietic stem and progenitor cells with proliferation marker Ki67. While we 
detected normal number of Ki67 negative LT-HSCs, we found more Ki67 negative 
multipotent progenitor cells (MPPs) than normal (Figure 25C, generated by Michihiro 
Kobayashi), indicating that Prl-2 null MPPs are more quiescent and less proliferative. 
SCF/Kit signaling pathway is not only critical for germ cell survival, but also 
plays an important role in hematopoietic stem and progenitor cells maintenance. To 
decipher the molecular mechanisms underlying the HSPC proliferation defects seen in 
the Prl-2-null mice, we examined basal and SCF stimulated activation of Akt and ERK 
signaling in Kit+ cells. We observed that the levels of pAkt473 and pERK1/2 are 
significantly lower in Prl-2-null Kit+ cells compared with those in wild‐type cells in the 
basal state (Figure 25D). Prl-2-null cells also displayed decreased activation of both 
pAkt and pERK1/2 at 30 minutes following SCF stimulation (Figure 25D), 
demonstrating that PRL-2 is important for sustaining SCF signaling in hematopoietic 
stem and progenitor cells. 
To investigate the mechanism by which Prl-2 deficiency attenuates Akt and ERK 
activation, we analyzed PTEN expression in both wild-type and Prl-2-null cells. PTEN 
is an antagonist of PI3K signaling pathway. In addition, PTEN has also been shown to 
negatively regulate the activation of the ERK pathway (157). We have shown that Prl-2 
deficiency led to elevated PTEN expression in both placenta and testis. We measured 
PTEN protein level in wild-type and Prl-2-null Kit+ cells. As shown in Figure 25D, 
PTEN expression was 1.4 ± 0.15 fold higher in Prl-2-null samples. Therefore, the data 
indicated that impaired HSPC proliferation in the Prl-2-null mice is likely due to 
elevated PTEN expression, resulting in defect of SCF/Kit signaling transduction. 
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4.4.8 PRL-2 negatively regulates PTEN stability 
Western blot of samples from placenta, testis and HSC suggested that loss of Prl-
2 elevated PTEN level. It was further evidenced by the down-regulation of PTEN as well 
as a higher basal Akt phosphorylation in HEK293 cells stably expressing FLAG-tagged 
PRL-2 (Figure 26A, generated by Yuanshu Dong). To determine whether PRL-2 affects 
PTEN protein stability, PRL-2 transfected or control HEK293 cells were treated with 
cycloheximide, which blocks protein synthesis. As shown in Figure 26B (Generated by 
Yuanshu Dong), PRL-2 overexpression promotes PTEN degradation, reducing its half-
life from more than 36 hrs to around 10 hrs (Figure 26B). Treatment with 20 μM of the 
proteasome inhibitor MG132 did not significantly affect PTEN level in control cells, but 
did potently increase PTEN in PRL-2 expressing cells (Figure 26B), indicating that PRL-
2 increases PTEN degradation through the proteasomal pathway. To further validate this, 
we generated GC-1 cell lines stably overexpressing Flag-tagged PRL-2. GC-1 cell was 
derived from mouse spermatogonia (158), which is physiologically relevant to the testis 
study. As shown in Figure 26C, increased PRL-2 expression (1-2-fold over endogenous 
PRL-2) in GC-1 cell lines results in 28 ± 5% reduction in PTEN level compared with the 
GC-1 vector control cells. Accordingly, PI3K/Akt signaling was activated, as evidenced 
by the 3.0 ± 0.3-fold increase in Akt phosphorylation in PRL-2 overexpressing GC-1 
cells. To determine whether PRL-2 also controls PTEN at the level of protein stability as 
we had observed in HEK293 cells, GC-1 cells were treated with the protein synthesis 
inhibitor cycloheximide. As expected, PRL-2 overexpression promotes PTEN 
degradation, and reduces PTEN’s half-life from much greater than 30 hrs to 24 hrs in 
GC-1 cells (Figure 26D). Thus, PRL-2 overexpression activates PI3K/Akt signaling by 
destabilizing PTEN in both HEK293 cells and GC-1 cells. 
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Figure 26. PRL-2 negatively regulates PTEN stability. 
A. Western blot analysis of signaling molecules on cell lysates from PRL-2-HEK293 
or vector control cells. B. PRL-2 negatively regulates PTEN stability in HEK293 cells. 
(Upper panel) Cycloheximide chase experiment. PRL-2-HEK293 stable cell line and its 
vector control were treated with cycloheximide (CHX) at 100 µg/mL, and cell lysates 
were then analyzed for PTEN and actin protein levels by Western blot. (Lower left 
panel) Quantitation of the cycloheximide chase experiment results. PTEN and actin 
signals were measured using ImageJ, and ratios of PTEN/actin were determined for each 
sample. The ratios were then calculated as folds of time 0 for each cell line as plotted. 
(Lower right panel) PRL-2-HEK293 cell line and its vector control were treated with 20 
µM MG132 for 6 hrs. Cells were lysed and PTEN and actin protein levels analyzed by 
Western blot. C. Western blot analysis of signaling molecules on cell lysates from 
PRL-2-GC-1 or vector control cells. D. PRL-2 negatively regulates PTEN stability in 
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GC-1 cells. (Upper panel) Cycloheximide chase experiment. PRL-2-GC-1 stable cell 
line and its vector control were treated with cycloheximide (CHX) at 5 µg/mL, and cell 
lysates were then analyzed for PTEN, β-Catenin and actin protein levels by Western 
blot. (Lower panel) Quantitation of the cycloheximide chase experiment results. PTEN, 
β-Catenin and actin signals were measured using ImageJ, and ratios of PTEN/actin and 
β-Catenin/actin were determined for each sample. The ratios were then calculated as 
folds of time 0 for each cell line as plotted. Panel A and B were generated by Yuanshu 
Dong. 
 
Phosphorylation of PTEN at Ser380, Thr382 and Thr383 enhances PTEN 
stability by protecting it from the proteasome-mediated degradation (159). Since PRL-2 
is a protein phosphatase, we tested the hypothesis that PRL-2 destabilizes PTEN by 
removing phosphates from these sites. We analyzed PTEN phosphorylation at the 
S380/T382/T383 cluster and the total PTEN protein in vector control and PRL-2 
expressing cells (Figure 26A). The ratios of phospho-PTEN/total PTEN were found to be 
constant as the levels of PRL-2 varied. Thus it appears that PRL-2 does not control 
PTEN phosphorylation at these sites. 
One mechanism by which PTEN protein could be stabilized is through formation 
of a complex with MAGI2 and β-Catenin at the adherens junctions, which prevents 
PTEN from degradation (84). The adherens junctions component Vinculin plays an 
important role in maintaining the stability of the complex, because the complex is 
disrupted and PTEN level is reduced in cells lacking Vinculin. This led us to examine 
whether PRL-2 altered the expression of Vinculin. Lysates from vector and PRL-2 
transfected cells were analyzed for Vinculin by Western blot. The results showed that 
Vinculin is down-regulated in PRL-2 over-expressing HEK293 cells (Figure 26A). Thus, 
one mechanism by which PRL-2 down-regulates PTEN may be through suppressing 
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Vinculin expression, which destabilizes PTEN by disrupting PTEN-MAGI-2-β-Catenin 
complex.  
In line with this observation, we found that Vinculin expression decreased 41 ± 
13% in PRL-2 overexpressing GC-1 cells (Figure 26C). Moreover, β-Catenin expression 
was also reduced by 29 ± 13% upon increased PRL-2 expression (Figure 26C). These 
observations support the notion that PRL-2 down-regulates PTEN via inhibition of 
Vinculin and β-Catenin expression, which likely leads to disruption of the PTEN-
MAGI2-β-Catenin complex and exposes PTEN for degradation. Interestingly, the rate of 
β-Catenin degradation was also increased in PRL-2-overexpressing GC-1 cells (Figure 
26D). More importantly, it appears that β-Catenin degradation (t1/2 16 h) precedes that of 
PTEN, indicating that the disassembly of the PTEN-MAGI2-β-Catenin complex may be 
responsible for PTEN degradation. Taken together, these results are in agreement with 
studies in HEK293 cells overexpressing PRL-2 and suggest that PRL-2 functions to 
destabilize the PTEN-MAGI2-β-Catenin complex to down-regulate PTEN, leading to 
enhanced PI3K/Akt signaling. 
4.5 Discussion 
Despite the apparent implication of PRLs in tumorigenesis and metastasis by 
plenty of information derived from cell culture, it is still unclear about the physiological 
function of these enzymes in mammals due to the absence of informative animal models. 
To establish the in vivo functions of all Prls, we sought to delete the three Prls 
individually in a mouse model. Prl-1 and Prl-2 knockout mouse lines were generated by 
the gene-trapping technology, while systemic deletion of Prl-3 in mice was achieved by 
homologous recombination in ES cells. Deletion of PRL proteins was confirmed by 
quantitative RT-PCR using spleen mRNA, and Western blot analysis using lung and 
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spleen lysates from wild-type, Prl-1, Prl-2 and Prl-3-null mice. A thorough examination 
on protein expression pattern of each PRL was performed by Western blot. As previous 
studies suggested, both PRL-1 and PRL-2 are broadly expressed in different organs in 
spite of relative lower expression level of PRL-1 than PRL-2. However, compared to the 
restricted expression pattern of PRL-3 in heart and skeletal muscle as suggested by 
previous report by Northern blot (14), we found a more ubiquitous protein expression 
pattern of PRL-3 in multiple organs including brain, lung, colon, small intestine, spleen, 
thymus, skeletal muscle and heart, which is consistent with recent studies by 
Zimmerman et al. (26,111).  
Even though mice with deletion of each Prl genes are viable, the birth rate of 
these knockouts are significantly lower than the predicted Mendelian ratios, suggesting 
that all Prl genes are important for normal development, and deficiency of individual Prl 
genes causes partial perinatal lethality. While the body weights of Prl-1 and Prl-3-null 
mice are comparable with their wild-type littermates, Prl-2 knockouts are significantly 
smaller, suggesting a growth retardation phenotype in these animals with Prl-2 deletion. 
Further investigation demonstrated that the smaller body weight of Prl-2-null embryo is 
due to impaired placental development as evidenced by thinner decidua and 
spongiotrophoblast layers and less glycogen cells observed in the placenta of Prl-2-null 
mice. Significantly decreased proliferation contributes to the loss of glycogen cells in the 
spongiotrophoblast layer. Normal placental development is essential for transporting 
nutrients, while impaired placenta function will lead to restricted fetal growth or even 
embryonic death (154). Furthermore, a careful anatomical examination revealed that 
testis and spleen from Prl-2-null mice were significantly smaller than those from wild-
type mice, suggesting that PRL-2 may play important roles in spermatogenesis and 
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hematopoiesis. As expected, deletion of Prl-2 causes impaired spermatogenesis and 
insufficient hematopoiesis due to increased germ cells apoptosis and decreased 
hematopoietic stem cell self-renewal, respectively. These developmental defects 
resulting from lack of Prl-2 are in accordance with the oncogenic role of excess PRL-2 
in tumorigenesis. However, these phenotypes were not observed in Prl-1 or Prl-3 mice, 
suggesting a possible compensation from more abundantly expressed PRL-2. Thus, it is 
interesting to generate and characterize Prl-1/Prl-2, Prl-1/Prl-3 and Prl-2/Prl-3 double 
knockout or even Prl-1/Prl-2/Prl-3 triple knockout mice (see details in Chapter 5).  
The mouse models with deficiency of each Prl genes are useful tools not only for 
studying the phenotypic alterations in the absence of each gene, but also for investigating 
the underlying mechanism of PRL actions. At the molecular level, these three defects 
observed in Prl-2-null mice converged to impaired PI3K/Akt signaling pathways, as 
evidenced by the lower basal Akt phosphorylation in placenta tissue, isolated germ cells 
and hematopoietic stem and progenitor cells from Prl-2 deficient mice. The impaired 
PI3K/Akt activation in these samples is attributed to increased PTEN level in the 
absence of Prl-2, which is in agreement with cell based experiments that PRL-2 
overexpression activates PI3K/Akt signaling by down-regulating PTEN. Mechanistically, 
PRL-2 negatively regulates PTEN protein level by destabilizing the PTEN-MAGI2-β-
Catenin complex thereby exposing PTEN for degradation. It is in need of further 
investigation on how PRL-2 destabilizes the complex. 
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CHAPTER 5: THE ROLE OF PRL-1 IN SPERMATOGENESIS 
5.1 Overview 
PRLs play a positive role in cell signaling events and are suggested as oncogenes 
and therapeutic targets in several cancers (152,153). Overexpression of PRLs was 
frequently found in tumor cell lines, and cells expressing high levels of PRLs exhibited 
enhanced proliferation, anchorage-independent growth, cell migration and invasion 
(11,12,69,86,95,96). Clinically, up-regulation of PRLs has been observed in many types 
of advanced stage tumors as well as metastatic lesions (153). It has been suggested that 
PRLs promote cell proliferation and migration through activation of several signaling 
pathways, including the Rho family of small GTPases, Src, ERK1/2, and PI3K 
(16,59,79,86,137). PRLs are strongly implicated as a driving force in malignancy, but 
limited knowledge is available regarding the exact physiological function(s) of these 
phosphatases. Our current understanding of PRLs came primarily from observations in 
clinical patient samples or cell culture models either overexpressing or silencing PRLs. 
To define the biological function of the PRLs, we generated PRL-1, PRL-2, and PRL-3 
knockout mice (see details in Chapter 4) to study the effects of PRL deletion in the 
animal model. 
5.2 Hypothesis and Specific Aims 
We previously reported that Prl-2 deficiency causes growth retardation in both 
embryos and adult mice due to placenta insufficiency (80), and that Prl-2 deletion 
impairs male reproductive ability resulting from deficient spermatogenesis (81), and that 
deficiency of Prl-2 led to insufficient hematopoiesis (83). Biochemically, all three 
phenotypes are caused by Akt inactivation as a result of up-regulation of the tumor 
suppressor PTEN in Prl-2-/-. However, Prl-1 deficient mice were viable, normally 
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developed and did not reveal any obvious phenotypic alteration compared to normal 
mice.  
Since PRL-1 and PRL-2 share high amino acid sequence identity and similar 
tissue distribution in whole body and PRL-1 protein level is always lower than PRL-2, it 
is highly possible that PRL-2 can compensate for the loss of Prl-1. To further investigate 
the physiological role of PRL-1, I proceeded to generate Prl-1/Prl-2 double knockout 
mice. Unfortunately, Prl-1/Prl-2 double knockout is embryonic lethal. During this 
process, however, Prl-1-/-/Prl-2+/- and Prl-1+/-/Prl-2-/- mice were also generated and they 
were found to be viable and already show much severe testis phenotype compared to 
Prl-1-/- and Prl-2-/- mice, respectively. Similar to Prl-2-/-, Prl-1-/-/Prl-2+/- male mice also 
have impaired reproductive ability. More strikingly, Prl-1+/-/Prl-2-/- male mice are 
completely sterile. Based on these observations, I hypothesized that PRL-1 plays an 
important role in spermatogenesis. I have two specific aims to test this hypothesis: 1) 
to characterize the testis phenotype, and to measure the reproductive function of Prl-1-/-
/Prl-2+/- and Prl-1+/-/Prl-2-/- male mice; and 2) to elucidate the mechanism by which 
deletion of one additional Prl-1 allele in the Prl-2-/- mice results in male sterility. These 
investigations are the first to definitively examine the role of PRL-1 in a knockout mouse 
model, and will provide the first in vivo evidence of an important role of PRL-1 in male 
reproductive system.  
5.3 Materials and Methods 
5.3.1 Generation of Prl-1-/-/Prl-2+/- and Prl-1+/-/Prl-2-/- mice 
Generation and genotyping of Prl-1-/- and Prl-2-/- mice were previously described 
(Chapter 4, and Figure 19A). We obtained Prl-1-/-/Prl-2+/- and Prl-1+/-/Prl-2-/- mice by 
crossing the Prl-1+/-/Prl-2+/- males with females. Mice used in this study were all on a 
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C57BL6/129P2 mixed genetic background. Experiments on mice were carried out in 
accordance with the regulations of The Institutional Animal Care and Use Committees at 
Indiana University. 
5.3.2 Reproductive performance evaluation 
Age matched wild-type, Prl-1-/-, Prl-2-/-, Prl-1-/-/Prl-2+/- and Prl-1+/-/Prl-2-/- males 
were each mated with 4 wild-type virgin females every day for 6 consecutive days. 
Vaginal plugs were monitored every morning, and plugged females were removed and 
replaced with virgin females. After 6 days, the total number of females plugged by each 
male was counted. Plugged females were kept for an additional month to determine the 
number of pregnant mice and their litter sizes. The percentage of pregnant mice among 
the plugged and the average litter size were calculated for each male. 
5.3.3 Sperm Count 
Caudal epididymis were isolated from age-matched male mice with different 
genotypes, minced in 10 mL BWW buffer (NaCl 5.54 g/L, KCl 0.356 g/L, CaCl2•2H2O 
0.250 g/L, KH2PO4 0.162 g/L, MgSO4•7H2O 0.294 g/L, NaHCO3 2.1 g/L, glucose 1.0 
g/L, Sodium pyruvic acid 0.03 g/L, BSA 3.5 g/L), and incubated at 32 °C for 15 min. 
After mixed by pipetting, the motile and total sperm numbers were counted using 
hemocytometer. 
5.3.4 Histology 
Tissues were fixed in 4% paraformaldehyde (PFA) overnight at 4 °C, embedded 
in paraffin, serially sectioned (7 μm), and stained with H&E according to standard 
methods. For immunohistochemistry, de-paraffined and hydrated sections were 
subjected to antigen retrieval by boiling in 10 mM sodium citrate for 20 min. Sections 
were then incubated with diluted antibodies (1:50 – 1:400) at 4 °C overnight. Signals 
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were detected by VECTASTAIN Elite ABC kit and developed using DAB substrate 
from Vector laboratory (Burlingame, CA). Antibodies used were PLZF, Kit (Santa Cruz 
Biotechnology, CA), Vimentin, PCNA and cleaved PARP (Cell Signaling Technology, 
MA). Images were captured on a Leica DM2500 stereomicroscope. All images are 
representative of at least 3 samples. 
5.3.5 Western blot analysis 
Testes were lysed in lysis buffer supplied with phosphatase and protease inhibitor 
mixture (Roche Applied Science). Equal amounts of protein were resolved by SDS-
PAGE, transferred to nitrocellulose membrane and subjected to immunoblotting. Anti-
PRL-1/2 antibody was kindly provided by Dr. Qi Zeng. All other antibodies were from 
Cell Signaling Technology. 
5.3.6 Statistical analysis 
All statistical significant differences were calculated using student’s t-test and 
represented by asterisks: *P<0.05, **P<0.01, ***P<0.001. 
5.4 Results 
5.4.1 Generation and characterization of Prl-1-/-/Prl-2+/- and Prl-1+/-/Prl-2-/- mice 
As I mentioned earlier, Prl-1-/- mice are viable and have no obvious phenotypic 
alterations compared to wild-type mice. In contrast, we have reported that Prl-2 deficient 
mice showed growth retardation, impaired spermatogenesis and insufficient 
hematopoiesis (80,81,83). PRL-1 and PRL-2 share 86% amino acid sequence identity, 
and both PRL-1 and PRL-2 are broadly expressed in almost all organs, suggesting that 
PRL-1 and PRL-2 may have similar function. However, PRL-1 expression level is 
relatively lower than PRL-2, indicating that Prl-2 could potentially compensate for Prl-1 
deficiency. Interestingly, relative PRL-1/PRL-2 protein level is significantly higher in 
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testis compared to all other organs, implicating that PRL-1 may also play a role in testis 
function (Figure 21D). 
Table 6. Distribution of offspring by double heterozygous-double heterozygous mating at weaning. 
Prl-1 +/+ +/- -/- 
n χ2 p 
Prl-2 +/+ +/- -/- +/+ +/- -/- +/+ +/- -/- 
Observed 22 56 30 54 110 27 18 35 0 352 45.10 <0.001 
Expected 22 44 22 44 88 44 22 44 22    
 
To test whether Prl-2 indeed compensates for loss of Prl-1 and whether both 
PRL-1 and PRL-2 were required for spermatogenesis, we tried to generate Prl-1/Prl-2 
double knockout mice by crossing Prl-1/Prl-2 double heterozygous males with females. 
We analyzed more than 300 pups, but none of them were double knockouts, suggesting 
that mice with both Prl-1 and Prl-2 deletion are embryonic lethal (Table 6). We made a 
lot of efforts to investigate at which stage the embryos are dead, and expected to isolate 
MEF cells from the double knockout embryos. However, we are still unable to get 
double knockout as early as embryo stage E9.5 days, indicating loss of both Prl-1 and 
Prl-2 results in early embryonic lethality. Fortunately, Prl-1+/-/Prl-2-/- mice and Prl-1-/-
/Prl-2+/- mice are viable, even though they displayed survival disadvantage as evidenced 
by the reduced birth rate (Table 6).  PCR analysis was used to determine the deletion of 
Prl-1 and Prl-2 alleles (Figure 27A). Deletion of PRL protein products were determined 
by Western blot on lung lysates from mice with different genotypes using PRL-1/2 
antibody (Figure 27B). To characterize the overall phenotypic changes, we first 
measured the body weight of more than 20 4-weeks-old males and females with different 
genotypes. As mentioned earlier, Prl-2-/- mice exhibited a roughly 20% decrease in body 
weight compared with wild-type and Prl-1-/- mice. More strikingly, the body weights of 
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Prl-1-/-/Prl-2+/- and Prl-1+/-/Prl-2-/- male mice decreased 38 ± 13% and 41 ± 10% 
compared with that of wild-type males, and 23 ± 16% and 27 ± 12% compared to the 
body weights of Prl-2-/- males. Similarly, body weights of Prl-1-/-/Prl-2+/- and Prl-1+/-
/Prl-2-/- female were also decreased 30 ± 13% and 26 ± 14% compared to wild-type 
females. However, even though Prl-1-/-/Prl-2+/- and Prl-1+/-/Prl-2-/- females are also 
smaller than Prl-2-/- females, no significant difference was observed (Figure 27C & 27D). 
More data points are needed to establish statistical significance.  
 
Figure 27. Generation of Prl-1-/-/Prl-2+/- and Prl-1+/-/Prl-2-/- mice. 
A. PCR strategy for genotyping using mouse tail DNA. B. Endogenous PRL-1 and PRL-
2 protein products were determined by Western blot on lung lysates from different 
genotypes. C-D. Body weights of 4-weeks-old male mice (C) or female mice (D) with 
different genotypes were determined. Body weights of Prl-2-/-, Prl-1-/-/Prl-2+/- and Prl-
1+/-/Prl-2-/- males and females were significantly less than those of wild-type and Prl-1-/- 
males and females. Body weights of Prl-1-/-/Prl-2+/- and Prl-1+/-/Prl-2-/- males were 
also significantly less than those of Prl-2-/- males. 
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5.4.2 Prl-1 is essential for male reproductive ability 
In order to evaluate the physiological function of PRL-1 in testis development, 
anatomical examination was performed on adult males with different genotypes. Our 
previous study (81) revealed that the testis of Prl-2 null mice is about 50% smaller than 
that of wild-type mice (Figure 28A & 28B). Similarly, we found a 43 ± 8% reduction in 
testis weight of Prl-2 null mice. Strikingly, deletion of a single allele of Prl-1 gene from 
Prl-2 null mice caused an additional 59 ± 16% reduction of testis size, indicating that 
Prl-1 gene is indeed involved in testis development (Figure 28A & 28B). It is further 
strengthened by the discovery that the testes of Prl-1-/-/Prl-2+/- male mice were also 
markedly smaller than those of wild-types (33 ± 14% reduction) (Figure 28A & 28B), 
despite the fact that testis development in either Prl-1-/- or Prl-2+/- mice is normal. Since 
the body weight of Prl-1-/-/Prl-2+/- and especially Prl-1+/-/Prl-2-/- mice was also reduced 
(Figure 27C), we normalized testis weight to body weight and still found a significant 
reduction of the testis/body weight ratio in Prl-1-/-/Prl-2+/- and especially Prl-1+/-/Prl-2-/- 
mice. As shown in Figure 28C, while testis/body weight ratio observed in Prl-2-/- males 
decreased 33 ± 16% compared to the wild-type animals, deletion of one more Prl-1 
allele resulted in a 69 ± 9% reduction in normalized testis size. Moreover, although no 
significant difference was observed in Prl-1-/- mice, the testis/body weight ratio of Prl-1-
/-/Prl-2+/- testis reduced 19 ± 12% compared to the wild-type mice (Figure 28C).  
To determine whether the reduced testis size correlates with impaired 
reproductive ability, 3-months-old Prl-1-/-/Prl-2+/- and Prl-1+/-/Prl-2-/- male mice were 
mated with wild-type virgin females. These mice showed similar sexual desire measured 
by the percentage of female mice plugged by male mice (Figure 29A). However, the real 
115 
 
 Figure 28. Prl-1 also contributes to the normal testis development. 
A. Representative testis picture from five different genotypes. B-C. Testis weights (B) or 
testis weight/body weight ratios (C) from five different genotypes were determined. 
 
pregnant percentage after plugging, as well as the litter size from Prl-1-/-/Prl-2+/- mice 
group were significantly lower compared to the wild-type group (Figure 29B & 29C). 
More strikingly, none of the females that were plugged by Prl-1+/-/Prl-2-/- male mice 
were pregnant, indicating that a single Prl-1 allele deletion in Prl-2 deficient mice results 
in male infertility (Figure 29B & 29C). To further characterize the functionality of testis, 
the number of sperm from epididymis was directly counted using hemocytometer. In 
agreement with previous results (Figure 24C), the number of sperm from Prl-2 KO mice 
was only 54 ± 18% of the wild-type controls (Figure 29D). Similarly, Prl-1-/-/Prl-2+/- 
mice also showed significantly decreased sperm numbers (68 ± 9% of wild-type) (Figure 
29D), suggesting that both Prl-1 and Prl-2 contribute to sperm production. Not 
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surprisingly, Prl-1+/-/Prl-2-/- male mice lost 93 ± 5% of sperms in the epididymis (Figure 
29D), which explained their sterility. Consistent with this observation, HE staining on 
caudal epididymis, where mature spermatozoa accumulate, also revealed that no 
morphologically normal spermatozoa were observed in the epididymis of Prl-1+/-/Prl-2-/- 
mice (Figure 29E). Although more round-shaped non-spermatozoa cells were found in 
the epididymis of Prl-2-/- and Prl-1-/-/Prl-2+/- mice, most of the cells are morphologically 
normal spermatozoa (Figure 29E). All these data imply that, in addition to PRL-2, PRL-
1 also controls sperm production, which directly affects reproductive ability. 
5.4.3 Prl-1 is important for maintaining spermatogenesis 
To investigate how PRL-1 is involved in controlling testis organ size and sperm 
production, the histological structure of male testis derived from different genotypes 
were analyzed by H&E staining. Even though the overall structures of seminiferous 
tubules of 3-month-old male mice were similar between different genotypes, the 
diameters of the seminiferous tubules were changed (Figure 30A & 30B). Consistent 
with our previous study (81), the diameter of the seminiferous tubules from the Prl-2-/- 
testis decreased 21 ± 6% in comparison to those from the wild-type and Prl-1-/- mice. 
There was also a 17 ± 3% and 27 ± 5% reduction in Prl-1-/-/Prl-2+/- and Prl-1+/-/Prl-2-/- 
testis size, respectively (Figure 30B). Moreover, loss of certain types of cells was 
evidenced by the “empty space” observed inside of the seminiferous tubules of Prl-2-/- 
testis, and this was even more severe in the Prl-1+/-/Prl-2-/- testis (Black arrows in Figure 
30A). In line with this observation, numerous round-shaped cells were released into the 
caudal epididymis of Prl-2-/- mice, and even more round-shaped cells were observed in 
the caudal epididymis of Prl-1+/ -/Prl-2 - / -  mice (Figure 29E).  These data 
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Figure 29. Deletion one Prl-1 allele in Prl-2-/- results in male infertility due to no sperm production. 
A. Sexual desire was measured by plug rate. B-C. Reproductive performance was 
measured by pregnancy rate (B) and little size (C). D. The sperm number was 
determined by calculating the sperms from epididymis. E. Caudal epididymis sections 
from 3 months old male mice were histologically examined by H&E staining. 
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Figure 30. Prl-1 also plays a role in maintaining spermatogenesis. 
A. Testis sections from 3 months or 2 weeks old male mice were histologically 
examined by H&E staining and immunohistochemical staining for Vimentin, PLZF and 
Kit. B-E. Relative seminiferous tubule diameters (B), number of Vimentin positive cell 
per seminiferous tubule (C), number of c-Kit positive cell per tubule (D) and number of 
PLZF positive cell per tubule (E) in testis sections from all five genotypes were 
quantificated. For each mouse, at least 20 tubules were counted. n=3 for each genotype. 
Data represent mean ± SD. 
 
indicated that the reduced testis size is mainly attributed to decreased cellularity in the 
seminiferous tubules. 
There are two major cell types within seminiferous tubules, Sertoli cells and 
germ cells. Sertoli cells are responsible for maintaining stem cell renewal, differentiation 
of spermatogonia into mature germ cells and the release of spermatozoa in the process of 
spermatogenesis. To determine whether the development and growth of Sertoli cells 
were normal and whether the number of Sertoli cells was affected, Vimentin (a Sertoli 
cell specific marker) staining was performed to visualize Sertoli cells from different 
genotypes by immunohistochemistry (Figure 30A). Even though the Sertoli cell structure 
was significantly affected in Prl-2-/- and Prl-1+/-/Prl-2-/- testis, the number of Sertoli cells 
from all five genotypes was similar (Figure 30A & 30C), suggesting that reduced 
cellularity is possibly due to loss of germ cells but not Sertoli cells. Since Sertoli cells 
interact with germ cells in the seminiferous tubules (160,161), loss of germ cells would 
potentially affects the Sertoli cell organization in the seminiferous tubules.  
Spermatogenesis is a process by which spermatozoa are formed from primordial 
germ cells by continuous mitosis and meiosis. Different types of germ cells are located 
in the seminiferous tubules from the base to lumen, including undifferentiated 
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Figure 31. Prl-1 is also required to prevent germ cells from apoptosis. 
A. Testis sections from 3 month old male mice were histologically examined by 
immunohistochemical staining for Cleaved PARP and PCNA. B-C. Number of cleaved-
PARP positive cell per field (B) and percentage of PCNA positive cells per tubule  (C) 
in testis sections from five genotypes were determined. For each mouse, at least 10 fields 
or 20 tubules were counted. n=3 for each genotype. Data represent mean ± SD. 
 
spermatogonia, differentiating spermatogonia, primary spermatocytes, secondary 
spermatocytes, round spermatid and elongated spermatid. To determine exactly which 
cell population is affected in the testis of different genotypes, PLZF staining (a specific 
marker for undifferentiated spermatogonia) and Kit staining (a specific marker for 
differentiating spermatogonia and primary spermatocytes) were performed (162,163). 
Our previous report suggested that testis structure alteration in Prl-2 deficient mice 
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appears at 2-week-old (81). At this stage, Sertoli cells, undifferentiated spermatogonia, 
differentiating spermatogonia and primary spermatocytes are the major cell types residing 
in the seminiferous tubules (81). Thus, it is much easier for us to tell which cell 
population is altered. Since previous immunohistochemistry analysis indicated that 
differentiating spermatogonia and primary spermatocytes (Kit positive), but not 
undifferentiated spermatogonia (PLZF positive), are significantly reduced in Prl-2-/- testis, 
we hypothesized that deletion of one more Prl-1 allele in Prl-2-/- testis will further 
aggravate the loss of Kit-positive cells. As shown in Figure 30A & 30E, the number of 
PLZF-positive cells is comparable in all five genotypes, suggesting that undifferentiated 
spermatogonia are not affected by deletion of Prl-1 and Prl-2. However, Kit-positive cell 
number varied between genotypes (Figure 30A & 30E). Consistent with previous results, 
the number of Kit-positive cells in Prl-2-/- testis dropped 30 ± 4% compared to that of 
wild-type controls (Figure 30A & 30E). Comparable to Prl-2-/- testis, the Kit-positive cell 
number also decreased 35 ± 10% in Prl-1-/-/Prl-2+/- testis (Figure 30A & 30D). As we 
expected, loss of Kit-positive cells are more pronounced in Prl-1+/-/Prl-2-/- testis (58 ± 
8% less than wild-type), in which many tubules are totally empty compared to Prl-2-/- and 
Prl-1-/-/Prl-2+/- testis (Figure 30A & 30D). Taken together, the combination of Prl-1+/-and 
Prl-2-/- intensified the Kit-positive germ cell loss observed in Prl-2-/- testis, leading to 
complete blockage of spermatogenesis and infertility. 
5.4.4 Prl-1 is also required to prevent germ cells from ectopic apoptosis 
Spermatogenesis is a precisely controlled process including germ cell 
proliferation, differentiation, self-renewal and apoptosis. Germ cell loss occurs normally 
during spermatogenesis in all mammals, and control of germ cell apoptosis during 
spermatogenesis is especially important. To determine whether loss of Kit-positive germ 
122 
 
cells was due to decreased proliferation or increased apoptosis, we performed 
immunohistochemistry with PCNA (Proliferating Cell Nuclear Antigen, a proliferation 
marker) staining and cleaved PARP (Poly ADP-Ribose Polymerase, an apoptosis marker) 
staining to label proliferating cells and apoptotic cells respectively. As shown in Figure 
31A & 31C, the percentage of proliferating cells in the testis was similar in all five 
genotypes. In contrast, the number of cleaved PARP positive cells was 3-fold higher in 
Prl-2-/- compared to wild-type or Prl-1-/- testis (Figure 31A & 31B). Prl-1-/-/Prl-2+/- mice 
also showed a 1.6 fold higher apoptosis in seminiferous tubules compared to control 
groups (Figure 31A & 31B). More importantly, knocking out one additional Prl-1 allele 
in Prl-2-/- increased another 3-fold of apoptosis compared to Prl-2-/- itself (Figure 31A & 
31B). The aggravated phenotype of Prl-1+/-/Prl-2-/- mice compared to Prl-2-null mice 
would then suggest an important role of PRL-1, in addition to PRL-2, in spermatogenesis 
by promoting Kit-positive germ cell survival. 
5.4.5 Loss of total PRL-1 and PRL-2 dose-dependently up-regulates PTEN level 
SCF-Kit is a major pathway that regulates the proliferation and survival of 
differentiating spermatogonia and spermatocytes. We have shown that in Prl-2 deficient 
testis, SCF-Kit signaling is compromised as a result of elevated PTEN expression. Since 
deletion of one allele of Prl-1 from Prl-2 null mice showed aggravated phenotype, it is 
understandable to propose that PRL-1 share a same regulatory mechanism on PTEN 
stability with PRL-2. To further substantiate that PRL-1 also negatively regulates PTEN 
expression level in testis, we compared the PTEN protein level by Western blot in five 
genotypes (Figure 32). As we expected, PTEN expression was 33 ± 5% higher in Prl-2-/- 
testis compared to wild-type (Figure 32A & 32B). Prl-1-/- and Prl-1-/-/Prl-2+/- testes also 
showed a 9 ± 11% and 21 ± 18% PTEN elevation, respectively (Figure 32A & 32B), 
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even though no statistical significance was observed. More obviously, PTEN protein 
level is further increased in Prl-1+/-/Prl-2-/- testis and displayed a 67 ± 11% up-regulation 
than wild-type (Figure 32A & 32B).  
 
Figure 32. Both PRL-1 and PRL-2 negatively regulate PTEN stability. 
A. Germ cells isolated from testis of male mice with different genotypes were analyzed 
for PTEN, PRL-1 and PRL-2by Western blot. B. Relative PTEN level normalized to 
Actin. C. Relative total PRL-1 and PRL-2 level normalized to Actin. 
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We also measured PRL-1 and PRL-2 protein level. If we assume PRL-1 and 
PRL-2 have similar function in regulating PTEN, and combined PRL-1 and PRL-2 
protein level as total PRL level, we observed a 36 ± 1%, 71 ± 11%, 58 ± 20% and 83 ± 
18% reduction of total PRL level in Prl-1-/-, Prl-2-/-, Prl-1-/-/Prl-2+/- and Prl-1+/-/Prl-2-/- 
testes, respectively (Figure 32A & 32C). More interestingly, we found a negative 
correlation between the total PRL level and the PTEN level, namely the less total PRL 
left, the more PTEN will be observed in the testis, suggesting that PTEN level is dose-
dependently regulated by the total PRL-1 and PRL-2 level and that PRL-1 and PRL-2 
are biochemically identical in terms of PTEN regulation.  
Moreover, if we link the previous functional and histological study with total 
PRL level in testes from different genotypes, we still can find this negative correlation. 
For example, testis weight (Figure 28), reproductive ability (Figure 29), loss of Kit+ 
germ cells (Figure 30) and increased apoptosis (Figure 31) are all dose-dependently 
associated with the total PRL levels, suggesting that both PRL-1 and PRL-2 are required 
for maintaining normal spermatogenesis and male reproductive ability. Even though 
further investigation is still required to fully establish the detailed mechanism, here we 
provide the first evidence that, in addition to PRL-2, PRL-1 also plays a significant role 
in maintaining spermatogenesis by down-regulation PTEN. 
5.5 Discussion 
The family of PRL phosphatases has three members, PRL-1, PRL-2 and PRL-3. 
The amino acid sequences of these three phosphatases are extremely similar, suggesting 
that they are biochemically equivalent. Numerous experiments supported this notion, 
because overexpression of any one member of this family induces similar cancer-
associated phenotypes in cells. However, the in vivo function of these three phosphatases 
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may differ due to the different expression pattern and level. Among the three PRL 
isoforms, both PRL-1 and PRL-2 are broadly expressed in adult human tissues, while 
PRL-3 is primarily expressed in heart and skeletal muscle (14,25). PRL-2 has the most 
abundant expression compared to PRL-1’s overall lower level in the same tissues or cell 
types (14,24,164). To investigate the physiological roles of PRLs, gene knockout mice 
lacking each Prl isoform are required. Recently, several studies on Prl-2 and Prl-3 
deficient mice have been reported from our group and others (26,80,81,83,111). Prl-2-
null mice displayed placenta dysfunction (80), impaired reproductive ability in male mice 
(81) and insufficiency in hematopoietic system (83), while Prl-3-null mice showed no 
obvious development problems but reduced colon cancer formation in the presence of 
carcinogen azoxymethane and dextran sodium sulfate (26), and Prl-3 promotes VEGF 
signaling and endothelial cell motility (111). However, to date, there are no reports on 
gene targeted mouse models for disruption of the Prl-1 genomic locus. Furthermore, 
given the similar but relatively lower expression pattern of PRL-1 compared to PRL-2, 
we were also interested in generating Prl-1 and Prl-2 double knockout mice.  
This study is the first to reveal that PRL-1 also plays an important role in the 
spermatogenesis in addition to PRL-2. Previous report suggested that Prl-2-/- male mice 
display impaired reproductive ability, testis hypotrophy, and decreased sperm production 
as a result of compromised spermatogenesis, and ablation of PRL-2 expression causes 
ectopic germ cell apoptosis, which primarily affects the Kit-positive cell population. In 
contrast to Prl-2, Prl-1-null male mice show normal reproductive function comparable to 
wild-type controls. Considering the high similarity of sequence, and always higher 
expression level of PRL-2 than PRL-1 in all the organs, it is highly possible that, in Prl-
1-null male testis, the original role of PRL-1 is maintained by PRL-2. In line with this 
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notion, Prl-1-/-/Prl-2+/- male mice also have impaired reproductive ability, testis 
hypotrophy, and decreased sperm production similar to the phenotype observed in Prl-2-/- 
alone. Most strikingly, deletion of one additional allele of Prl-1 in Prl-2-null male mice 
results in infertility. Compared to the subfertility of Prl-2-null mice, the infertile Prl-1-/-
/Prl-2+/- male mice has an additional 50% reduction in testis weight, almost 2 fold higher 
apoptosis in Kit-positive germ cells and no sperm production, suggesting that PRL-1 
plays an important role in maintaining the survival of Kit-positive germ cells in the testis. 
Mechanistically, Prl-2 deletion results in Akt activation through up-regulating the 
expression of PTEN, which antagonizes PI3K by dephosphorylating phosphatidylinositol 
(3,4,5) triphosphate (PIP3). In agreement with this mechanism, I have shown that the 
PTEN level is further increased in Prl-1+/-/Prl-2-/- male testis, leading to enhanced ectopic 
apoptosis of Kit-positive germ cells. These data suggested that PRL-1 shares the same 
regulatory mechanism with PRL-2 on PTEN stability, and PRL-1 also exerts an essential 
role in promoting germ cell survival and maintaining the normal spermatogenesis. 
It has been well established that the Kit-PI3K-Akt signaling pathway is critical for 
regulating the proliferation and survival of germ cells in testis. Animal models with Kit 
pathway component mutation or functional impairment also showed similar testicular 
phenotypes observed in the Prl-1+/-/Prl-2-/- mice. Germline homozygous-null mutations 
of either Scf or Kit cause infertility in male mice owing to failure of germ cell 
development (165,166). Spermatogonia differentiation was blocked by application of Kit 
antibody (167). KitW-lacZ/+ mice with only one functional Kit allele has reduced 
spermatogenesis, less differentiating spermatogonia and higher apoptosis in testes of the 
heterozygous mice due to Kit haplodeficiency (168). Mice bearing a point mutation in Kit 
to specifically disrupt p85 binding exhibit male sterility due to decreased proliferation 
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and increased apoptosis of spermatogonia and the failure of producing sperms (169,170). 
Knock-in male mice with inactive p110β, an isoform of PI3K, are sub-fertile due to 
severe loss of Kit-positive cells (171). Since Akt is responsible for transducing the 
survival signal from Kit to downstream effectors (172), it is not surprising that Akt1 
knockout male mice are also sub-fertile with decreased testis size, attenuated 
spermatogenesis and increased germ cell apoptosis (172,173). Akt1 has also been 
reported to protect germ cells from radiation-induced apoptosis in testis (174), 
demonstrating an important survival function of Akt1 in spermatogenesis. Taken together 
the data support an essential role for the Kit-PI3K-Akt pathway in regulating the growth 
and survival of germ cells in testis. Our results suggest that, similar to PRL-2, PRL-1 may 
also promote SCF-Kit pathway in the testis by down-regulating PTEN. However, 
additional experiments should be done to validate that deletion one Prl-1 allele in Prl-2 
deficient mice further attenuates the Kit-PI3K-Akt pathway leading to germ cell 
apoptosis and infertility. 
Give the significant role of PTEN in down-regulating Kit-PI3K-Akt signaling, it 
is understandable that loss of heterozygosity in Pten+/- mice causes testicular germ cell 
cancer (175). PTEN is one of the most well-known tumor suppressors that frequently 
mutated, and commonly down-regulated in cancer (176). Loss of function mutations of 
PTEN or even a 20% reduction in PTEN expression can amplify PI3K signaling and 
promote tumorigenesis in a variety of experimental models of cancer (177). Previous 
study indicated that PRL-2 down-regulates PTEN through the disruption of adherens 
junctions components Vinculin and β-Catenin (81). Even if additional investigations are 
required to further demonstrate whether PRL-1 regulates PTEN through the same 
mechanism, our finding that both PRL-1 and PRL-2 down-regulate PTEN offers a 
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plausible explanation for the oncogenic potential of both PRL-1 and PRL-2 in promoting 
cell proliferation and migration. Together with the previous finding that PRL-3 also 
down-regulates PTEN through increasing its degradation (79), our animal studies 
suggested that PRLs could be potential therapeutic targets for cancer treatment by 
manipulating PTEN expression.  
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CHAPTER 6: FINAL CONCLUSION AND FUTURE DIRECTION 
6.1 Final conclusion 
The overall goal of this dissertation is to gain insight into the biological function 
and therapeutic value of PRLs by biochemical and genetic approaches. The results 
presented in this dissertation explained the molecular mechanism by which PRL-1 
activates ERK1/2 and RhoA; established a novel anti-cancer approach by disrupting 
PRL-1 trimerization; and examined the physiological role of PRLs in animal models. 
While PRLs have been studied extensively for their implication in tumorigenesis and 
metastasis, limited information is available on their natural substrates or binding proteins, 
which hindered the process of understanding on mechanisms at molecular level of PRL 
functions. In addition, although PRLs have been considered as potential therapeutic 
targets for cancer treatment, only a few PRLs inhibitors have been developed and the 
therapeutic potential of these active site inhibitors has not been well-studied. Moreover, 
while standard tissue culture systems contributed a lot to the current understanding of the 
oncogenic role of PRLs in human malignancies, little is known about their physiological 
function in in vivo processes. Therefore, in the PRL field, significant gaps exist between 
oncogenic implication and molecular mechanism, possibility as potential drug target and 
real therapeutic value, as well as well-established in vitro function and poorly understood 
in vivo function. This dissertation definitively filled these gaps and improved our 
understanding on PRLs biology.  
Recent biochemical studies suggested that PRL-1 activates both ERK1/2 and 
RhoA of the Rho family small GTPases to facilitate cell proliferation and invasion. 
However, the mechanism by which PRL-1 up-regulates ERK1/2 and RhoA is still not 
established. In an effort to identify novel effectors of PRL-1, an unbiased phage display 
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screening against recombinant (His)6-tagged PRL-1 was performed, and Peptide 1 
(GWWSLIPPKYIT) was identified as a putative PRL-1 binding peptide. In a BLAST 
search, we found this peptide corresponds to a sequence motif in the SH3 domain of 
p115 RhoGAP, suggesting that this protein is a bona fide PRL-1 binding protein. 
Biochemical and cellular data suggested that the PRL-1 association with p115 RhoGAP 
relies on its SH3 domain. The co-crystal structure of PRL-1•Peptide 1 revealed that 
PRL-1 recognizes a conserved sequence motif in the canonical PxxP ligand binding site 
of the SH3 domain in p115 RhoGAP. p115 RhoGAP, a member of srGAP family, 
mainly expresses in nervous system and is implicated in cell migration and axon 
outgrowth. It has been shown that p115 RhoGAP associates with MEKK1, through 
which p115 RhoGAP inhibits ERK/MAP kinase signaling pathway. We found that the 
interaction between PRL-1 and p115 RhoGAP displaces MEKK1 from the inhibition of 
p115 RhoGAP and prevents the interaction between RhoA and p115 RhoGAP, leading 
to the ERK1/2 and RhoA activation, respectively. This study provides a potential 
mechanistic explanation for PRL-1 induced ERK1/2 and RhoA activation. Furthermore, 
two PRL-1-activated signaling pathways, MAP kinase and Rho GTPases, converge to 
the same protein, p115 RhoGAP. 
Structural analysis of PRL-1 and PRL-3 revealed an identical trimeric 
arrangement (22,23,137). We have shown that trimerization is essential for the PRL-1-
mediated cell growth and migration by providing a membrane-binding surface with C-
terminal prenylation motif and the adjacent polybasic residues to anchor PRL-1 on the 
acidic inner membrane (17). To test the hypothesis that targeting PRL-1 trimer interface 
by small molecule inhibitors could block PRL-1 induced cell proliferation and migration, 
virtual screening was used to develop novel small molecule inhibitors targeting PRL-1 
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trimer interface. 56 hits were selected for further validation, and one of those compounds, 
Cmpd-43, was identified as potential PRL-1 trimer disruptors by biochemical assays. 
Cellular studies further demonstrated that Cmpd-43 reduced PRL-1-induced cell 
proliferation and migration. Analog-3, one of Cmpd-43 analogs, had similar cellular 
activity as Cmpd-43 in inhibiting PRL-1 mediated cell proliferation and migration. Most 
importantly, while the structure of PRL-1 alone is a trimer, co-crystal structure of PRL-1 
with Analog-3 revealed a monomer structure of PRL-1, demonstrating that Analog-3 
indeed blocked the trimer formation of PRL-1. Finally, Cmpd-43 effectively decreased 
the cell proliferation and migration in breast cancer cell line MDA-MB-231 and lung 
cancer cell line H1299, further implicating the potential therapeutic value of this 
compound in cancer treatment. All these data support our hypothesis that targeting PRL 
trimer interface is a novel strategy for anti-cancer treatment.  
Even though extensive studies have been done to elucidate the role of PRL 
family of proteins in cancer development, we still know little about their physiological 
roles in vivo. To answer this question, we generated knockout mice deficient for 
individual Prls. While Prl-1 and Prl-3 knockout mice have no obvious developmental 
problems, Prl-2-null mice showed growth retardation, impaired male reproductive ability 
and ineffective hematopoiesis. Given the similar sequence identity and expression 
pattern, and the relative lower expression of PRL-1 compared to PRL-2, it is highly 
likely that PRL-1 plays a similar role with PRL-2 and PRL-2, to some extent, can 
compensate for loss of PRL-1. To reveal the physiological function of Prl-1, we tried to 
generate Prl-1 and Prl-2 double knockout mice. Even though we were unable to obtain 
any double knockout animal, deletion of one Prl-1 allele in Prl-2-null mice already 
displayed significant smaller testis compared to Prl-2-null mice. Functionally, Prl-1+/-
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/Prl-2-/- mice are infertile due to no sperm production. Histological study revealed that 
Prl-1+/-/Prl-2-/- males had dramatic reduction of Kit-positive germ cells in the 
seminiferous tubules due to enhanced ectopic apoptosis. At the molecular level, PTEN 
expression is further up-regulated in the testis of Prl-1+/-/Prl-2-/- male mice compared to 
Prl-2-null mice, suggesting similar function of PRL-1 and PRL-2 in regulating PTEN 
stability. This study is the first to reveal the physiological role of PRL-1 in maintaining 
spermatogenesis by modulating Kic-PI3K-Akt signaling pathways. 
Overall, this dissertation is an important milestone in understanding the 
biological function of PRLs. The results presented here explained the mechanism by 
which PRL-1 activates ERK1/2 and RhoA; explored the therapeutic value of targeting 
PRL-1 trimer interface for cancer treatment; established and characterized Prl-1, Prl-2 
and Prl-3 knockout mice; and revealed a significant role of PRL-1 in spermatogenesis. 
6.2 Future Direction 
Although the results presented in this thesis provided mechanistic insight 
regarding the actions of PRLs, no definitive substrate(s) has been identified for the PRLs, 
which represents a significant obstacle to our understanding of the true biological role of 
PRLs. Given the multifunctional roles of PRLs in different signaling pathway, it is 
possible that PRLs can dephosphorylate many proteins. Indeed, substrate-trapping 
mutant PRL-2-C101S/D69A is able to pull-down several proteins including PTEN, p53 
and β-Catenin, suggesting that these proteins are potential PRL-2 substrates. These 
candidates, as well as the phosphorylation sites, should be further validated for their 
potential as direct PRLs substrates. 
The novel interaction between PRL-1 and p115 RhoGAP not only offers a 
mechanistic explanation for PRL-1 induced ERK1/2 and RhoA activation, but also 
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identifies a novel p115 RhoGAP binding site in PRL-1 for the development of anticancer 
therapeutics by blocking the interaction between PRL-1 and p115 RhoGAP. It is worthy 
of further investigation to screen small molecule inhibitors targeting the binding sites 
between PRL-1 and p115 RhoGAP. One may expect that treatment with such inhibitors 
could block the interaction between PRL-1 and p115 RhoGAP and the activation of 
ERK1/2 and RhoA signaling, leading to the inhibition of cell proliferation and migration. 
Additionally, the significance of the novel interaction between PRL-1 and p115 
RhoGAP in the physiological condition is still unclear. Given the co-expression of PRL-
1 and p115 RhoGAP in nervous system, it is highly possible that PRL-1 is involved in 
determining axon growth and cell migration in nervous system.   
Cellular studies indicated that small molecule inhibitors targeting PRL-1 trimer 
interface effectively reduced PRL-1-mediated cell proliferation and migration in human 
cancer cells, but further evaluation using animal tumor models is required to measure the 
compound activity towards tumorigenesis and metastasis. Furthermore, the mechanism 
by which PRL-1 trimerization affects PRL-1-mediated signaling pathways also needs 
further investigation. Both of these future directions will benefit our understanding of the 
therapeutic significance of targeting PRL-1 trimerization. 
Gene knockout mouse model offers an extremely valuable tool for studying the 
function of PRLs in development. Given the similar expression pattern and highly 
homologous sequence between PRL-1 and PRL-2, it is interesting to evaluate the 
phenotypes in double knockout mice. However, PRL-1 and PRL-2 double knockout 
mice are embryonic lethal in early stage, suggesting they play an essential role in 
embryonic development. Conditional gene knockout is required to overcome the early 
embryonic lethality of PRL-1 and PRL-2 double knockout mice. One great advantage of 
134 
 
the conditional knockout animal model is the ability to perform time-specific and/or 
tissue-specific knockout of interested gene. Time-specific gene deletion enables us to 
bypass the critical stage in embryonic development. Tissue-specific knockout facilitates 
our studies in distinguishing which specific cell type is responsible for the observed 
phenotypes. Finally, generating triple knockout that deletes all three PRLs could add 
considerable insight about the in vivo function of this PTP subfamily. 
Given the implication of PRLs overexpression in cancer development, it is 
reasonable to expect that PRLs deficiency mice would develop fewer tumors. This is 
supported by recent reports that deletion of PRL-3 reduced colon tumors induced by 
carcinogen azoxymethane and dextran sodium sulfate (26). To date, different types of 
mouse tumor models have been established such as liver, breast, or leukemia (178,179). 
It would be very interesting to examine the effect of PRLs deletion in these cancer 
models. In addition, mice with heterozygous loss of PTEN and mice with homozygous 
loss of p53 develop spontaneous tumors in a variety of organs and tissues (180,181). 
Considering the direct regulation of PRLs on PTEN and p53, it is interesting to examine 
the effect of PRL deletion on spontaneous tumor development by crossing PRLs 
knockout mice with PTEN or p53 deficient mice. This could not only provide insight for 
the oncogenic role of PRLs, but also benefit our understanding of signaling pathways 
regulated by the PRLs. 
Finally, it has been reported that adenoviral-mediated PTEN expression 
significantly inhibits tumor growth in multiple animal models (182-185), demonstrating 
that restoration of PTEN level may be an effective strategy for tumor therapy. Given the 
negative regulatory role of PRLs in PTEN stability, small molecule inhibitors of PRLs 
may increase PTEN expression. Unlike inhibitors of the PI3K-Akt pathway, PRLs 
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inhibitors may restore not only the canonical PTEN function but also tumor-suppressive 
nuclear activities of PTEN that are unrelated to its lipid phosphatase activity. Further 
investigation is necessary to explore the efficiency of PRLs inhibitors as new therapeutic 
approaches to a number of malignancies associated with gain-of-function mutations in 
the Kit gene. Furthermore, a combination of PRLs inhibitors with PI3K-Akt inhibitors 
may have synergistic effect in cancer treatment.  
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